The 2026 Clinical Playbook: Preventing Post-Inflammatory Hyperpigmentation in Fitzpatrick IV-VI Laser Treatments

8/28/2026 65,186 words 326 min read

Preventing post-inflammatory hyperpigmentation (PIH) in patients with Fitzpatrick skin types IV to VI during laser treatment requires meticulous and specific clinical protocols. As of August 29, 2026, there is no single international standard uniformly recognized as the “Fitzpatrick IV to VI Laser Safety Protocol.” Instead, a comprehensive 2026 clinical playbook synthesizes information from leading consensus reports, controlled trials, device instructions, and adverse event data. This approach acknowledges that rigid, fixed settings are insufficient given the variability across different devices, indications, body sites, and individual patient responses. The core challenge in treating darker skin types is the inherent melanin in the epidermis, which absorbs a portion of the laser energy, thus narrowing the therapeutic window between effective treatment and potential complications such as excessive heat, inflammation, burns, PIH, or even permanent pigment loss.

This report outlines a strategic, step-by-step approach for minimizing the risk of PIH in individuals with Fitzpatrick skin types IV to VI. It emphasizes that Fitzpatrick classification is merely one factor within a broader, comprehensive risk assessment. Key areas covered include thorough diagnosis and risk screening, pre-treatment skin stabilization, careful device selection tailored to skin type, the critical role of delayed test spots, conservative energy delivery strategies, and active post-treatment inflammation control. We also highlight the importance of ongoing safety measurement and acknowledge the persistent gaps in current evidence, particularly concerning Fitzpatrick type VI skin, where much of the guidance relies on physiological understanding, small studies, and expert clinical opinion.

Key Takeaways

• No Single Protocol: The “2026 Clinical Playbook” is a synthesis of best practices, not a unified international standard, emphasizing individualized care over fixed settings. (Another reason we offer Electrolysis or Laser)
• Fitzpatrick Limitations: The Fitzpatrick scale is an initial guide; a comprehensive risk assessment must include detailed patient history, objective measurements, and current skin condition.
• Narrow Therapeutic Window: High epidermal melanin in darker skin significantly reduces the margin between effective treatment and adverse events like PIH.
• Strategic Steps are Crucial: Preventing PIH requires a multi-stage approach: risk screening, stabilization, device selection, delayed test spots, conservative energy delivery, and post-treatment inflammation control.
• Nd:YAG Preferred: For hair reduction in Fitzpatrick V and VI, the long-pulsed 1064 nm Nd:YAG laser is generally the safest due to lower epidermal melanin absorption.
• Evidence Gaps Remain: Data for PIH prevention, especially in Fitzpatrick type VI, is limited, relying heavily on expert opinion and small studies.
• Sunscreen is Fundamental: Daily broad-spectrum sunscreen, with visible-light protection for prone individuals, is a core component of long-term care.

1. Executive Summary

Preventing post-inflammatory hyperpigmentation (PIH) in Fitzpatrick skin types IV to VI during laser treatment requires careful and specific clinical protocols. As of August 29, 2026, no single international standard exists called the “Fitzpatrick IV to VI Laser Safety Protocol.” Instead, a 2026 clinical playbook combines information from consensus reports, controlled trials, device instructions, and adverse event data. This approach recognizes that fixed settings cannot apply across different devices, indications, body sites, or patients ¹. The core challenge is that melanin in the epidermis absorbs a portion of the laser energy. This reduces the gap between an effective treatment and harmful outcomes such as excess heat, inflammation, burns, PIH, or loss of pigment ².

This executive summary outlines key steps and best practices for minimizing PIH risk in individuals with Fitzpatrick skin types IV to VI. It emphasizes that Fitzpatrick type is one factor among many in a comprehensive risk assessment. The summary covers diagnosis and risk screening, skin stabilization, careful device selection, delayed test spots, conservative energy delivery, and active inflammation control after treatment. It also highlights the need for ongoing safety measurement and acknowledges gaps in current evidence, particularly for Fitzpatrick type VI skin.

The available evidence for PIH prevention has grown, but it remains limited. A 2026 network meta-analysis included 14 randomized controlled trials, with 11 suitable for network comparison ³. This marks a shift toward comparative evidence, yet the trial base is still small considering the range of devices, settings, indications, and skin tones used ³. No single preventive regimen can be considered a universal standard ³. A 2025 systematic review included 369 cases of PIH, with 95.4% linked to laser procedures and 85.3% occurring on the face ⁴. However, among the classified participants, only 4.1% were Fitzpatrick type V, and none were Fitzpatrick type VI ⁴. This means protocols for Fitzpatrick type VI rely heavily on physiological understanding, small studies, expert opinion, and careful clinical practice ⁴.

The Foundational Principles of Fitzpatrick IV-VI Laser Safety

The approach to laser treatment in Fitzpatrick IV-VI skin types is guided by several core principles designed to reduce the risk of PIH. These principles acknowledge the unique characteristics of darker skin, where higher melanin content in the epidermis increases the potential for unwanted thermal injury. A 2025 Delphi study involving 22 skin-of-color experts found that 95% agreed or strongly agreed that the current Fitzpatrick system has clinical and research limitations ⁵. This highlights the need for a more detailed assessment beyond a simple Fitzpatrick classification. A 2026 study of 789 adults also showed significant differences between subjective skin ratings and objective color measurements ⁶.

The central safety issue is that epidermal melanin absorbs part of the laser energy. This reduces the difference between energy levels needed for effective treatment and levels that cause excess heat, inflammation, burns, PIH, or loss of pigment ². Longer wavelengths, conservative settings, controlled skin coverage, and epidermal cooling can help reduce this risk, but they do not make treatment risk-free ². The playbook emphasizes a step-by-step process, beginning long before the laser is fired and continuing through post-treatment care and follow-up.

Key Steps in the Clinical Playbook

The 2026 clinical playbook for preventing PIH in Fitzpatrick IV-VI skin types is structured around six critical steps:

1. Diagnosis and Risk Screening: This initial step confirms the treatment goal and thoroughly assesses patient risk factors ⁷. It includes documenting prior PIH, scarring, current inflammation, recent tanning, previous procedures, medications, and the patient’s normal untanned skin color ⁷. For existing PIH, topical treatment should usually precede laser intervention ⁷.
2. Stabilization: This step involves deferring elective laser treatment if there is a recent tan or active inflammatory skin condition in the treatment area ⁸. The 2025 global consensus recommends avoiding irritants close to procedures and preparing high-risk skin before treatment ⁸. However, evidence for routine use of hydroquinone or other lightening agents remains inconsistent ⁸.
3. Device Selection: Choosing the right device is crucial. For hair reduction in Fitzpatrick types V and VI, long-pulsed 1064 nm Nd:YAG is generally the safest laser option due to its lower epidermal melanin absorption compared to shorter wavelengths ⁹. Diode systems may be used with care, while Alexandrite 755 nm and broad-spectrum IPL require much greater caution in dark or tanned skin ⁹.
4. Delayed Test Spot: A test spot must be performed using the same device, wavelength, body site, cooling method, and planned settings ¹⁰. The spot should be reviewed after enough time for any delayed pigment change to appear. One manufacturer protocol suggests a 1 to 2 week wait in Fitzpatrick IV to VI skin, but timing must follow specific device instructions ¹⁰.
5. Conservative Energy Delivery: Evidence from fractional laser treatments suggests that treatment density (the amount of skin covered) can be as important as, or more important than, energy per microbeam ¹¹. A study observed PIH in 43% of lower-density areas and 71% of higher-density areas with the same 40 mJ setting, emphasizing the importance of total tissue burden ¹¹.
6. Active Inflammation Control After Treatment: Post-treatment care includes managing inflammation. A split-face trial of 40 Fitzpatrick IV patients showed that PIH occurred on 75% of facial sides treated with petrolatum alone, compared to 40% of sides treated with two days of prescription clobetasol followed by petrolatum ¹². This supports short, clinician-directed anti-inflammatory care after selected ablative procedures, but not routine self-use of strong steroids ¹².

In addition to these steps, daily broad-spectrum sunscreen is a core component of care, with visible-light protection considered for patients prone to pigment changes ¹³. A small 2026 trial found that a tested sunscreen reduced induced pigmentation by about 16 Individual Typology Angle (ITA) degrees and improved secondary color measures by 48% to 87% in Fitzpatrick IV and V participants ¹³.

Analysis of Key Safety Challenges and Data

The Limitations of Fitzpatrick Type for Risk Assessment

The Fitzpatrick skin phototype classification system, while widely used, has significant limits for laser safety in darker skin. It was originally developed to describe how skin reacts to sun exposure (burning and tanning) rather than as a direct measure of epidermal melanin or laser injury risk ⁵. A 2025 Delphi study with 22 skin-of-color experts found 95% agreement that the Fitzpatrick system has important clinical and research limitations ⁵. This means clinics must go beyond a simple Fitzpatrick classification for a complete risk assessment. A comprehensive assessment should include the patient’s normal untanned skin color, current color, recent sun exposure, history of PIH, previous burns, scar history, the specific treatment site, target depth, and any current inflammation ². A person classified as Fitzpatrick type IV can have vastly different treatment risks depending on these other factors ².

Objective measurements are also crucial. The 2026 Lipnick study involved 789 participants and 33,856 assessments, revealing that depending on the method, 7%, 14%, 16%, 23%, or 26% of the same group could be classified as having dark skin ⁶. This demonstrates how subjective scales can significantly alter who is placed in a high-risk group ⁶. For clinics, this implies a need for structured intake forms that gather detailed pigment history and environmental changes, rather than relying solely on a Fitzpatrick dropdown menu ⁵. Repeatable photographs under consistent conditions (room, camera, distance, lighting, patient position) and, where possible, colorimetry or spectrophotometry, can provide more reliable data ⁶.

The specific diagnosis also plays a role in treatment response. Brown epidermal PIH and blue-gray dermal PIH, for instance, do not respond the same way to laser treatment ¹. Active inflammatory conditions should be managed before laser treatment. The 2025 global consensus advises against laser or IPL during active inflammatory stages of acquired dermal pigment disorders because treatment may worsen pigmentation ¹.

The Critical Role of Screening, Stabilization, and Test Spots

Implementing a rigorous pre-laser checklist for Fitzpatrick IV-VI skin is non-negotiable. This begins with a clear deferral gate. Laser treatment should be postponed if there is visible tanning, recent sunburn, active dermatitis, uncontrolled acne inflammation, or unresolved irritation ¹⁴. A 2025 FDA adverse event report described a tanned patient who developed burns after an operator switched from Nd:YAG to alexandrite, underscoring the risk of treating tanned skin ¹⁴.

Detailed patient history is another key element. Reviewing previous PIH, hypopigmentation, blistering, keloids, infection, and poor wound healing helps identify heightened risk ¹⁵. Medications and skin products should also be reviewed for factors that might increase light sensitivity, irritation, bleeding, infection, or delay healing ¹⁵.

The test spot is a vital safety measure. It must be performed in the actual treatment area, matching the planned wavelength, spot size, pulse width, fluence, cooling method, and number of passes ¹⁰. A Candela protocol, cited in an FDA report, suggests a 1 to 2 week waiting period for Fitzpatrick IV-VI or tanned skin before full treatment ¹⁰. However, this timing is an example, not a universal rule; practitioners must follow specific device instructions ¹⁰. High-risk consultations and test spots should be treated as separate stages, and clinics should factor the extra visit and waiting time into pricing and scheduling ¹⁴. Rushing consultations and immediate high-energy treatments can create unnecessary clinical risk ¹⁴.

Skin priming, which involves preparing the skin before treatment, is an area with mixed evidence. The 2025 global consensus supports using lightening agents for higher-risk procedures and avoiding irritants close to treatment ⁸. In contrast, a 2026 network analysis found no significant prevention benefit for whitening agents over sunscreen alone ³. One trial included in the review started topical care two weeks before laser, while 71.4% of interventions began after treatment ⁸. Despite these differences, beginning photoprotection before the procedure is advisable. A 2026 trial found about 16 ITA degrees of net protection from a broad-spectrum formula after combined inflammation and light exposure ¹³. Iron-oxide formulas have also shown better performance than non-tinted mineral SPF 50 products against visible-light pigmentation in Fitzpatrick IV skin ¹⁶.

Device Selection and Energy Delivery for Darker Skin

Selecting the appropriate laser device and settings is central to safety. For hair reduction in Fitzpatrick types V and VI, the long-pulsed 1064 nm Nd:YAG laser is the primary choice ⁹. Its longer wavelength means less absorption by epidermal melanin, making it safer than 755 nm alexandrite. Diode systems (around 800-810 nm) can be used cautiously in specific patients with good pulse control and cooling, but they offer less safety margin than 1064 nm in very dark or tanned skin ¹⁷.

Even with safer devices, risks remain. In a cohort of 150 Fitzpatrick IV-VI patients, long-pulsed Nd:YAG achieved a mean hair reduction of 54.3% after an average of 8.9 sessions ¹⁸. While 86% experienced no complications, temporary hyperpigmentation was the most common issue among those who did ¹⁸. A separate meta-analysis found paradoxical hair growth in 3% of laser and IPL hair removal patients, primarily on the face and neck, highlighting the importance of specific consent for these areas ¹⁹.

For pigment procedures, shorter wavelengths (e.g., 532 nm) interact strongly with epidermal pigment and demand heightened caution in Fitzpatrick V and VI skin ²⁰. The European laser position statement recommends using the minimum effective fluence in darker skin ²⁰. Low-fluence 1064 nm Nd:YAG may be considered for resistant pigment disorders, but repeated “laser toning” can cause mottled pigment loss ²⁰. For resurfacing, the goal is to reduce total tissue injury. Fractional rather than full-field treatment should be used when appropriate. Lower density, fewer passes, longer intervals between treatments, and avoiding pulse overlap help reduce accumulated inflammation ¹¹. Studies have shown significantly higher PIH rates with greater treatment density, even at the same energy settings ²¹.

Vascular procedures require their own distinct protocols. A review found only nine pulsed dye laser studies involving 241 Fitzpatrick IV-VI patients, indicating limited evidence ²². While benefits were possible, hyperpigmentation, hypopigmentation, and scarring remained concerns ²². Clinics must avoid reusing hair removal protocols for vascular or pigment treatment simply because the device platform is the same ²².

When hair lacks sufficient pigment, refusing laser treatment can be the safer choice. Some practices, like Bio2 Laser Studio, offer both laser hair reduction and electrolysis ²³. This allows patients with blonde, red, gray, white, or very fine hair to receive effective treatment without relying on light absorption by hair pigment ²³. Electrolysis, while not laser, still causes local tissue injury and requires its own PIH prevention measures ²³.

Treatment-Day Protocols and Safety Measures

The procedures followed on the day of treatment are as important as the laser machine itself. Every session must begin with a formal time-out to confirm the patient, treatment area, diagnosis, device, wavelength, handpiece, spot size, pulse width, fluence, cooling setting, and the result of the test spot ²⁴. The device screen and handpiece should be checked before the first pulse and after any interruption or mode change ²⁴. This is a direct lesson from FDA reports detailing wrong wavelength selection incidents, which can lead to serious injuries like burns ¹⁴.

Accurate and thorough documentation is essential. Every setting and clinical endpoint must be recorded in a laser log, including current skin color, tan status, skin preparation, cooling, number of passes, overlap pattern, pain response, and immediate tissue response ²⁵. This ensures that any future operator can reconstruct the session without relying on memory alone ²⁵. It is crucial not to copy fluence numbers from papers or other devices, as pulse shape, handpiece calibration, spot size, cooling, repetition rate, and beam profile can all affect the skin’s reaction ¹⁴.

Limiting heat accumulation is another key aspect. This involves using mapped passes, preventing unplanned overlap, and allowing adequate cooling between adjacent pulses as required by the device ¹¹. This clinical inference comes from fractional studies showing increased PIH with greater skin coverage and from reviews linking PIH to thermal injury and inflammation ¹¹. Cooling methods must be applied precisely according to device validation and while skin response remains visible to the operator ²⁶. Cooling cannot correct an incorrect wavelength or an excessive setting ²⁶. While the 2026 network analysis favored epidermal cooling over sunscreen alone, the 2025 skin-of-color review found that some cooling-air approaches worsened outcomes ²⁶. This highlights the need for method-specific adherence to instructions rather than blanket rules.

Operators must know when to stop treatment. Blistering, epidermal lifting, sharply patterned discoloration, or pain out of proportion to the expected response are immediate stop criteria ²⁷. Eye protection is also a mandatory safety control. A 2026 review reported ocular complications in about 2.1% of a 70-case periocular subset, underscoring the importance of proper eye safety ²⁷.

Post-Treatment Care and Early PIH Detection

Aftercare plays a vital role in preventing PIH and managing any early signs. The immediate goal is to reduce inflammation and protect the skin barrier ¹². The wound care method specified for the procedure should be used, often a bland occlusive for ablative treatments ¹². Patients should be advised to avoid rubbing, picking, excessive heat, unapproved acids, retinoids, exfoliation, and fragranced products while the skin barrier is healing ¹².

Short-term, prescription anti-inflammatory treatment can be beneficial after selected ablative procedures. The 40-person Fitzpatrick IV trial showed that two days of clobetasol reduced PIH incidence from 75% to 40% ¹². However, clobetasol is a strong steroid, and its facial misuse can cause harm; therefore, such regimens should remain under the control of a qualified prescriber ¹².

Sunscreen should be considered base care, regardless of differing opinions in prevention reviews ²⁸. While a 2026 network analysis found sunscreen alone ineffective against placebo in its network, the 2025 skin-of-color review found sunscreen to be the only measure with consistent prevention results ²⁸. Controlled light-exposure studies also confirm that ultraviolet and visible light can deepen pigment ²⁸.

Tranexamic acid is an emerging medical option, not a standard spa protocol. Intradermal treatment showed a relative risk of 0.02 against sunscreen in the 2026 analysis, but the included trials were small, and injection discomfort and bruising were reported ²⁹. Oral or injected use requires medical assessment ²⁹.

Delayed follow-up is critical for early detection of PIH. A practical schedule includes a photo check at 48 to 72 hours, another at 7 to 14 days, and reassessment before the next session ³⁰. This timing is based on studies that followed patients at various intervals, allowing time for inflammation or new pigment to develop ³⁰. If PIH appears, further energy treatment should stop ³¹. Active inflammation or acne should be treated, photoprotection strengthened, and appropriate topical care initiated under local clinical rules ³¹. The global consensus advises topical treatments first, reserving laser or peels for resistant cases, as immediate repeat laser treatment can worsen the initial injury ³¹.

Measuring and Improving Clinical Safety Systems

To ensure continuous improvement, clinics need to implement measurable safety systems. This means maintaining separate, detailed protocols for each device, wavelength, indication, body site, and skin-risk group ²⁵. Each protocol should clearly define deferral rules, test-spot procedures, permitted starting ranges, cooling requirements, acceptable endpoints, stop criteria, follow-up timing, and escalation steps ²⁵. There should not be a single Fitzpatrick IV-VI parameter chart ²⁵.

Tracking denominator-based outcomes is vital for objective assessment. Useful measures include the percentage of eligible patients receiving test spots, the number of recent-tan deferrals, PIH rates at 2 and 6 weeks, burns or blisters per 1,000 sessions, hypopigmentation events, unplanned medical referrals, and adverse events broken down by operator, device, wavelength, site, and measured skin color ²⁵. Inconsistent reporting in the literature is a key reason why current complication estimates vary widely ²⁵.

Training events and mode-selection errors should be audited regularly. FDA cases show that a machine cleared for darker skin can still cause injury if the operator selects the wrong wavelength, treats a tan, skips a test spot, or fails to follow instructions ¹⁴. Device clearance means it can be used safely, not that it will always be operated safely ¹⁴.

Pricing and consent must be carefully managed. Conservative settings often mean more sessions are needed. The 150-patient Nd:YAG cohort for hair reduction, for example, averaged 8.9 treatments for a 54.3% mean reduction ¹⁸. Clinics should avoid promising one-session results and clearly explain the potential need for maintenance treatments, electrolysis, topical care, or specialist referral ¹⁸.

Finally, clinics can help address the Fitzpatrick VI evidence gap through strong internal reporting. No Fitzpatrick VI patients were included in the 2025 prevention review, and only 6% of classified participants in the broader 2024 treatment review were Fitzpatrick VI ⁴, ³². Clinics that serve diverse populations can gather valuable safety data, provided it is collected with consent, consistent definitions, and objective color measurements ⁴.

For example, Bio2 Laser Studio lists both laser hair reduction and electrolysis services ²³. While its public site does not provide audited PIH rates, burn rates, or outcomes by skin tone, this operational model of offering multiple treatment modalities is valuable ²³. Bio2 Laser Studio and similar clinics could enhance public trust by reporting clear, denominator-based safety measures without turning the data into promotional claims ³³.

Conclusion and Outlook

The 2026 clinical playbook for preventing PIH in Fitzpatrick IV-VI skin types is not a rigid set of rules but a flexible framework built on current best practices and emerging evidence. It moves beyond a simplistic reliance on Fitzpatrick type toward a comprehensive risk assessment that considers individual patient factors, specific device capabilities, and a careful, step-by-step approach from pre-treatment screening to post-treatment care. The increasing understanding of tissue burden, the importance of delayed test spots, and the cautious use of anti-inflammatory measures highlight a maturing field. While significant gaps remain in the evidence base, especially for Fitzpatrick type VI, continuous data collection, transparent reporting, and adherence to structured safety protocols are essential for providing safer and more effective laser treatments for all patients.

The subsequent sections of this report will provide a more detailed exploration of each step outlined in this executive summary, offering deeper insights into the specific methodologies, supporting evidence, and practical considerations for implementation.

Summary Table of Key Data Points

Key Metric	Finding/Statistic	Source
Expert agreement on Fitzpatrick limits	95% of 22 experts agreed or strongly agreed on limits of Fitzpatrick system 5	Delphi Study, 2025 5
Objective vs. subjective skin ratings	789 participants, 33,856 assessments showed varying “dark skin” classifications (7%-26%) based on method 6	Lipnick et al., 2026 6
Randomized controlled trials for PIH prevention	14 trials included in 2026 network meta-analysis (11 suitable for comparison) 3	Lasers in Surgery and Medicine, 2026 3
Procedure-linked prevention cases (PIH)	369 cases in 2025 review; 95.4% laser-related, 85.3% on face 4	Mar et al., 2025 4
Fitzpatrick VI representation in prevention review	0% of classified participants (339 cases) were Fitzpatrick VI 4	Mar et al., 2025 4
PIH treatment evidence (skin of color)	1,356 patients in 2024 review; 40% F IV, 34% F V, 6% F VI 32	Journal of Cutaneous Medicine and Surgery, 2024 32
Post-laser steroid trial (PIH reduction)	PIH fell from 75% (petrolatum only) to 40% (clobetasol + petrolatum) in 40 F IV patients 12	Cheyasak et al., 2015 12
Low-density fractional laser PIH rate	2.2% PIH across 181 sessions (119 F III-V patients) with 1550 nm fractional laser 21	Ramathibodi Laser Center, 2011 21
Impact of treatment density on PIH	Same energy (40 mJ): 43% PIH at lower density vs. 71% at higher density 11	Summarized in 2017 review 11
Long-pulsed Nd:YAG hair reduction	54.3% mean hair reduction in 150 F IV-VI patients over 8.9 sessions 18	Journal of Cutaneous and Aesthetic Surgery, 2011 18
Paradoxical hair growth (pooled prevalence)	3% overall in laser/IPL hair removal; 0.08% for non-facial/non-neck 19	Meta-analysis, 2021 19
Pulsed dye laser evidence in F IV-VI	9 studies, 241 patients in 2023 review; limited data, concerns for PIH/hypopigmentation 22	Journal of Cutaneous Medicine and Surgery, 2023 22
Sunscreen net protection (induced pigmentation)	About 16 ITA degrees net protection in 20 F IV/V participants 13	Dermatology and Therapy, 2026 13

References

1. Global consensus on the management of melanin hyperpigmentation disorders. Journal of the European Academy of Dermatology and Venereology. December 2025. ^[1]
2. Special considerations for darker-skinned patients. PubMed. ^[2]
3. Interventions to Prevent Postinflammatory Hyperpigmentation After Laser and Energy-Based Device Treatments: A Systematic Review and Network Meta-Analysis. Lasers in Surgery and Medicine, PubMed Central. 2026. ^[3]
4. Prevention of Post-Inflammatory Hyperpigmentation in Skin of Colour: A Systematic Review. Australasian Journal of Dermatology. May 2025. ^[4]
5. Beyond Fitzpatrick Skin Types: A Delphi Consensus on Key Considerations for a Universal Skin Typing Classification. Journal of the American Academy of Dermatology and Skin of Color Society. 2025. ^[5]
6. Comparison of Methods for Characterizing Skin Pigment Diversity in Research Cohorts. British Journal of Dermatology. January 6, 2026. ^[6]
7. Global consensus on the management of melanin hyperpigmentation disorders. Journal of the European Academy of Dermatology and Venereology. December 2025. ^[7]
8. Global consensus on the management of melanin hyperpigmentation disorders. Journal of the European Academy of Dermatology and Venereology. December 2025. ^[8]
9. Laser and Light Treatments for Hair Reduction in Fitzpatrick Skin Types IV-VI: A Comprehensive Review of the Literature – PubMed. ^[9]
10. MAUDE Adverse Event Report: CANDELA GENTLEMAX PRO; GMAX PRO. U.S. Food and Drug Administration. ^[10]
11. Nonablative Fractional Laser Resurfacing in Skin of Color: Evidence-based Review – PMC. 2017. ^[11]
12. Topical corticosteroids minimise the risk of postinflammatory hyper-pigmentation after ablative fractional CO2 laser resurfacing in Asians – PubMed. February 2015. ^[12]
13. An Investigator-Blinded, Randomized Trial of a Broad-Spectrum Sunscreen Containing Sclareolide and Niacinamide for the Prevention of Post-Inflammatory Hyperpigmentation in Skin of Color – PubMed. January 2026. ^[13]
14. MAUDE Adverse Event Report: EL.EN. ELECTRONIC ENGINEERING S.P.A. ELITE IQ. U.S. Food and Drug Administration. ^[14]
15. Complications of dermatologic lasers in high Fitzpatrick phototypes and management: an updated narrative review – PubMed. ^[15]
16. Impact of Iron-Oxide Containing Formulations Against Visible Light-Induced Skin Pigmentation in Skin of Color Individuals – PubMed. July 1, 2020. ^[16]
17. Lasers and light-based therapies in ethnic skin: treatment options and recommendations for Fitzpatrick skin types V and VI. PubMed. ^[17]
18. Long-pulsed Nd:YAG laser-assisted hair removal in Fitzpatrick skin types IV-VI – PubMed. 2011. ^[18]
19. Paradoxical Hypertrichosis Associated With Laser and Light Therapy for Hair Removal: A Systematic Review and Meta-Analysis. Journal of Drugs in Dermatology. 2021. ^[19]
20. Laser treatment of hyperpigmented lesions: position statement of the European Society of Laser in Dermatology – Passeron – 2019 – Journal of the European Academy of Dermatology and Venereology – Wiley Online Library. ^[20]
21. Side effects and complications of fractional 1550 nm erbium fiber laser treatment among Asians. Journal of Cosmetic Dermatology. 2011. ^[21]
22. A Review of Treatment of Port-Wine Stains With Pulsed Dye Laser in Fitzpatrick Skin Type IV to VI. Journal of Cutaneous Medicine and Surgery. 2023. ^[22]
23. Laser Hair Removal | Electrolysis | RF Body Contouring. Bio2 Laser Studio. Accessed August 2026. ^[23]
24. Facial laser complications (A Five Year Review) | Lasers in Medical Science | Springer Nature Link. ^[24]
25. Facial laser complications (A Five Year Review) | Lasers in Medical Science | Springer Nature Link. ^[25]
26. Interventions to Prevent Postinflammatory Hyperpigmentation After Laser and Energy-Based Device Treatments: A Systematic Review and Network Meta-Analysis – PMC. 2026. ^[26]
27. Facial laser complications (A Five Year Review) | Lasers in Medical Science | Springer Nature Link. ^[27]
28. Interventions to Prevent Postinflammatory Hyperpigmentation After Laser and Energy-Based Device Treatments: A Systematic Review and Network Meta-Analysis – PMC. 2026. ^[28]
29. Interventions to Prevent Postinflammatory Hyperpigmentation After Laser and Energy-Based Device Treatments: A Systematic Review and Network Meta-Analysis – PMC. 2026. ^[29]
30. Topical corticosteroids minimise the risk of postinflammatory hyper-pigmentation after ablative fractional CO2 laser resurfacing in Asians – PubMed. February 2015. ^[30]
31. Global consensus on the management of melanin hyperpigmentation disorders. Journal of the European Academy of Dermatology and Venereology. December 2025. ^[31]
32. Treatment of Post-Inflammatory Hyperpigmentation in Skin of Colour: A Systematic Review – PMC. 2024. ^[32]
33. Laser Hair Removal | Electrolysis | RF Body Contouring. Bio2 Laser Studio. Accessed August 2026. ^[33]

2. Introduction to Laser Safety for Darker Skin

Providing safe and effective laser treatments for individuals with darker skin tones, specifically Fitzpatrick Skin Types IV to VI, presents particular challenges. These challenges stem from the biological differences in melanin distribution and absorption in darker skin compared to lighter skin types. Melanin, the pigment that gives skin its color, is present in higher concentrations in the epidermis of individuals with Fitzpatrick IV to VI skin. This epidermal melanin strongly absorbs laser energy, especially at shorter wavelengths. While this absorption is essential for targeting specific chromophores like hair melanin or pigmented lesions, it also carries a higher risk of unintended epidermal heating. When the epidermal melanin absorbs too much laser energy, it can lead to thermal injury, inflammation, and undesirable side effects such as post-inflammatory hyperpigmentation (PIH), burns, or even permanent pigment loss ^[3]. The core safety problem lies in the narrow margin between effective treatment and tissue damage ^[3].

The current field of laser safety protocols for darker skin is not standardized. As of August 29, 2026, no single international standard exists specifically titled the “Fitzpatrick IV to VI Laser Safety Protocol” ^[1]. Instead, practitioners must rely on a combination of consensus reports from expert panels, results from controlled clinical trials, specific device instructions, and data from adverse event reports ^[1]. This complex situation requires a clinical playbook that offers adaptable guidance rather than fixed settings, acknowledging that laser parameters cannot be universally applied across different devices, treatment indications, body sites, or individual patients ^[1].

The focus of this clinical playbook for 2026 is to address the safety concerns related to epidermal melanin absorption and to provide structured steps for minimizing risks, particularly the risk of PIH. PIH is a common and distressing complication in darker skin, characterized by darkening of the skin in areas of previous injury or inflammation. Preventing PIH requires a comprehensive approach that considers patient factors, device selection, treatment techniques, and post-procedure care. This introduction defines the scope of this playbook by highlighting the need for a multi-faceted risk assessment that goes beyond simple skin typing, emphasizing proactive measures, and detailing the current evidence base for laser safety in Fitzpatrick IV to VI skin.

The Limitations of the Fitzpatrick Skin Type System in Laser Safety

The Fitzpatrick Skin Type (FST) system was developed in 1975 by Thomas B. Fitzpatrick to classify skin based on its response to sun exposure, specifically how it burns and tans ^[16]. While it has been widely adopted in dermatology and aesthetic medicine, its utility as the sole determinant for laser safety, especially in darker skin, has significant limitations. A 2025 Delphi study, which involved 22 skin-of-color experts, revealed that 95% of these experts agreed that the current Fitzpatrick system has clinical and research limits ^[6]. This strong consensus underscores the need for a more detailed and objective approach to risk assessment in 2026 and beyond.

The fundamental issue is that the Fitzpatrick system was not designed as a direct measure of epidermal melanin content or as a precise predictor of laser injury risk ^[16]. Instead, it offers a broad categorization that may not capture the nuances of individual skin physiology, tanning history, or specific treatment parameters. For instance, a person classified as Fitzpatrick IV can present with a wide range of actual melanin content and varied responses to laser treatment depending on recent tanning, the specific body area being treated, any prior skin injuries, and the wavelength of laser light used ^[18]. This variability means that relying solely on a Fitzpatrick type can lead to either overly cautious treatment settings that are not effective or, conversely, settings that are too aggressive, increasing the risk of adverse events.

Subjective nature further compounds the issue. The classification often relies on a patient’s self-assessment or a clinician’s visual estimation. A 2026 study involving 789 adults highlighted large differences between subjective skin ratings and objective color measurements ^[7]. Lipnick and colleagues observed that depending on the assessment method used, the percentage of individuals classified as having “dark skin” within the same cohort varied significantly: 7% by a stricter objective threshold, 14% by another objective threshold, 16% by Monk Skin Tone, 23% by perceived FST, and 26% by perceived FST for very dark skin ^[17]. These discrepancies demonstrate that subjective scales can dramatically alter which patients are placed into a high-risk category, potentially leading to misclassification and inappropriate treatment plans ^[17].

To address these limitations, a comprehensive risk assessment for laser treatments in darker skin must incorporate multiple inputs beyond just Fitzpatrick type. This should include detailed documentation of the patient’s normal untanned skin color, current skin color (accounting for any recent sun exposure), a history of PIH, prior burns or scarring, current inflammation, and any medications that might affect light sensitivity or healing ^[3]. Objective measurements, such as colorimetry or spectrophotometry, can provide valuable data when available, offering a more precise and repeatable assessment of skin pigment ^[18]. Repeatable photographs, taken under consistent lighting and positioning, can also serve as a crucial tool for baseline assessment and monitoring of treatment outcomes ^[18]. The diagnosis of the condition being treated also plays a pivotal role; for example, brown epidermal PIH requires a different approach than blue-gray dermal PIH ^[18]. Active inflammatory conditions in the treatment area should be controlled before any elective laser procedures, as treatment during an inflammatory stage can worsen pigmentation ^[3].

Therefore, for clinics like Bio2 Laser Studio and others offering laser services, the implication is clear: a structured intake form that gathers comprehensive data is essential. This form should move beyond a simple Fitzpatrick dropdown menu to include a more detailed pigment history and environmental exposure information. Patients should be informed that a thorough consultation might lead to a deferral of treatment, a recommendation for topical treatments first, the need for a test spot, or the suggestion of an alternative device or procedure, such as electrolysis for hair removal, if laser is deemed too risky for their skin and hair combination. This approach ensures that treatment decisions are based on a holistic understanding of the patient’s risk factors rather than a single, potentially misleading, skin classification ^[16].

The Central Safety Challenge: Epidermal Melanin Absorption

The central safety challenge in laser treatments for Fitzpatrick IV to VI skin is the absorption of laser energy by epidermal melanin ^[3]. Melanin is the primary chromophore (light-absorbing molecule) in the skin. In darker skin, there is a higher concentration of melanin in the epidermis, the outermost layer of the skin ^[3]. When laser light passes through the epidermis to reach its target chromophore (e.g., hair follicle melanin for hair reduction, or deeper dermal pigments), a significant portion of its energy can be absorbed by the epidermal melanin itself.

This absorption is a two-edged sword. While it allows for effective treatment of pigmented targets, it also creates a narrow therapeutic window ^[3]. The margin between an effective dose of laser energy that targets the desired chromophore and an excessive dose that causes unwanted heating of the surrounding epidermal melanin is smaller in darker skin types. If too much energy is absorbed by the epidermis, it can result in complications such as:

• Excess Heat and Inflammation: Overheating of the epidermis triggers an inflammatory response.
• Burns: Severe overheating can lead to epidermal burns, which are painful and can increase the risk of infection and scarring.
• Post-Inflammatory Hyperpigmentation (PIH): This is one of the most common and challenging adverse effects in darker skin. Inflammation or injury to the skin can stimulate melanocytes (melanin-producing cells) to produce more pigment, leading to dark patches that can last for months or even years.
• Loss of Pigment (Hypopigmentation or Depigmentation): In some cases, damage to melanocytes can lead to a reduction or complete loss of pigment, resulting in lighter patches of skin.

None of these side effects makes treatment risk-free ^[3]. The presence of these risks necessitates specific protocols and precautions. The strategies to mitigate this central safety problem include:

1. Using Longer Wavelengths: Longer laser wavelengths, such as the 1064 nm Nd:YAG laser, are absorbed less by epidermal melanin compared to shorter wavelengths like 755 nm Alexandrite or broad-spectrum intense pulsed light (IPL) ^[4]. This allows the energy to penetrate deeper into the skin with less epidermal heating, reaching targets like hair follicles more safely. For hair reduction in Fitzpatrick V and VI, the long-pulsed 1064 nm Nd:YAG is generally the safest starting point ^[4]. Diode systems may be used cautiously, but Alexandrite and IPL require much greater caution in dark or tanned skin ^[4].
2. Conservative Settings: Employing lower fluences (energy density), longer pulse durations, and reduced treatment densities can minimize the heat generated in the epidermis ^[8]. For example, fractional laser evidence suggests that treatment density (the amount of skin covered by microbeams) can be as important, or even more important, than the energy per microbeam ^[8]. A study showed PIH in 43% of lower-density areas compared to 71% in higher-density areas, even with the same 40 mJ setting ^[8].
3. Controlled Skin Coverage: In fractional laser treatments, carefully managing the treatment density and avoiding excessive overlap between pulses can prevent heat accumulation in the epidermis. Studies have shown that lower treatment density and less overlap can lead to fewer PIH events, even with higher energy per treatment point ^[12].
4. Epidermal Cooling: Effective cooling of the skin surface before, during, and after laser pulse delivery can draw heat away from the epidermis, protecting it from thermal damage ^[3]. Cooling methods include contact cooling, cryogen spray, and chilled air. However, cooling data can appear to conflict, with some studies reporting worse outcomes with certain cooling-air protocols ^[1]. Therefore, cooling should be applied precisely according to device instructions and validated methods ^[1].

Despite these measures, laser treatment in darker skin is never entirely risk-free ^[3]. The physiological realities of melanin absorption mean that careful patient selection, careful technique, and realistic patient expectations are critical components of a safe and effective treatment plan.

The Six-Step Clinical Playbook for Preventing PIH in 2026

Given the absence of a single international standard protocol for Fitzpatrick IV-VI skin, a structured, step-by-step clinical playbook becomes essential. This playbook is built from current consensus reports, clinical trials, device instructions, and adverse event data. It outlines a systematic approach to minimizing the risk of PIH and other complications, moving from initial patient assessment to post-treatment care.

Step 1: Diagnosis and Risk Screening

The initial and most critical step is a thorough diagnosis and risk screening. This goes beyond simple skin typing and involves a detailed evaluation of the patient’s skin, medical history, and lifestyle ^[18].

• Confirm the Treatment Target: Clearly identify what is being treated (e.g., hair, pigment, vascular lesion) and ensure the chosen laser is appropriate for that target ^[3].
• Document Prior PIH or Scarring: A history of PIH, hypopigmentation, blistering, keloids, or poor wound healing significantly increases the risk of recurrence and should inform treatment decisions ^[19].
• Assess Current Skin Status: Note any current inflammation (e.g., active acne, dermatitis), recent tanning, or sunburn in the treatment area ^[3]. These conditions are contraindications for elective laser treatment.
• Review Medications and Products: Identify any medications (oral or topical) or skincare products that might increase photosensitivity, irritation, bleeding, or impair healing ^[19]. Patients should not stop prescription drugs without consulting their prescriber ^[19].
• Determine Normal Untanned Skin Color: Establish the patient’s baseline skin color, as recent tanning can increase epidermal melanin and elevate risk ^[3]. Repeatable photographs with consistent lighting and patient positioning are recommended for documentation ^[18]. Objective color measurements using devices like colorimeters or spectrophotometers can also provide valuable data where available ^[18].
• Consider the Diagnosis: Different types of pigmentation (e.g., epidermal PIH vs. dermal PIH) respond differently to laser treatment. Active inflammatory conditions should be managed before laser treatment ^[18]. The 2025 global consensus advises against laser or IPL during active inflammatory stages of acquired dermal pigment disorders ^[3].

For example, if a patient presents with existing PIH, laser treatment should usually follow topical management rather than being the first line of therapy ^[3]. This structured approach helps in making informed decisions and setting realistic patient expectations.

Step 2: Stabilization

Before any laser procedure, the skin needs to be in a stable, non-inflamed state. This step focuses on preparing the skin and avoiding conditions that elevate risk.

• Defer Treatment for Recent Tan or Active Inflammation: Elective laser treatment should be deferred if there is a recent tan, sunburn, active dermatitis, or uncontrolled inflammation (e.g., active acne) in the treatment area ^[3]. An FDA adverse event report from 2025 described burns in a tanned patient after an operator switched from Nd:YAG to Alexandrite laser ^[20].
• Avoid Irritants: The 2025 global consensus recommends avoiding irritants (e.g., retinoids, strong acids, abrasive scrubs) close to procedures ^[3]. This helps reduce skin sensitivity and the potential for an exaggerated inflammatory response.
• Skin Priming (Mixed Evidence): While the 2025 global consensus suggests preparing high-risk skin with lightening agents (e.g., hydroquinone) before treatment, the evidence for routine use of these agents remains mixed ^[3]. A 2026 network analysis found no significant prevention benefit for whitening agents over sunscreen monotherapy ^[1]. If used, such priming should begin several weeks before the laser session.
• Initiate Photoprotection: Begin daily broad-spectrum sunscreen use (with visible-light protection for pigment-prone patients) before the procedure, rather than waiting for pigment changes ^[15]. A 2026 trial in 20 Fitzpatrick IV and V participants showed that a tested sunscreen provided about 16 Individual Typology Angle degrees of net protection against induced pigmentation ^[15]. Iron-oxide formulas have also shown superior performance against visible light-induced pigmentation in Fitzpatrick IV skin compared to non-tinted mineral SPF 50 products ^[21].

High-risk consultations and test spots should be treated as distinct workflow stages, requiring separate appointments and waiting periods. Clinics need to build this extra time into their scheduling and pricing, ensuring that sales pressure does not compromise clinical safety ^[20].

Step 3: Device Selection

Choosing the correct laser device and wavelength is fundamental for safe treatment in darker skin. The goal is to maximize absorption by the target chromophore while minimizing absorption by epidermal melanin.

• Wavelength for Hair Reduction: For hair reduction in Fitzpatrick V and VI skin, the long-pulsed 1064 nm Nd:YAG laser is generally considered the safest starting point ^[4]. Its longer wavelength penetrates deeper with less absorption by epidermal melanin ^[4]. Diode systems (around 800-810 nm) can be used cautiously with appropriate pulse control and cooling, but they offer a smaller safety margin than 1064 nm in very dark or tanned skin ^[22]. Alexandrite (755 nm) and broad-spectrum IPL require significantly greater caution ^[4].
• Understanding “Safer” Does Not Mean Risk-Free: Even with the safest devices, complications can occur. In a retrospective study of 150 Fitzpatrick IV to VI patients treated with long-pulsed Nd:YAG for hair reduction, the mean hair reduction was 54.3% after an average of 8.9 sessions ^[13]. While 86% had no complications, temporary hyperpigmentation was the most frequent complication among those who did ^[13]. Additionally, paradoxical hair growth (increased hair growth after laser treatment) occurred in 3% of laser and IPL hair removal patients in a meta-analysis, primarily on the face and neck ^[14].
• Wavelengths for Pigment Procedures: Shorter wavelengths, such as 532 nm, interact strongly with epidermal pigment and demand extreme caution in Fitzpatrick V and VI skin ^[23]. The European laser position statement recommends using the minimum effective fluence in darker skin ^[23]. Low-fluence 1064 nm Nd:YAG might be considered for resistant pigment disorders, but repeated “laser toning” can lead to mottled pigment loss ^[23].
• Resurfacing Procedures: For resurfacing, fractional rather than full-field treatment is generally preferred where clinically suitable, as it reduces total tissue injury ^[23]. Techniques like lower density, fewer passes, longer intervals between sessions, and avoiding pulse overlap help reduce accumulated inflammation and PIH risk ^[24]. Studies comparing lower-density versus higher-density fractional methods reported PIH rates of 7.1% versus 12.4% and 43% versus 71%, respectively ^[12].
• Vascular Procedures: These require specific protocols. A review found only nine pulsed dye laser studies involving 241 Fitzpatrick IV to VI patients ^[14]. While benefits were possible, hyperpigmentation, hypopigmentation, and scarring remained concerns ^[14]. A hair removal protocol should never be adapted for vascular or pigment treatment simply because the device platform is the same.
• Consider Alternatives: When hair lacks enough pigment (e.g., blonde, red, gray, white, or very fine hair), laser treatment is ineffective. In such cases, refusing laser treatment and recommending alternative methods, like electrolysis, is the safer choice. Bio2 Laser Studio, for example, offers both laser hair reduction and electrolysis, providing an alternative that does not rely on light absorption by hair pigment ^[18]. Electrolysis still causes local tissue injury and requires its own PIH controls ^[18].

Step 4: Delayed Test Spot

A test spot is a non-negotiable safety measure, particularly for Fitzpatrick IV to VI skin. It allows the clinician to observe the skin’s response to specific laser settings before treating a larger area.

• Procedure: The test spot must be performed in the actual treatment area using the exact device, wavelength, body site, cooling method, and planned settings ^[5].
• Timing: A critical aspect is the delayed review of the test spot. Unlike lighter skin where immediate reactions might suffice, darker skin can exhibit delayed pigment changes. One manufacturer protocol cited in an FDA report suggested a 1 to 2 week waiting period in Fitzpatrick IV to VI or tanned skin before full treatment ^[5]. This timing must always follow the specific device instructions and clinical judgment, as immediate checks alone are insufficient for facial protocols where PIH is a dominant concern ^[3].
• Purpose: The test spot helps determine the skin’s sensitivity, identify appropriate endpoints, and establish the safest and most effective parameters for the patient’s unique skin type and condition.

Step 5: Conservative Energy Delivery

During the actual treatment session, careful attention to energy delivery is essential to prevent heat accumulation and minimize inflammation.

• Formal Time-Out: Begin each treatment with a formal time-out. This involves confirming the patient, treatment area, diagnosis, device, wavelength, handpiece, spot size, pulse width, fluence, cooling setting, and the results of the test spot ^[25]. The screen and handpiece should be checked before the first pulse and after any interruption or mode change. This prevents errors like using the wrong wavelength, as seen in FDA reports ^[20].
• Record Every Setting: Maintain a detailed laser log for each session, documenting current skin color, tan status, skin preparation, cooling method, number of passes, overlap pattern, pain response, and immediate tissue response ^[26]. This ensures that future operators can reconstruct the session accurately without relying on memory ^[26].
• Do Not Copy Fluence Numbers: Fluence numbers from research papers or other devices cannot be directly applied. Factors such as pulse shape, handpiece calibration, spot size, cooling efficacy, repetition rate, and beam profile can all influence the skin’s response to a given fluence ^[27]. For example, an FDA case involved a tanned patient who developed burns and blisters after being treated with a 755 nm Alexandrite laser at 15 J/cm², 20 ms, and an 18 mm handpiece, despite starting treatment with a safer Nd:YAG ^[20].
• Limit Heat Accumulation: Use mapped passes, avoid unplanned overlap, and allow adequate cooling time between adjacent pulses as per device instructions. This helps prevent excessive heat buildup, which is a significant contributor to PIH ^[28]. Studies on fractional lasers demonstrate that greater skin coverage leads to more PIH, highlighting the importance of managing total tissue injury ^[8].
• Appropriate Cooling: Cooling methods should strictly adhere to validated procedures for the specific device ^[1]. Cooling should be applied in a way that protects the epidermis but still allows the operator to observe immediate skin responses. It is a protective measure, not a corrective one for wrong wavelengths or excessive settings ^[1].
• Recognize Stop Criteria: Immediately stop treatment if blistering, epidermal lifting, sharply patterned discoloration, or disproportionate pain occurs ^[29]. Eye protection is mandatory for both patient and operator ^[29].

Step 6: Active Inflammation Control After Treatment

Post-treatment care is crucial for minimizing inflammation and preventing PIH.

• Calm Inflammation and Protect Barrier: The primary goal is to reduce inflammation and protect the skin barrier. Use the wound care method specified for the procedure, often a bland occlusive like petrolatum for ablative treatments ^[9]. Patients should avoid rubbing, picking, excessive heat, unapproved acids, retinoids, exfoliation, and fragranced products while the skin barrier is impaired ^[9].
• Prescription Anti-inflammatory Treatment: For selected ablative procedures, short-term use of prescription anti-inflammatory treatments can be beneficial. A split-face trial in 40 Fitzpatrick IV patients showed that two days of prescription clobetasol (a strong steroid) followed by petrolatum reduced PIH from 75% to 40% compared to petrolatum alone ^[9]. However, strong facial steroids like clobetasol require medical supervision to prevent misuse and adverse effects ^[9]. This regimen should not become a standard retail instruction.
• Consistent Sunscreen Use: Daily broad-spectrum sunscreen is foundational post-treatment care ^[1]. Even though prevention reviews might show conflicting results on sunscreen monotherapy’s efficacy against placebo in a network analysis ^[1], other reviews find it to be a consistent preventive measure ^[1]. Controlled light-exposure studies confirm that UV and visible light can deepen pigment ^[1].
• Emerging Medical Options (Tranexamic Acid): Intradermal tranexamic acid shows promise as an emerging medical option, with a relative risk of 0.02 against sunscreen in a 2026 analysis ^[2]. However, trials were small, and it requires medical assessment and trained administration, not routine salon use ^[2].
• Delayed Follow-Up: Implement a schedule for delayed follow-up to detect delayed pigment changes early ^[30]. Practical schedules include photo checks at 48-72 hours, another at 7-14 days, and reassessment before the next session ^[30]. Treatment should not be repeated if inflammation or new pigment is still developing ^[30].
• Manage Appearing PIH: If PIH develops, immediately stop further energy treatment ^[3]. Focus on managing active inflammation or acne, strengthening photoprotection, and initiating appropriate topical care under local clinical guidance. Immediate repeat laser treatment can worsen the initial injury and deepen pigmentation ^[3]. The global consensus prioritizes topical treatments first, reserving laser or peels for resistant cases ^[3].

The Evidence Base: Small but Growing

The evidence base specifically on PIH prevention in Fitzpatrick IV to VI skin is still developing. A 2025 systematic review, for instance, included 369 cases of PIH following procedures ^[1]. However, it found that 100% of the reported ethnicity was Asian, only 4.1% of classified participants were Fitzpatrick V, and none were Fitzpatrick VI ^[1]. This highlights a significant gap in the literature: evidence for protocols becomes thinner as skin pigmentation increases, particularly for Fitzpatrick VI skin ^[1]. Consequently, protocols for Fitzpatrick VI largely depend on understanding skin physiology, insights from small studies, expert opinion, and cautious clinical practice ^[1]. Claims of proven Fitzpatrick VI safety should therefore be approached with caution ^[4].

Despite these limitations, the field is progressing. A 2026 network meta-analysis searched for evidence on interventions to prevent PIH after laser and energy-based device treatments. It included 14 randomized controlled trials, with 11 suitable for network comparison ^[1]. This marks a shift from solely narrative advice to comparative evidence. However, this trial base remains small given the vast number of devices, settings, indications, and skin tones in use ^[1]. This means no single preventive regimen can be declared a universal standard ^[1].

Furthermore, a 2024 systematic review on PIH treatment in skin of color reported more diverse representation: 40% Fitzpatrick IV, 34% V, and 6% VI among cases with phototype data ^[5]. Of participants with reported race or ethnicity, 70% were Black, 27% Asian, and 3% Hispanic or Latin ^[5]. While this shows better representation in treatment studies, treatment results cannot be automatically assumed to answer prevention questions ^[5]. These reviews indicate that while laser can offer partial improvement in 66% of treated patients and complete resolution in a subgroup (up to 26% in one review, but lower in others), worsening PIH can also occur ^[6][7]. This reinforces that laser treatment for PIH has variable outcomes and requires a clear discussion of risks during the consent process ^[6].

Measuring and Improving Safety in Clinical Practice

For clinics, establishing a measurable safety system is as important as implementing clinical protocols.

• Customized Protocols: Maintain separate, detailed protocols for each device, wavelength, treatment indication, body site, and skin risk group ^[31]. Each protocol should clearly define deferral rules, test spot requirements, permitted starting ranges, cooling methods, acceptable clinical endpoints, stop criteria, follow-up timing, and escalation steps. There should be no single “Fitzpatrick IV to VI parameter chart” that is applied uniformly ^[31].
• Denominator-Based Outcome Tracking: Track specific outcomes using denominator-based measures. This includes the percentage of eligible patients receiving test spots, recent-tan deferrals, PIH rates at 2 and 6 weeks, burn or blister incidents per 1,000 sessions, hypopigmentation rates, unplanned medical referrals, and adverse events broken down by operator, device, wavelength, treatment site, and objectively measured skin color ^[32]. Inconsistent reporting in the literature is a major reason why complication estimates vary widely; clinics can contribute by tracking their own data ^[32].
• Training and Error Audits: Audit training events and review mode-selection errors. FDA reports demonstrate that even machines cleared for darker skin can cause injury if operators select the wrong wavelength, treat tanned skin, skip test spots, or fail to follow instructions ^[20]. Device clearance is a condition of safe use, not a guarantee of safe operation ^[20].
• Careful Pricing and Consent: Be transparent with patients about pricing and the expected number of sessions. Conservative settings often require more treatments. For example, the 150-patient Nd:YAG cohort averaged 8.9 treatments for only a 54.3% mean hair reduction ^[13]. Clinics should avoid promising single-session results and clearly explain the potential need for multiple sessions, maintenance treatments, adjunctive therapies like electrolysis, topical care, or specialist referrals ^[13].
• Closing the Fitzpatrick VI Evidence Gap: Clinics serving diverse populations have an opportunity to collect valuable safety data, especially for Fitzpatrick VI patients, who were absent in the 2025 prevention review and only accounted for 6% of participants in the 2024 treatment review ^[1][5]. This data should be collected with informed consent, consistent definitions, and objective color measurements to contribute to the wider knowledge base ^[1].

For example, Bio2 Laser Studio’s public website outlines laser and electrolysis services but, like many clinics, does not provide detailed metrics on session counts, PIH rates, burn rates, outcomes by skin tone, or follow-up completion ^[18]. While this is typical, it represents a wider disclosure gap in the industry. By reporting clear, denominator-based safety measures without framing them as promotional claims, Bio2 Laser Studio and its peers could enhance public trust and contribute significantly to improving laser safety standards for darker skin types ^[18]. This level of transparency fosters a culture of safety and continuous improvement, which is vital for the responsible advancement of laser aesthetics in diverse populations.

Conclusion of the Introduction

The journey toward safer laser practices for Fitzpatrick IV to VI skin in 2026 demands a shift from generalized guidelines to precise, evidence-based protocols. The core problem of epidermal melanin absorption necessitates a strategic approach involving careful patient selection, advanced device technology, conservative treatment parameters, and diligent post-treatment care. The absence of a singular international standard reinforces the importance of this comprehensive, step-by-step playbook, which integrates insights from global consensus reports, clinical trials, and adverse event data. By moving beyond the sole reliance on Fitzpatrick typing to a holistic risk assessment, clinics can significantly reduce the incidence of complications like PIH. The continuous collection and transparent reporting of outcome data will be crucial for refining these protocols and ensuring the highest standards of care for all patients, especially those with darker skin.

The subsequent sections of this report will explore deeper into each of these steps, providing practical guidance, detailed considerations, and case examples to equip practitioners with the knowledge and tools necessary to implement the Fitzpatrick IV-VI Laser Safety Protocol effectively. This will include specific details on device parameters, patient preparation strategies, immediate and delayed skin reactions, and management of potential complications, ensuring a strong framework for clinical safety.

3. Limitations of Fitzpatrick Skin Typing

The Fitzpatrick Skin Phototype (FST) scale was first developed in 1975 by Dr. Thomas Fitzpatrick to classify skin response to ultraviolet light. It categorizes skin based on tanning and burning behaviors. While it served as an initial step toward understanding skin diversity, its application in modern laser and energy-based treatments, especially for darker skin tones (Fitzpatrick IV-VI), presents considerable limits. The central problem for laser safety is that epidermal melanin absorbs part of the treatment energy¹. This reduces the range between an effective treatment and effects such as excess heat, inflammation, burns, post-inflammatory hyperpigmentation (PIH), or permanent loss of pigment¹. Clinicians and researchers recognize that relying solely on the Fitzpatrick system for assessing laser injury risk is insufficient and can lead to adverse outcomes². As of August 29, 2026, there is no single international standard called the “Fitzpatrick IV to VI Laser Safety Protocol.” Instead, a safer approach involves a clinical playbook built from consensus reports, controlled trials, device instructions, and adverse event data³. This section details the specific limits of the Fitzpatrick system and the clear need for more comprehensive risk assessment methods.

3.1 The Origins and Fundamental Limits of the Fitzpatrick Scale

The Fitzpatrick scale was designed to predict a person’s risk of sunburn and tanning². It was not created to measure epidermal melanin directly or to predict laser injury risk². This is a critical distinction because laser treatments interact with melanin in specific ways, and a subjective classification of skin color alone cannot accurately predict these interactions or the skin’s individual response to energy delivery. For instance, skin that tans easily (a characteristic of darker Fitzpatrick types) also contains more melanin, which can absorb laser energy and lead to complications like PIH if settings are not carefully chosen¹.

A 2025 Delphi study, involving 22 skin-of-color experts, found that 95% of these experts agreed that the current Fitzpatrick system has clinical and research limits². This high level of consensus from specialists highlights the recognized shortcomings of the system in practical clinical settings. The original scale is subjective, relying on self-reported tanning and burning history, which can be influenced by patient perception, memory, and recent sun exposure⁴. These subjective factors introduce variability and potential inaccuracies in risk assessment. A patient classified as Fitzpatrick IV, for example, can have differing treatment risks based on recent tanning, the body site being treated, prior injury, and the specific laser wavelength planned⁴.

Moreover, the Fitzpatrick scale does not account for the wide range of melanin distribution patterns, variations in skin thickness, or the presence of specific chromophores that may impact laser absorption¹. These factors are crucial for precise laser treatment planning. The inherent subjectivity means that different operators might classify the same patient differently, leading to inconsistent treatment protocols and outcomes⁵. This variability is a significant safety concern, particularly when treating skin with higher melanin content, where the margin for error is already smaller¹.

The need for objective measures beyond the Fitzpatrick scale is further supported by a 2026 study of 789 adults. This study found large differences between subjective skin ratings and objective color measurements⁵. Specifically, Michael S. Lipnick and colleagues published a comparative study on January 6, 2026, which applied three subjective methods and two objective instruments across several body sites. Their measured results showed that depending on the method used, between 7% and 26% of the same cohort could be classified as dark⁵. This demonstrates that subjective scales can change who is considered a high-risk patient⁶.

3.2 Insufficient Representation of Darker Skin Tones in Research

A significant limit of the existing research for PIH prevention and treatment is the lack of detailed data for Fitzpatrick VI skin types. This gap makes it difficult to establish strong, evidence-based protocols for this population. The available prevention evidence is still thin⁷. A 2025 systematic review on PIH prevention included 369 cases, but reported ethnicity was 100% Asian⁷. Among the classified participants in this review, only 4.1% were Fitzpatrick V, and none were Fitzpatrick VI⁷. This means that protocols for Fitzpatrick VI skin rely heavily on physiology, small studies, expert opinion, and careful clinical practice rather than extensive trial data⁷. The evidence for PIH prevention becomes thinner as skin pigmentation rises, meaning claims of proven Fitzpatrick VI safety should be viewed with caution⁸.

Even in studies focused on PIH treatment, Fitzpatrick VI skin types remain underrepresented. A 2024 systematic review of PIH treatment included 1,356 patients with skin of color and showed greater diversity than the prevention literature⁹. In this review, 40% were Fitzpatrick IV, 34% were V, and 6% were VI among cases with phototype data⁹. Of participants with reported race or ethnicity, 70% were Black, 27% Asian, and 3% Hispanic or Latin⁹. While this study offered more representation, Fitzpatrick VI still accounted for a small share of the total⁹. This limits the generalizability of treatment results to prevention questions, as different mechanisms and outcomes may apply⁹.

Similarly, a 2023 review of pulsed dye laser (PDL) use in Fitzpatrick IV-VI skin highlighted the same issue. Despite decades of PDL use, only nine eligible studies involving 241 patients were found by December 2022¹⁰. This demonstrates the limited evidence base for many laser types in darker skin. The review noted that hyperpigmentation, hypopigmentation, and scarring remained concerns even with PDL, which is generally considered safer for vascular lesions¹⁰. Such gaps in the literature underscore the need for careful protocols and monitoring, especially when treating patients with Fitzpatrick VI skin, as there is no strong evidence to claim proven safety for this group⁸.

The table below summarizes the representation of darker Fitzpatrick skin types in key research reviews:

Study/Review	Year	Topic	Fitzpatrick III	Fitzpatrick IV	Fitzpatrick V	Fitzpatrick VI
Mar et al. Systematic Review7	2025	PIH Prevention	42.2%	53.7%	4.1%	0%
2024 Systematic Review9	2024	PIH Treatment	Not specified	40%	34%	6%
PDL Review10	2023	PDL in Darker Skin	Not specified	Included	Included	Included (limited studies/patients)

3.3 The Role of Melanin and the Narrow Safety Margin

The fundamental safety problem in laser treatment of darker skin tones is that epidermal melanin absorbs part of the laser’s energy¹. Melanin, a primary chromophore in the skin, is the target for many laser treatments (e.g., hair removal) but also an unintended target in others (e.g., vascular lesions, pigmented lesions, or resurfacing). In lighter skin types, the melanin content is lower, providing a wider margin between the energy needed for treatment and the energy that could cause thermal injury to the surrounding tissue¹. However, in Fitzpatrick IV-VI skin types, the higher concentration of epidermal melanin means that this safety margin is much narrower¹.

This narrowed margin means that even small deviations in laser parameters can lead to significant adverse effects, including excessive heat, inflammation, burns, PIH, or even permanent hypopigmentation¹. PIH, in particular, is a common and distressing complication for patients with darker skin, manifesting as darkening of the skin in areas of previous injury or inflammation. This is why careful parameter selection and rigorous safety protocols are paramount for these skin types.

Several strategies are used to reduce this risk. These include using longer wavelengths, conservative settings, controlled skin coverage, and epidermal cooling¹. For example, for hair reduction in Fitzpatrick V and VI skin, long-pulsed 1064 nm Nd:YAG lasers are generally considered the safest starting point because their longer wavelength has lower epidermal melanin absorption compared to shorter wavelengths like 755 nm alexandrite¹¹. Diode systems may be used with caution, but alexandrite 755 nm and broad-spectrum intense pulsed light (IPL) require much greater caution in dark or tanned skin¹¹. Despite these measures, no treatment is entirely risk-free¹.

The skin’s immediate response to laser energy provides critical feedback for the operator. Observing the correct clinical endpoint, such as perifollicular edema for hair removal or mild erythema for skin rejuvenation, indicates effective energy delivery without overtreatment. However, the subjective nature of these endpoints, combined with individual patient variability, still poses a challenge. This highlights the need for advanced operator training and experience when treating Fitzpatrick IV-VI skin. Even with experienced operators, constant vigilance and adherence to detailed protocols are required.

3.4 Beyond Fitzpatrick: Comprehensive Risk Assessment Inputs

Given the limits of the Fitzpatrick scale, a comprehensive approach to risk assessment is needed. This approach moves beyond a single subjective rating to include multiple objective and subjective inputs that provide a more complete picture of the patient’s risk profile. The 2026 protocol should retain Fitzpatrick type as one input, but it must be supplemented with more direct measures of risk².

3.4.1 Detailed Patient History and Examination

The first step in a thorough risk assessment is a detailed patient history and physical examination. This includes documenting:

• Prior PIH or Scarring: A history of PIH, hypopigmentation, blistering, keloids, infection, or poor wound healing significantly increases the risk of adverse events¹². Patients with a history of PIH are more likely to develop it again.
• Current Inflammation or Active Disease: Elective laser treatment should be deferred if there is active inflammatory disease (e.g., acne, dermatitis) or a recent tan in the treatment area¹³. The 2025 global consensus advises against laser or IPL during active inflammatory stages of acquired dermal pigment disorders because treatment may worsen pigmentation⁴.
• Recent Tanning or Sun Exposure: Tanned skin contains more melanin, making it more prone to absorbing laser energy and causing thermal damage¹. An FDA adverse event report from 2025 described a tanned patient developing burns after an operator switched from an Nd:YAG to an alexandrite laser¹³.
• Medications and Skin Products: Reviewing current medications and skin products is crucial, as some can increase light sensitivity (photosensitizers), irritation, bleeding, or impair healing¹². Patients should not be instructed to stop prescription drugs without consulting their prescriber¹².
• Normal Untanned Skin Color: Documenting the patient’s normal, untanned skin color provides a baseline for comparison. This helps account for temporary changes due to sun exposure⁴.
• Treatment Site and Target Depth: Different body sites have varying skin thickness, hair follicle depth, and blood supply, which can affect laser penetration and response. The specific target (e.g., hair follicle, pigment, blood vessel) also dictates the required wavelength and energy settings⁴.

3.4.2 Objective Skin Color Measurement

Objective skin color measurement tools can supplement or eventually replace subjective Fitzpatrick ratings. These tools provide quantifiable data on skin pigmentation, reducing inter-observer variability and improving accuracy. Examples include:

• Colorimetry and Spectrophotometry: These devices measure skin reflectance at different wavelengths to quantify melanin and hemoglobin content. They provide numerical values (e.g., L*a*b* color space values or Individual Typology Angle – ITA) that offer a more precise and repeatable measure of skin color than subjective visual assessment⁴. The 2026 Lipnick study found that five assessment methods applied to 789 people produced materially different estimates of how many participants had dark skin, emphasizing the impact of measurement method⁵.
• Repeatable Photographs: Standardized photography, using the same room, camera, distance, lighting, and patient position, can provide a visual record of skin color changes over time and aid in monitoring treatment outcomes⁴.

3.4.3 Test Spots and Delayed Review

A crucial safety measure for Fitzpatrick IV-VI skin is the use of delayed test spots. This involves treating a small, inconspicuous area of skin with the planned laser settings and observing the response over time before proceeding with full treatment. The test spot should match the actual treatment area, device, wavelength, spot size, pulse width, fluence, cooling method, and planned settings¹⁴.

The timing for reviewing test spots is important to allow for delayed pigment changes to appear. One manufacturer protocol cited in an FDA report recommended a 1 to 2 week wait in Fitzpatrick IV to VI skin or tanned skin before full treatment¹⁴. This timing, however, is a manufacturer example and not a universal rule for every device, meaning specific device instructions must be followed¹⁴. This approach helps to identify individual skin sensitivity and reduce the risk of widespread adverse reactions. High-risk consultations and test spots should be separate workflow stages, and clinics should incorporate the extra visit and waiting period into their pricing and scheduling to prevent rushing the process¹⁵.

3.4.4 Diagnosis and Treatment Goal

The specific diagnosis and treatment goal play a large role in risk assessment. Brown epidermal PIH and blue-gray dermal PIH, for example, do not respond to laser treatment in the same way⁴. Active inflammatory conditions should be controlled before laser treatment⁴. The global consensus published in 2025 advises against laser or IPL for active inflammatory stages of acquired dermal pigment disorders because it may worsen pigmentation⁴.

For hair removal, the target is melanin within the hair follicle. For pigmented lesions, the target is melanin in the epidermis or dermis. For vascular lesions, the target is hemoglobin. Each target requires different wavelengths and pulse durations for optimal effect and safety in darker skin. For instance, long-pulsed 1064 nm Nd:YAG is the main laser option for hair reduction in Fitzpatrick V and VI skin due to its lower epidermal melanin absorption¹⁶. For pigment procedures, shorter wavelengths like 532 nm interact strongly with epidermal pigment and require greater caution in Fitzpatrick V and VI skin¹⁷. The European laser position statement recommends using the minimum effective fluence in darker skin¹⁷.

3.4.5 Operator Training and Experience

The expertise of the operator is a critical, yet often overlooked, factor in risk assessment. A well-trained operator can interpret subtle skin responses, adjust parameters as needed, and recognize early signs of complications. FDA cases show that a machine cleared for darker skin can still cause injury when the operator selects the wrong wavelength, treats a tan, skips a test spot, or fails to follow instructions¹⁸. Device clearance is a condition of safe use, not a guarantee of safe operation¹⁸. This means that rigorous training, ongoing education, and adherence to structured protocols are as important as the technology itself.

3.5 Implications for Clinical Practice and Research

The discussion on the limits of Fitzpatrick skin typing has clear implications for both clinical practice and future research. Providers need structured intake forms that go beyond a single Fitzpatrick dropdown menu⁴. These forms should capture baseline color measurements, pigment history, recent environmental changes, and other risk factors. Patients, in turn, should expect that a safe consultation may include deferral of treatment, initial topical treatment, a test spot, a different device, or no laser treatment at all if the risks outweigh the benefits⁴. Clinics should ensure that high-risk consultations and test spots are distinct workflow stages, allowing adequate time for assessment and review¹⁵.

For research, there is a clear call for more studies that include a greater representation of Fitzpatrick VI patients. Researchers and device makers should report objective pigment data alongside Fitzpatrick type to provide a more consistent and verifiable basis for analysis⁴. The current reliance on expert opinion and small studies for Fitzpatrick VI skin highlights the need for larger, more diverse randomized controlled trials (RCTs) specifically designed to address safety and efficacy in this population.

For businesses like Bio2 Laser Studio, which offers both laser hair reduction and electrolysis, there is an opportunity to route patients with pigment-poor hair away from ineffective laser exposure to electrolysis¹⁹. This operating model acknowledges that not all hair and skin combinations are suitable for laser treatment. However, it is also important for such clinics to track and report their outcomes. Bio2 Laser Studio’s public site, for example, does not provide audited PIH rates or other clinical outcome evidence²⁰. This is a common gap across the industry. Clinics could improve public trust by reporting clear, denominator-based safety measures without framing them as promotional claims²⁰.

The adoption of comprehensive safety systems that can be measured and audited is essential. This includes maintaining separate protocols for each device, wavelength, indication, body site, and skin-risk group, with clear deferral rules, test-spot rules, starting ranges, cooling requirements, endpoints, stop criteria, follow-up timing, and escalation steps²¹. Tracking outcomes like the percentage of patients receiving test spots, deferrals due to recent tans, PIH rates at different intervals, and adverse events per session can provide valuable data for continuous improvement²¹.

The limitations of the Fitzpatrick skin typing system are well-recognized by experts. While it remains a useful initial guide, it is not sufficient for comprehensive laser risk assessment, especially for Fitzpatrick IV-VI skin. Moving forward, a more thorough, multi-faceted approach incorporating detailed patient history, objective skin color measurements, test spots, and careful procedure protocols is essential to enhance patient safety and optimize outcomes in laser and energy-based treatments.

The next section will build upon these recognized limits by outlining specific risk screening and stabilization steps that clinics should implement before any laser treatment.

References

1. pubmed.ncbi.nlm.nih.gov. Special considerations for darker-skinned patients.¹
2. skinofcolorsociety.org. Beyond Fitzpatrick skin types: A Delphi consensus on key considerations for a universal skin typing classification.²
3. beiersdorf.com. Global consensus on the management of melanin hyperpigmentation disorders.³
4. skinofcolorsociety.org. Beyond Fitzpatrick skin types: A Delphi consensus on key considerations for a universal skin typing classification.⁴
5. pubmed.ncbi.nlm.nih.gov. Comparison of methods for characterizing skin pigment diversity in research cohorts.⁵
6. pubmed.ncbi.nlm.nih.gov. Comparison of methods for characterizing skin pigment diversity in research cohorts.⁶
7. pmc.ncbi.nlm.nih.gov. Prevention of Post‐Inflammatory Hyperpigmentation in Skin of Colour: A Systematic Review.⁷
8. pmc.ncbi.nlm.nih.gov. Prevention of Post‐Inflammatory Hyperpigmentation in Skin of Colour: A Systematic Review.⁸
9. pmc.ncbi.nlm.nih.gov. Treatment of Post-Inflammatory Hyperpigmentation in Skin of Colour: A Systematic Review.⁹
10. pubmed.ncbi.nlm.nih.gov. A review of treatment of port-wine stains with pulsed dye laser in fitzpatrick skin type IV-VI.¹⁰
11. pubmed.ncbi.nlm.nih.gov. Laser and Light Treatments for Hair Reduction in Fitzpatrick Skin Types IV-VI: A Comprehensive Review of the Literature – PubMed.¹¹
12. pubmed.ncbi.nlm.nih.gov. Complications of dermatologic lasers in high Fitzpatrick phototypes and management: an updated narrative review – PubMed.¹²
13. accessdata.fda.gov. MAUDE Adverse Event Report: EL.EN. ELECTRONIC ENGINEERING S.P.A. ELITE IQ.¹³
14. accessdata.fda.gov. MAUDE Adverse Event Report: CANDELA GENTLEMAX PRO; GMAX PRO.¹⁴
15. accessdata.fda.gov. MAUDE Adverse Event Report: EL.EN. ELECTRONIC ENGINEERING S.P.A. ELITE IQ.¹⁵
16. pubmed.ncbi.nlm.nih.gov. Lasers and light-based therapies in ethnic skin: treatment options and recommendations for Fitzpatrick skin types V and VI.¹⁶
17. onlinelibrary.wiley.com. Laser treatment of hyperpigmented lesions: position statement of the European Society of Laser in Dermatology – Passeron – 2019 – Journal of the European Academy of Dermatology and Venereology – Wiley Online Library.¹⁷
18. accessdata.fda.gov. MAUDE Adverse Event Report: EL.EN. ELECTRONIC ENGINEERING S.P.A. ELITE IQ.¹⁸
19. bio2laserstudio.com. Laser Hair Removal | Electrolysis | RF Body Contouring.¹⁹
20. bio2laserstudio.com. Laser Hair Removal | Electrolysis | RF Body Contouring.²⁰
21. link.springer.com. Facial laser complications (A Five Year Review) | Lasers in Medical Science | Springer Nature Link.²¹

4. Pre-Treatment Diagnosis and Risk Screening

Effective pre-treatment diagnosis and risk screening are critical steps for preventing post-inflammatory hyperpigmentation (PIH) in patients undergoing laser treatments, especially those with Fitzpatrick skin types IV to VI. The central safety issue with treating darker skin types is that epidermal melanin absorbs part of the treatment energy. This absorption narrows the margin between an effective treatment and excessive heat, inflammation, burns, PIH, or loss of pigment ^[3]. Therefore, a careful and systematic approach to patient assessment is not merely good practice but a fundamental requirement for patient safety. This section details the necessary steps for confirming treatment targets, comprehensively documenting patient history, and accurately assessing skin color and condition before any laser procedure.

The development of a standardized protocol for laser safety in Fitzpatrick IV to VI skin types is a continuous effort. As of August 29, 2026, no single international standard exists under the specific name “Fitzpatrick IV to VI Laser Safety Protocol.” Instead, best practices are compiled from consensus reports, controlled trials, device instructions, and data on adverse events. A crucial understanding is that fixed settings cannot be universally applied across different devices, treatment indications, body sites, or individual patients ^[1]. The process of pre-treatment screening, often referred to as “Step 1” in a clinical playbook, involves confirming the treatment target, documenting prior PIH, scarring, current inflammation, recent tanning, previous procedures, medications, and the patient’s normal untanned skin color ^[4]. This detailed screening allows for a personalized risk assessment, moving beyond a simplistic classification based solely on Fitzpatrick type.

4.1. Limitations of the Fitzpatrick Skin Type System in Risk Assessment

The Fitzpatrick skin type (FST) system classifies skin based on its response to sun exposure, specifically its tendency to burn or tan. While historically useful, this system has significant limits when used as the primary tool for laser risk assessment, particularly for skin of color ^[2]. A 2025 Delphi study involving 22 skin-of-color experts revealed that 95% agreed or strongly agreed that the current Fitzpatrick system has important clinical and research limits ^[6]. This consensus indicates a strong need for more comprehensive evaluation methods.

The primary concern with relying solely on FST for laser treatment is that it does not directly measure epidermal melanin content, which is the key determinant of laser energy absorption and potential thermal injury. Instead, FST is an indirect measure, primarily focusing on tanning and burning responses. This can lead to inaccuracies in predicting individual patient responses to laser energy. For instance, a person classified as Fitzpatrick IV might have significantly different treatment risks depending on their current tanning status, the specific body site being treated, any prior injuries, and the particular laser wavelength planned for use ^[3].

A 2026 study conducted by Lipnick and colleagues further highlighted the discrepancies between subjective skin ratings and objective color measurements. This study involved 789 adults and performed 33,856 assessments, applying five different methods for characterizing skin pigment. The findings showed that depending on the method used, the percentage of participants classified as “dark” varied significantly: 7%, 14%, 16%, 23%, or 26% of the same cohort ^[7]. This variability demonstrates that subjective scales, including the Fitzpatrick type, can lead to different individuals being placed into a high-risk group, potentially over- or underestimating risk. Therefore, relying on FST alone can lead to either overly aggressive treatment settings, increasing the risk of adverse events like PIH, or overly conservative settings, reducing treatment efficacy and requiring more sessions.

To improve accuracy in risk assessment, clinics in 2026 should move beyond a single Fitzpatrick dropdown on intake forms. Instead, they should incorporate additional, more direct measures of risk. This includes recording the patient’s normal untanned skin color, their current skin color, recent sun exposure, and a detailed history of PIH or other adverse reactions. Objective measurement tools like colorimetry or spectrophotometry can provide valuable additional data where available, offering a more precise evaluation of skin pigment ^[6]. These repeatable measurements, alongside consistent photographic documentation, ensure that skin color assessment is as objective and comprehensive as possible.

4.1.1. Skin Color Measurement and Documentation

Accurate assessment of skin color involves more than a visual estimation. Repeatable photographs are essential, taken under standardized conditions with consistent room lighting, camera settings, distance from the patient, and patient positioning ^[6]. This documentation provides a reliable baseline and allows for objective comparison of skin changes over time, especially during test spots and follow-up appointments. The 2026 Lipnick study on skin pigment diversity underscores the importance of such objective measures, demonstrating how subjective classifications can lead to inconsistent risk group assignments ^[7].

For practices with access to advanced technology, colorimetry or spectrophotometry can provide quantitative data on skin melanin levels and color parameters. These instruments offer a more precise and objective assessment of skin pigmentation, which can complement or even refine the FST classification. However, even without these tools, careful visual assessment combined with a detailed patient history remains foundational.

4.2. Comprehensive Patient History and Risk Factors

A thorough patient history is indispensable for identifying individual risk factors for PIH and other complications. This history should encompass previous skin reactions, current skin conditions, medication use, and lifestyle factors. The goal is to build a detailed picture of the patient’s skin health and potential sensitivities to laser treatment.

4.2.1. History of Post-Inflammatory Hyperpigmentation (PIH) and Scarring

Patients with a history of PIH are at a significantly higher risk of developing it again after laser treatment. It is crucial to document any prior episodes of PIH, including their cause (e.g., acne, injury, previous laser treatments), duration, and response to treatment. Laser treatment of existing PIH should generally follow topical treatment rather than serving as the first intervention ^[4]. The approach to treating existing PIH can vary; a 2024 systematic review noted that among 1,356 patients with skin of color treated for PIH, laser therapy resulted in partial improvement in 66% and complete resolution in 26% of a subgroup, but worsening PIH also occurred ^[5][6]. This underscores the need for caution and careful patient selection for laser treatment of existing PIH.

Similarly, a history of abnormal scarring, such as keloids or hypertrophic scars, indicates a higher risk of adverse wound healing following laser treatment. This information should prompt extra caution and possibly deferral of treatment or the use of more conservative settings and test spots. Blistering, hypopigmentation, and infection history also fall under this category, indicating skin fragility or compromised healing capabilities ^[18].

4.2.2. Current Inflammation and Active Skin Conditions

Active inflammatory skin conditions in the treatment area are absolute contraindications for elective laser procedures. These include active dermatitis, uncontrolled acne, or other forms of inflammation. Treating inflamed skin increases the risk of aggravating the condition and inducing PIH. The 2025 global consensus on melanin hyperpigmentation disorders recommends avoiding laser or intense pulsed light (IPL) during active inflammatory stages of acquired dermal pigment disorders because treatment may worsen pigmentation ^[3]. Therefore, the presence of inflammation should lead to the deferral of laser treatment until the condition is stable and controlled ^[4].

The term “stabilization” refers to preparing high-risk skin before treatment. This means deferring elective laser treatment when there is a recent tan or active inflammatory disease in the area ^[5]. This also includes avoiding irritants close to procedures, although evidence for routine hydroquinone or other lightening agents for skin preparation remains mixed ^[5].

4.2.3. Recent Tanning and Sun Exposure

Recent tanning, whether from sun exposure or artificial sources, significantly increases the risk of complications from laser treatment. Tanned skin has a higher concentration of epidermal melanin, which will absorb more laser energy, leading to an elevated risk of burns and PIH. A 2025 FDA adverse event report highlighted this risk, describing a tanned patient who developed burns after an operator switched from an Nd:YAG laser to an alexandrite laser ^[17]. This incident underscores the importance of strong screening for recent tanning and the necessity of deferring treatment when present.

Clinics should implement a clear deferral policy for patients with recent tans or sunburns. This policy ensures patient safety and avoids unnecessary complications. The duration of deferral depends on the depth and duration of the tan, typically requiring several weeks for the tan to fade. Patients should be educated on avoiding sun exposure before and after treatment, and consistent use of broad-spectrum sunscreen is paramount ^[15].

4.2.4. Prior Procedures and Treatments

Information about any prior cosmetic procedures, including other laser treatments, chemical peels, microdermabrasion, or injectables, is crucial. This helps to understand the skin’s healing capacity and any potential interactions with the planned laser treatment. It also provides insight into previous adverse reactions or satisfactory outcomes. For example, knowing if a patient has previously undergone laser hair reduction with a different device or at another clinic can inform expectations and potential risks. In the context of Bio2 Laser Studio, which offers both laser hair reduction and electrolysis, understanding previous treatments is vital for selecting the most appropriate and safest method for each client ^[18].

4.2.5. Medications and Topical Products

A comprehensive list of all current medications, both prescription and over-the-counter, as well as topical skincare products, is necessary. Certain medications can increase photosensitivity, thin the skin, or impair wound healing. Examples include retinoids (oral and topical), certain antibiotics, non-steroidal anti-inflammatory drugs (NSAIDs), and immunosuppressants ^[18]. Patients should not be instructed to stop prescription drugs without consulting their prescriber. The purpose of this review is to identify factors that might increase light sensitivity, irritation, bleeding, infection, or delay healing ^[18].

Topical products containing active ingredients such as alpha hydroxy acids (AHAs), beta hydroxy acids (BHAs), or strong retinoids can also increase skin sensitivity. Patients may need to discontinue use of these products for a specified period before and after laser treatment to minimize irritation and reduce the risk of PIH.

4.3. Confirming Treatment Targets and Goals

Before any laser treatment begins, the specific treatment target must be clearly identified and confirmed with the patient. This involves a clear diagnosis of the condition to be treated and an understanding of the patient’s goals. Different skin concerns, such as hair reduction, pigmentary disorders, or skin resurfacing, require different laser types, wavelengths, and treatment protocols. The diagnosis matters as much as skin tone. For instance, brown epidermal PIH and blue-gray dermal PIH do not respond in the same way ^[6].

4.3.1. Hair Reduction Targets

For hair reduction in Fitzpatrick V and VI skin types, the long-pulsed 1064 nm Nd:YAG laser is generally considered the safest starting point. This is because its longer wavelength is absorbed less by epidermal melanin compared to shorter wavelengths like the 755 nm alexandrite laser ^[23]. Diode systems operating near 800-810 nm may be used with caution in selected patients, provided there is suitable pulse control and epidermal cooling. However, these systems offer a narrower safety margin in very dark or tanned skin compared to the 1064 nm Nd:YAG ^[23]. Alexandrite 755 nm and broad-spectrum IPL require much greater caution in dark or tanned skin due to their higher melanin absorption ^[5].

It is important to manage patient expectations regarding the number of sessions required. A 2011 retrospective cohort study of 150 Fitzpatrick IV to VI patients treated with long-pulsed Nd:YAG laser for hair reduction showed a mean hair reduction of 54.3% after an average of 8.9 sessions ^[13]. While 86% of patients experienced no complications, temporary hyperpigmentation was the most frequent complication reported. This indicates that while 1064 nm is safer, it is not risk-free and requires multiple conservative sessions for effective and safe results ^[13].

A notable complication for hair removal is paradoxical hypertrichosis, or increased hair growth, which occurred in 3% of patients in a 2021 meta-analysis of laser/IPL hair removal patients. This complication was mainly concentrated on the face and neck, with only 0.08% prevalence in non-facial and non-neck areas ^[14]. Women undergoing face or neck treatment must be specifically consented about this possibility.

When hair lacks sufficient pigment, laser treatment will be ineffective because the laser targets melanin in the hair follicle. In such cases, electrolysis is a viable alternative. Bio2 Laser Studio, for example, lists both laser hair reduction and electrolysis among its services ^[18]. This dual-modality approach allows patients with blonde, red, gray, white, or very fine hair to receive effective treatment without the risks associated with laser treatment on pigment-poor hair. However, electrolysis also causes local tissue injury and requires its own set of PIH prevention controls.

4.3.2. Pigmentary Disorder Targets

For pigmentary disorders, shorter wavelengths like 532 nm interact strongly with epidermal pigment and require extreme caution in Fitzpatrick V and VI skin types ^[24]. The European laser position statement recommends using the minimum effective fluence in darker skin ^[24]. Low-fluence 1064 nm Nd:YAG may be considered for selected resistant pigment disorders, but repeated “laser toning” can lead to mottled loss of pigment ^[24]. Active inflammatory conditions should be controlled before considering laser treatment for pigmentation, as treatment may worsen pigmentation ^[3].

4.3.3. Resurfacing Targets

For skin resurfacing in darker skin types, the goal is to reduce total tissue injury. Fractional laser treatments are generally preferred over full-field treatments when clinically suitable ^[25]. Strategies to minimize PIH include using lower treatment density, fewer passes, longer intervals between sessions, and avoiding pulse overlap to reduce accumulated inflammation ^[25]. Studies comparing lower-density and higher-density methods have shown significantly higher PIH rates with greater density. For instance, one small split-face study found PIH rates of 43% at lower density versus 71% at higher density with the same 40 mJ setting ^[8]. Another study observed PIH rates of 7.1% versus 12.4% when comparing higher-energy, lower-density treatment with lower-energy, higher-density treatment ^[12]. These findings emphasize that treatment density is a major safety control, and lower tissue coverage and adequate time for inflammation to settle may be more important than using very low energy at high density ^[10].

4.3.4. Vascular Lesion Targets

Vascular procedures present their own specific considerations for Fitzpatrick IV to VI skin types. A 2023 review identified only nine studies involving 241 Fitzpatrick IV to VI patients treated with pulsed dye lasers ^[15]. While benefits were possible, concerns regarding hyperpigmentation, hypopigmentation, and scarring remained ^[15]. It is crucial never to reuse a hair removal protocol for vascular or pigment treatment simply because the device platform is the same. Vascular laser protocols require conservative fluence and careful endpoint monitoring to minimize risks.

4.4. The Pre-Laser Checklist: A Structured Approach

A structured pre-laser checklist is essential for ensuring all critical screening steps are completed. This checklist helps standardize the intake process and reduces the likelihood of overlooking important risk factors.

Category	Specific Items to Document and Assess	Rationale
Patient Demographics	Full name, contact information, date of birth.	Basic patient identification.
Treatment Target	Specific condition (e.g., hair reduction, melasma, scars), body site, patient goals.	Ensures clear understanding of treatment purpose and expectation alignment.
Skin Type Assessment	Fitzpatrick Skin Type (I-VI), normal untanned skin color, current skin color.	Initial risk stratification, but not sole determinant.
Objective Color Measurement	Colorimetry or spectrophotometry readings (if available).	Quantitative assessment of melanin, more precise than FST alone.
Photographic Documentation	Standardized photos (consistent lighting, angle, distance) of treatment area.	Baseline for monitoring changes and outcomes.
History of PIH and Scarring	Previous PIH episodes (cause, duration, treatment), keloids, hypertrophic scars, hypopigmentation, blistering.	Identifies predisposition to adverse skin reactions and poor healing.
Current Skin Conditions	Active dermatitis, uncontrolled acne, eczema, psoriasis, other inflammatory conditions.	Contraindications for treatment; increases PIH risk.
Recent Sun Exposure/Tanning	Sunbathing, tanning beds, recent vacation, sunburns.	High epidermal melanin content increases burn and PIH risk. Leads to deferral.
Medications	Prescription (e.g., retinoids, antibiotics), over-the-counter drugs, herbal supplements.	Identifies photosensitizing agents, skin thinners, or those affecting healing.
Topical Products	Retinoids, AHAs, BHAs, exfoliating agents, hydroquinone.	May increase skin sensitivity and require temporary discontinuation.
Prior Cosmetic Procedures	Previous laser, IPL, peels, microdermabrasion, injectables, electrolysis.	Assesses skin history, prior reactions, and potential interactions.
Allergies and Sensitivities	Topical anesthetics, cooling agents, latex, other medical supplies.	Prevents allergic reactions during treatment.
Pregnancy/Breastfeeding Status	Confirmed or suspected pregnancy, current breastfeeding.	Absolute contraindication for most laser treatments.
Informed Consent	Discussion of risks (PIH, burns, scarring, paradoxical hair growth), benefits, alternatives, costs, multiple sessions needed.	Ensures patient understanding and autonomy.

4.4.1. Deferral Gates

Establishing clear deferral gates is a fundamental aspect of the pre-treatment process. Visible tanning, recent sunburn, active dermatitis, uncontrolled acne inflammation, or unresolved irritation in the treatment area should all result in the deferral of elective laser treatment ^[17]. This is a crucial safety measure to prevent complications. As seen in the 2025 FDA adverse event, a tanned patient suffered burns when an operator proceeded with an inappropriate laser setting ^[17]. Such incidents highlight the severe consequences of bypassing deferral rules.

The 2025 global consensus supports lightening-agent priming for higher-risk procedures and avoiding irritants close to treatment ^[5]. However, the 2026 network analysis found no significant prevention benefit for whitening agents over sunscreen monotherapy, and trials varied on when topical care began, with most starting after treatment ^[5]. This mixed evidence suggests that while priming may be considered, deferral based on active inflammation or recent tan is a more direct and universally accepted safety measure.

4.4.2. Photoprotection as a Pre-Treatment Measure

Beginning photoprotection before the procedure is advisable, rather than waiting for pigment changes to appear ^[15]. A 2026 trial involving 20 Fitzpatrick IV and V participants demonstrated that a tested broad-spectrum sunscreen provided about 16 Individual Typology Angle (ITA) degrees of net protection after combined inflammation and light exposure ^[15]. Protected, barrier-disrupted skin improved by 5.96 ITA degrees, while unprotected skin worsened by 9.88 degrees. Secondary color measures improved by 48% to 87%. Additionally, iron-oxide formulas have shown better performance than non-tinted mineral SPF 50 products against visible-light pigmentation in Fitzpatrick IV skin ^[16]. This evidence supports the importance of initiating daily broad-spectrum sunscreen, especially those offering visible-light protection, for pigment-prone patients even before laser treatment.

4.4.3. The Role of the Test Spot

A delayed test spot is an indispensable safety measure for Fitzpatrick IV to VI skin types. This involves applying laser pulses to a small, inconspicuous area of the actual treatment site using the same device, wavelength, body site, cooling method, and planned settings ^[5]. The test spot is then reviewed after enough time has passed for any delayed pigment changes to appear. This waiting period is crucial because PIH may not manifest immediately. One manufacturer protocol cited in an FDA report suggested a 1 to 2 week wait in Fitzpatrick IV to VI skin, but the exact timing must follow the specific device instructions ^[4]. The test spot provides critical information on how the individual patient’s skin reacts to the planned laser parameters, allowing for adjustments to be made before full treatment. It serves as a personalized calibration for the treatment. High-risk consultations and test spots should be treated as separate workflow stages, with clinics building the extra visit and waiting period into price quotes and scheduling. Same-day consultation and high-energy treatment can transform sales pressure into clinical risk ^[17].

In conclusion, pre-treatment diagnosis and risk screening for Fitzpatrick IV to VI skin types require a careful, multi-faceted approach that extends well beyond a simple Fitzpatrick classification. It involves a detailed patient history, objective skin color assessment, thorough evaluation of current skin conditions, careful consideration of medications and prior procedures, and the diligent application of test spots. This comprehensive screening process is the cornerstone of preventing PIH and ensuring safe, effective laser outcomes for patients with darker skin tones.

The next section will focus on the crucial step of “Device Selection and Parameter Optimization,” building upon the detailed risk assessment discussed here to match the most appropriate laser technology and settings to each patient’s unique profile and treatment goals.

4.5. Detailed Overview of Pre-Treatment Diagnosis and Risk Screening Components

To further elaborate on the components of pre-treatment diagnosis and risk screening, this section will provide a detailed breakdown of each element, emphasizing their importance in developing a safe and effective treatment plan.

4.5.1. Comprehensive Medical History Intake

The initial patient intake form should be extensive, covering not just dermatological history but also general medical conditions that could influence laser treatment outcomes. This includes:

• Systemic Diseases: Conditions such as autoimmune disorders (e.g., lupus, scleroderma), diabetes, or bleeding disorders can affect wound healing or increase photosensitivity. For example, patients with active lupus might be more prone to photosensitive reactions.
• Allergies: Documenting allergies to medications, topical agents (e.g., anesthetics, cooling gels), or materials (e.g., latex) is vital to prevent adverse reactions during treatment.
• Infections: A history of herpes simplex virus (cold sores) in the treatment area necessitates prophylactic antiviral medication before laser resurfacing or other procedures that could reactivate the virus.
• Psychological Factors: Patient expectations, body dysmorphic disorder, or unrealistic goals should be assessed. Unrealistic expectations can lead to patient dissatisfaction even with technically successful outcomes.

4.5.2. Detailed Skin Examination

Beyond the treatment area, a general skin examination can reveal underlying issues or predispositions that might impact laser safety. This includes:

• Skin Integrity: Assessing for dryness, barrier dysfunction, or active lesions outside the treatment area. Compromised skin barrier function could indicate a higher risk of irritation or delayed healing.
• Distribution of Melanin: Observing variations in skin tone, presence of existing pigmented lesions, or areas of natural hyperpigmentation. This helps confirm the FST assessment and identify areas needing special caution.
• Hair Characteristics: For hair reduction, evaluating hair color, thickness, and density in both the treatment area and adjacent regions. Blonde, red, or very fine hairs will not respond well to laser, guiding the recommendation for alternative treatments like electrolysis.

4.5.3. Role of Patient Education and Consent

Informed consent is a process, not just a signature on a form. It involves a detailed discussion with the patient about the procedure, expected outcomes, potential risks (especially PIH for darker skin types), alternatives, and the importance of adherence to pre- and post-treatment instructions. This discussion should cover:

• Realistic Expectations: Emphasizing that multiple sessions are often needed for desired results, especially for hair reduction in darker skin types (e.g., 8.9 sessions for 54.3% hair reduction with Nd:YAG ^[13]). Clinics should avoid promising single-session clearances or guarantees ^[27].
• Risk of PIH: Clearly explaining that PIH is a known complication in skin of color, its appearance, and the time it might take to resolve. Discussing that laser can sometimes worsen PIH, even though it can also improve it ^[5].
• Post-Treatment Care: Reinforcing the importance of sunscreen, avoiding sun exposure, and following any prescribed topical regimens (e.g., anti-inflammatory creams, emollients).
• Potential for Paradoxical Hair Growth: Specifically for laser hair removal on the face and neck, patients should be made aware of the 3% pooled prevalence of paradoxical hypertrichosis ^[14].
• Financial Implications: Transparently discussing the costs associated with multiple sessions, potential test spots, and any necessary follow-up treatments for complications.

4.5.4. Objective Measurements Beyond Visual Assessment

While visual assessment of skin color remains important, objective tools offer greater precision and consistency. For practices that can invest, these tools provide valuable data:

• Spectrophotometers/Colorimeters: These devices measure the light reflectance of the skin to quantify color parameters (e.g., melanin index, erythema index, ITA). The ITA (Individual Typology Angle) is a quantitative measure of skin color, where higher positive values indicate lighter skin and negative values indicate darker skin ^[15]. A 2026 sunscreen study showed a net protection of about 16 ITA degrees against induced pigmentation in Fitzpatrick IV and V participants ^[15].
• Mexameters: Specifically designed to measure melanin and erythema levels in the skin, providing quantitative data that correlates with FST but offers more granular detail.
• High-Resolution Digital Photography: Standardized photography setups ensure consistent lighting, camera settings, and patient positioning. This allows for repeatable and comparable images over time, crucial for monitoring the success of treatments and detecting early signs of complications ^[6].

4.5.5. Skin Priming Strategies (with caution)

Skin priming refers to the use of topical agents before laser treatment to prepare the skin, often to reduce melanin content or inflammation. While the 2025 global consensus supports lightening-agent priming for higher-risk procedures, evidence for routine use of hydroquinone or other lightening agents remains mixed ^[5]. The 2026 network analysis found no significant prevention benefit for whitening agents over sunscreen monotherapy ^[5]. If used, such agents should be prescribed and managed by a qualified medical professional, given the potential for irritation or paradoxical darkening with improper use. Avoiding irritants close to procedures is a more universally accepted recommendation ^[5].

4.5.6. Operational Considerations for Clinics

The implications of this comprehensive screening process extend to clinic operations:

• Workflow Adjustments: The need for test spots and delayed follow-up requires scheduling additional appointments and allocating sufficient time. This should be communicated upfront to patients and factored into pricing ^[17].
• Training and Competency: All staff involved in patient intake and assessment must be thoroughly trained in identifying risk factors specific to Fitzpatrick IV to VI skin types. They must understand the limitations of FST and the importance of detailed history taking.
• Documentation Standards: Strict adherence to documenting every aspect of the screening, consent, and test spot process is essential for patient safety and liability. A future operator should be able to reconstruct the session without relying on memory ^[26].
• Referral Pathways: Establishing clear referral pathways to dermatologists or other specialists for complex cases or unresolved inflammatory conditions is important. For instance, if a patient presents with active, severe acne, referral for medical management before elective laser treatment is appropriate.

4.6. Summary of Key Elements in Pre-Treatment Diagnosis and Risk Screening

The following table summarizes the key elements discussed in this section, providing a concise reference for a strong pre-treatment process.

Element	Description and Rationale	Key Data/Evidence
Moving Beyond FST	FST alone is insufficient for risk assessment. It was not created to measure epidermal melanin or laser injury risk directly. Supplement with objective measures and patient history.	95% of experts agree on FST limits [6]. Lipnick (2026) showed subjective scales vary in classifying “dark” skin [7].
Detailed Patient History	Document prior PIH, scarring (keloids), current inflammation, recent tanning, previous procedures, and all medications/topicals.	Prior PIH increases risk [4]. Active inflammation/tan contraindicates treatment [5]. FDA report of burns on tanned patient [17].
Assessment of Normal Untanned Skin Color	Record baseline skin color in an untanned area. Use repeatable photographs; consider colorimetry/spectrophotometry for objective data.	Crucial for understanding skin’s natural melanin content and monitoring changes.
Confirming Treatment Target	Clearly diagnose the condition and align with patient goals. Tailor laser choice and parameters to specific indications (e.g., hair, pigment, vascular, resurfacing).	Brown epidermal PIH vs. blue-gray dermal PIH respond differently [6]. Nd:YAG for hair removal in IV-VI [23].
Deferral Gate	Postpone elective laser treatment if recent tan, active inflammatory disease, or unresolved irritation is present.	Global consensus recommends deferral for active inflammatory stages [3].
Pre-Treatment Photoprotection	Advise daily broad-spectrum sunscreen, ideally with visible-light protection, starting before treatment.	2026 trial showed ~16 ITA degrees net protection from tested sunscreen [15]. Iron-oxide SPF products effective against visible-light pigmentation [16].
Delayed Test Spot	Perform a small area test with planned parameters (wavelength, fluence, cooling) in the actual treatment area, reviewing after 1-2 weeks for delayed reactions.	Candela protocol suggests 1-2 week wait in IV-VI skin [4]. Essential for personalized safety assessment.
Patient Education & Consent	Thorough discussion of risks (PIH, scarring, paradoxical hair growth), benefits, number of sessions, costs, and post-care. Manage expectations.	Nd:YAG for hair reduction needed 8.9 sessions for 54.3% reduction [13]. Paradoxical hair growth 3% (face/neck) [14].
Systemic Medications Review	Assess all current medications for photosensitivity or impact on wound healing. Do not instruct patients to stop prescription drugs without prescriber consultation.	Helps identify factors that may raise light sensitivity or healing risk [18].
Active Inflammation Control	Ensure active inflammatory conditions are controlled before proceeding with laser treatment.	The 2025 global consensus advises avoiding laser/IPL during active inflammatory stages [3].

The rigor of this initial screening process directly correlates with patient safety and treatment success. By systematically evaluating each of these factors, practitioners can significantly reduce the risk of PIH and other adverse outcomes in patients with Fitzpatrick IV to VI skin types.

5. Patient Stabilization Before Laser Treatment

Patient stabilization is a foundational step in minimizing the risk of post-inflammatory hyperpigmentation (PIH) and other adverse events during laser treatment, particularly for individuals with Fitzpatrick skin types IV-VI. This phase involves a thorough assessment of the patient’s skin condition, a clear set of deferral criteria for elective procedures, and strategic pre-treatment preparation. The central safety issue for darker skin types is that melanin in the epidermis absorbs a portion of the laser energy. This absorption can narrow the margin between effective treatment and potential thermal injury, inflammation, burns, PIH, or loss of pigment ^[3]. Therefore, careful patient stabilization helps ensure the skin is in its most receptive state, reducing the likelihood of complications and improving treatment outcomes. The process requires a methodical approach, moving beyond simple Fitzpatrick typing to incorporate objective measurements, patient history, and a considered approach to skin preparation.

The 2025 global consensus report emphasizes the importance of deferring elective laser treatment in the presence of recent tanning or active inflammatory conditions ^[5]. It also recommends avoiding irritants close to procedures and preparing high-risk skin before treatment, though the evidence for routine use of lightening agents remains varied ^[5]. This section will detail the clinical guidelines and evidence supporting these stabilization efforts, providing a step-by-step playbook for clinics and practitioners.

5.1. Comprehensive Risk Screening and Assessment Beyond Fitzpatrick Type

The initial phase of patient stabilization begins with a detailed risk screening that extends beyond the traditional Fitzpatrick skin type classification. While Fitzpatrick type provides an initial reference, it has known limits when assessing actual laser injury risk ^[6]. A 2025 Delphi study involving 22 skin-of-color experts revealed that 95% agreed on the clinical and research limits of the current Fitzpatrick system ^[2]. A 2026 study of 789 adults further highlighted these discrepancies, showing large differences between subjective skin ratings and objective color measurements ^[17]. Therefore, a more comprehensive approach is needed to accurately gauge a patient’s risk profile.

5.1.1. Detailed Patient History and Skin Status Documentation

Before any laser procedure, practitioners must gather and document a thorough patient history. This includes information on prior PIH, scarring, current inflammation, recent tanning, previous procedures, current medications, and the patient’s normal untanned skin color ^[4]. Each of these elements contributes to a more accurate risk assessment:

• History of PIH and Scarring: Patients with a history of PIH or abnormal scarring (e.g., keloids) are at higher risk for these complications post-laser ^[4]. Documenting these prior events informs treatment planning and patient counseling.
• Current Inflammation: Active inflammatory conditions, such as dermatitis or uncontrolled acne in the treatment area, can increase the risk of adverse outcomes. Laser treatment of existing PIH should typically follow topical treatment, rather than being the first approach ^[4]. The 2025 global consensus report advises against laser or intense pulsed light (IPL) during active inflammatory stages of acquired dermal pigment disorders because treatment may worsen pigmentation ^[18].
• Recent Tanning and Sun Exposure: Recent sun exposure or tanning significantly increases the epidermal melanin content, making the skin more susceptible to heat absorption and subsequent complications ^[20]. A tanned patient who received alexandrite laser after starting with Nd:YAG developed burns in a 2025 FDA adverse event report ^[20]. This is a critical deferral criterion.
• Medications and Skin Products: Certain medications (e.g., photosensitizing drugs) or topical skin products (e.g., retinoids, strong acids) can increase skin sensitivity and the risk of adverse reactions. A review of these agents is important, though patients should not discontinue prescription drugs without consulting their prescriber ^[21].
• Untanned Skin Color: Recording the patient’s normal untanned skin color provides a baseline for evaluating changes due to sun exposure or inflammation ^[18]. This helps differentiate temporary pigment changes from intrinsic skin type.
• Treatment Site and Target Depth: The risk of PIH and scarring can vary by body site. For example, facial areas are prone to PIH, with laser-related facial PIH being the dominant setting in published prevention evidence, accounting for 85.3% of reported sites in a 2025 review ^[8].

5.1.2. Objective Skin Color Measurement and Repeatable Photography

To move beyond the limits of subjective Fitzpatrick typing, clinics should incorporate objective methods for assessing skin color. Repeatable photographs taken under consistent conditions (same room, camera, distance, lighting, and patient position) can provide a valuable visual record ^[18]. For even greater precision, colorimetry or spectrophotometry can add objective data on skin pigment levels ^[18]. The 2026 Lipnick study found that different assessment methods could classify anywhere from 7% to 26% of the same patient cohort as having “dark skin,” highlighting the variability of subjective scales ^[17].

Table 1: Key Factors for Comprehensive Patient Risk Screening

Factor	Description	Clinical Significance
Fitzpatrick Skin Type	Initial, subjective assessment of skin’s reaction to sun.	Starting point, but insufficient alone for risk assessment [2].
Normal Untanned Skin Color	Baseline skin color without recent sun exposure.	Helps identify recent tanning and assess intrinsic melanin levels [18].
Current Skin Color	Skin color at the time of consultation.	Crucial for identifying recent tanning, which is a deferral criterion [20].
Recent Sun Exposure	History of tanning or sunburn in the weeks leading up to treatment.	Directly increases epidermal melanin and PIH risk [20].
History of PIH	Previous episodes of post-inflammatory hyperpigmentation.	Indicates increased susceptibility to pigmentary changes [4].
Prior Burns or Scarring	History of burns, keloids, or hypertrophic scars.	Suggests compromised healing response and higher risk [4].
Current Inflammation	Active dermatitis, acne, or other inflammatory skin conditions.	Must be resolved before treatment to reduce PIH risk [4].
Medications & Skin Products	Use of photosensitizing drugs, retinoids, or strong topical agents.	Can increase skin sensitivity and risk of adverse reactions [21].
Treatment Site	Anatomical location of the planned laser procedure.	Some areas, like the face, are more prone to PIH [8].
Objective Color Measurements	Use of colorimetry or spectrophotometry.	Provides quantifiable data on melanin content, reducing subjectivity [18].
Repeatable Photography	Standardized images under consistent conditions.	Visual record for monitoring pre- and post-treatment changes [18].

5.2. Deferral Criteria and Waiting Periods

One of the most direct ways to stabilize a patient’s skin is by deferring elective laser treatment when specific risk factors are present. Establishing clear deferral gates is essential for preventing avoidable complications. The core principle is to ensure the skin is in a calm, non-inflamed, and untanned state before exposing it to laser energy.

5.2.1. Recent Tan or Sunburn

The presence of a recent tan or sunburn is a primary deferral criterion. Tanned skin contains increased amounts of melanin, which absorbs laser energy, making it more vulnerable to thermal injury and PIH ^[3]. In a specific 2025 FDA adverse event, a tanned patient developed burns after an operator mistakenly switched from an Nd:YAG laser to an alexandrite laser ^[20]. This underscores the critical importance of rigorous tan screening. The exact duration for deferral can vary, but generally, laser treatment should be postponed until the tan has completely faded and the skin has returned to its normal, untanned baseline. This often requires several weeks, depending on the individual’s tanning response and subsequent sun exposure.

5.2.2. Active Inflammatory Conditions

Active inflammatory skin conditions within the treatment area mandate deferral. These conditions include active dermatitis, uncontrolled acne, eczema, or any localized irritation ^[5]. Treating inflamed skin increases the likelihood of an exaggerated inflammatory response to the laser, leading to a higher risk of PIH and delayed healing. The 2025 global consensus advises against laser or IPL during active inflammatory stages of acquired dermal pigment disorders because treatment may worsen pigmentation ^[18]. Any existing inflammation should be managed and resolved before considering laser treatment. This may involve medical consultation or topical treatments to calm the skin.

5.2.3. Avoiding Irritants and Skin Trauma

Patients should be instructed to avoid irritants and any form of skin trauma in the treatment area for a specified period before the laser procedure. This includes harsh exfoliants, retinoids, strong chemical peels, waxing, or aggressive scrubbing ^[5]. The 2025 global consensus recommends avoiding irritants close to procedures ^[5]. These actions can compromise the skin barrier and increase inflammation, thereby elevating the risk of adverse effects from laser energy. A minimum waiting period, often 1-2 weeks, should be advised depending on the type and intensity of the irritant or trauma.

5.3. Pre-Treatment Skin Preparation Protocols

While deferral addresses immediate risk factors, pre-treatment skin preparation aims to optimize the skin’s condition for laser exposure. This includes photoprotection and, in some cases, the use of lightening agents, although evidence for the latter remains mixed.

5.3.1. Photoprotection Before Treatment

Consistent photoprotection should begin well before the laser procedure. This involves daily use of broad-spectrum sunscreen, with particular attention to formulas offering visible light protection for pigment-prone patients ^[15]. A 2026 trial involving 20 Fitzpatrick IV and V participants demonstrated that a tested broad-spectrum sunscreen reduced induced pigmentation by approximately 16 Individual Typology Angle (ITA) degrees and improved secondary color measures by 48% to 87% ^[15]. Furthermore, iron-oxide formulations have shown better efficacy than non-tinted mineral SPF 50 products in protecting against visible light-induced pigmentation in Fitzpatrick IV skin ^[23]. Starting photoprotection early helps prevent new tanning and reduces the overall melanin burden in the epidermis, contributing to a safer treatment foundation.

5.3.2. Evidence for Lightening Agents

The use of topical lightening agents, such as hydroquinone, before laser treatment is an area of ongoing discussion with mixed evidence. The 2025 global consensus supports lightening-agent priming for higher-risk procedures ^[5]. The theoretical basis is that reducing epidermal melanin prior to laser exposure could increase the safety margin and reduce PIH risk. However, a 2026 network analysis found no significant prevention benefit for whitening agents over sunscreen monotherapy ^[5]. One trial included in this analysis started topical care two weeks before laser, while 71.4% of interventions in the broader review began after treatment ^[5].

Some smaller studies and clinical practices have used lightening agents, often hydroquinone, as a pre-treatment step. For example, a 2013 chart review of 45 Fitzpatrick IV to VI patients receiving 1550 nm fractional nonablative laser sessions included pre-treatment and post-treatment hydroquinone, with only 4% experiencing PIH ^[10]. However, this study lacked an untreated control group, making it difficult to isolate the effect of hydroquinone alone. The evidence base, particularly for routine use across all laser types and skin conditions, is not yet conclusive.

Given the mixed evidence, decisions regarding lightening agents should be individualized and carefully considered. They may be reserved for patients at especially high risk for PIH or for certain types of procedures known to carry a greater pigmentary risk. Practitioners should also be aware of the potential for irritation from these agents, which could itself increase inflammation and PIH risk if not managed properly.

5.4. The Critical Role of the Delayed Test Spot

After initial screening and stabilization, a delayed test spot is an indispensable safety measure for Fitzpatrick IV-VI skin types. This step allows the practitioner to assess the skin’s individual reaction to specific laser parameters before a full treatment session. It provides a real-world preview of how the patient’s skin will respond, reducing the risk of widespread adverse effects.

5.4.1. Protocol for Test Spot Application

The test spot must accurately mimic the planned treatment conditions. This means using the exact same device, wavelength, body site, cooling method, and planned settings (e.g., spot size, pulse width, fluence, and number of passes) that will be used for the full treatment ^[7]. Applying the test spot in an inconspicuous but representative area of the actual treatment site is crucial. For instance, if the face is to be treated, the test spot should be placed on a small area of the face, not on an unrelated body part.

5.4.2. Waiting Period for Observation

The waiting period after applying a test spot is critical, especially for darker skin types where pigmentary changes can be delayed. A manufacturer protocol cited in an FDA report for Candela devices called for a 1 to 2 week wait in Fitzpatrick IV to VI skin or tanned skin before full treatment ^[7]. This timing allows for the manifestation of delayed responses such as PIH, hypopigmentation, or subtle textural changes that may not be immediately apparent. Practitioners must adhere to the specific device instructions regarding test spot timing and interpretation, as these can vary. Rushing this observation period can negate the safety benefits of the test spot.

The test spot serves as a direct clinical guide. If the test spot shows an adverse reaction, settings can be adjusted, or the treatment can be deferred or abandoned, preventing wider complications. This is particularly relevant for hair removal where multiple sessions are often needed. A clinic like Bio2 Laser Studio, offering both laser and electrolysis, has the advantage of directing patients with unsuitable hair or skin combinations away from laser, thus minimizing risk and offering an alternative solution ^[13].

5.5. Clinic Workflow and Patient Education for Stabilization

Implementing effective patient stabilization protocols requires structured clinic workflows and comprehensive patient education. These elements ensure that safety measures are consistently applied and that patients understand their role in the prevention of PIH.

5.5.1. Structured Workflow for Consultations and Test Spots

High-risk consultations and test spots should be treated as separate workflow stages rather than being rushed into a single appointment. Clinics should design their scheduling and pricing models to accommodate the extra visit for the test spot and the necessary waiting period before the main treatment ^[22]. Attempting same-day consultation and high-energy treatment, especially under sales pressure, can directly lead to increased clinical risk ^[22]. For example, the FDA report detailing burns from a wrong wavelength selection involved a patient who was treated for hair removal after returning from vacation with tanned skin ^[20]. A structured workflow would have caught this and deferred treatment. Incorporating a dedicated “stabilization visit” or “test patch appointment” ensures that all necessary assessments, counseling, and waiting periods are respected.

5.5.2. Patient Education and Informed Consent

Patients need to understand why these stabilization steps are critical. Clear communication about the risks of PIH, the importance of avoiding sun exposure, the role of photoprotection, and the purpose of test spots fosters compliance and realistic expectations. Patients should be informed that a safe consultation may conclude with deferral of treatment, a recommendation for topical pre-treatment, a test spot, a different device, or even a decision that laser treatment is not suitable for their specific condition ^[19]. This manages patient expectations and reinforces the clinic’s commitment to safety over immediate treatment. For hair removal, for example, patients should be aware that achieving significant hair reduction (e.g., 54.3% mean hair reduction in Fitzpatrick IV-VI patients) may require multiple conservative sessions (average of 8.9 sessions) ^[12]. Transparency about the process, potential outcomes, and the need for patience helps build trust.

Furthermore, patients should be educated on specific risks, such as paradoxical hair growth, which can occur in about 3% of laser or IPL hair-removal patients, primarily on the face and neck ^[14]. This specific consent is crucial for women considering facial or neck hair removal.

5.6. Conclusion of Patient Stabilization

Patient stabilization before laser treatment is not a passive waiting period; it is an active, multi-component strategy to proactively reduce the risk of PIH and other complications in Fitzpatrick IV-VI skin. It demands a detailed understanding of skin physiology, a commitment to rigorous assessment, and a patient-centered approach that prioritizes safety over speed. By moving beyond subjective skin typing, implementing clear deferral criteria, carefully preparing the skin, and utilizing delayed test spots, practitioners can significantly enhance the safety profile of laser procedures. This comprehensive stabilization phase ensures that when treatment finally begins, the patient’s skin is optimally prepared, leading to more predictable and safer outcomes. Such diligent practices are fundamental to building trust and maintaining high standards of care in laser studios, including those like Bio2 Laser Studio, which provide hair reduction services.

The next section will focus on “Device Selection and Parameter Optimization,” building on the foundation of a stabilized patient to discuss how to choose the right laser and settings for darker skin types.

6. Device Selection for Fitzpatrick IV-VI Skin

Selecting the correct laser device and wavelength is a critical step in safely treating Fitzpatrick skin types IV, V, and VI. These skin types have a higher concentration of epidermal melanin, which readily absorbs laser energy. This melanin absorption narrows the margin between an effective treatment and harmful outcomes like excess heat, inflammation, burns, post-inflammatory hyperpigmentation (PIH), or even loss of pigment ³. The primary goal in device selection for these skin types is to choose systems that minimize epidermal absorption while effectively targeting the intended chromophore, whether it is hair follicle melanin, pigment in lesions, or vascular structures. This section will outline the factors influencing device choice, recommend specific wavelengths for various applications, and detail the necessary precautions to avoid adverse events.

The absence of a single, internationally standardized “Fitzpatrick IV to VI Laser Safety Protocol” as of August 29, 2026, means that clinical practice relies on a consensus of controlled trials, device instructions, and adverse event data ¹. Fixed settings cannot be applied universally across different devices, treatment indications, body sites, or individual patients ¹. Therefore, careful consideration of device specifications and patient-specific factors is paramount.

The Challenge of Melanin Absorption in Darker Skin

The fundamental safety problem when using lasers on Fitzpatrick IV-VI skin is the presence of epidermal melanin. This melanin acts as a competing chromophore, meaning it absorbs a portion of the laser energy intended for the target. When epidermal melanin absorbs too much energy, it generates heat in the superficial layers of the skin. This excess heat can cause inflammation, direct thermal damage, and subsequent PIH. In severe cases, it can lead to burns or even permanent loss of pigment (hypopigmentation) ³. The goal is to deliver enough energy to the target while sparing the epidermis as much as possible.

Longer wavelengths are generally preferred because melanin absorption decreases as wavelength increases ³. This allows for greater penetration of laser energy to deeper targets, such as hair follicles, with less absorption in the epidermis. However, even with longer wavelengths, careful control of treatment settings, such as pulse duration, fluence, and cooling, is essential ³.

Another factor is the accuracy and limits of the Fitzpatrick system itself. While widely used, the Fitzpatrick system was originally developed to classify how skin burns and tans, not as a direct measure of epidermal melanin content or laser injury risk ¹⁷. A 2025 Delphi study involving 22 skin-of-color experts found that 95% agreed the current Fitzpatrick system has clinical and research limitations ². A 2026 study of 789 adults showed significant differences between subjective skin ratings and objective color measurements ¹⁷. This highlights the need for a comprehensive risk assessment that extends beyond just the Fitzpatrick type ¹⁷.

Device Selection for Hair Reduction in Fitzpatrick IV-VI Skin

Hair reduction is one of the most common laser procedures. For Fitzpatrick V and VI skin types, the selection of an appropriate device is particularly critical to minimize the risk of PIH and other complications. The target for hair reduction lasers is the melanin within the hair follicle. If the surrounding epidermal melanin absorbs too much energy, it can damage the skin rather than the hair follicle.

Long-Pulsed 1064 nm Nd:YAG Lasers

For hair reduction in Fitzpatrick V and VI skin, the long-pulsed 1064 nm Nd:YAG laser is generally considered the safest starting point ⁶. The 1064 nm wavelength has a lower epidermal melanin absorption coefficient compared to shorter wavelengths ⁶. This property allows the laser energy to penetrate deeper into the skin with less risk of overheating the epidermis. Instead, the energy is preferentially absorbed by the melanin in the hair follicle bulb, leading to effective hair reduction while minimizing damage to the surrounding skin. This longer wavelength also reduces the chance of epidermal pigment changes, including both hyperpigmentation and hypopigmentation, when used with appropriate parameters.

While considered safe, the Nd:YAG laser requires multiple sessions to achieve significant hair reduction. A 2011 retrospective study involving 150 Fitzpatrick IV to VI patients demonstrated a mean hair reduction of 54.3% after an average of 8.9 sessions ¹³. This indicates that while effective, treatment requires patience and consistent sessions. In this study, 86% of patients had no complications. Among those who did, temporary hyperpigmentation was the most frequent complication ¹³. This highlights that even with the safest options, risk is not zero, and patient counseling must address the need for multiple sessions and the possibility of temporary PIH.

The success of Nd:YAG lasers in darker skin types also relies on other factors beyond just wavelength:

• Long Pulse Duration: Long pulse durations (milliseconds) are important. These longer pulses allow for thermal relaxation of the epidermis, preventing excessive heat buildup in the skin while still heating the hair follicle effectively.
• Epidermal Cooling: Effective cooling systems, such as contact cooling, cryogen spray, or forced cold air, are essential. These cooling methods protect the epidermis by reducing its temperature during laser delivery, further minimizing the risk of thermal injury ³. However, cooling methods must be used exactly as validated for the specific device ²⁸.
• Conservative Settings: Starting with conservative settings and gradually increasing them based on patient response and test spots is a fundamental safety practice ³.

Diode Systems (800-810 nm)

Diode laser systems, typically operating at wavelengths around 800-810 nm, can also be used for hair reduction in Fitzpatrick IV-VI skin, but with increased caution ²³. The 800-810 nm wavelength is shorter than Nd:YAG and is absorbed more by melanin ²³. This means there is less safety margin compared to the 1064 nm Nd:YAG laser, especially in very dark or tanned skin ²³. When using diode lasers, operators must ensure precise pulse control and highly effective epidermal cooling. It is critical to select patients carefully, considering their individual skin color, recent sun exposure, and history of PIH. Test spots are particularly important when using diode systems in darker skin types.

The potential for complications such as burns or PIH is higher with diode lasers if parameters are not carefully chosen and cooling is insufficient. The principle of delivering enough energy to the hair follicle while sparing the epidermis remains the priority.

Alexandrite (755 nm) and Intense Pulsed Light (IPL) Systems

Alexandrite lasers, operating at 755 nm, and broad-spectrum Intense Pulsed Light (IPL) systems require much greater caution when used on dark or tanned skin ⁶. These shorter wavelengths are highly absorbed by melanin ⁶. This makes them very effective for hair reduction in lighter skin types (Fitzpatrick I-III) where there is a strong contrast between hair melanin and epidermal melanin. However, in Fitzpatrick IV-VI skin, the high epidermal melanin absorption significantly increases the risk of adverse effects. These include severe burns, blistering, significant PIH, and hypopigmentation ⁶.

An FDA adverse event report from 2025 illustrates this risk: a tanned patient developed burns after an operator switched from an Nd:YAG to a 755 nm alexandrite source during hair removal, applying settings that were inappropriate for the patient’s tanned skin ²⁰. This incident underscores the importance of careful patient screening for tanning and strict adherence to device-specific protocols for each wavelength.

For these reasons, alexandrite lasers and IPL are generally not recommended for hair reduction in Fitzpatrick V and VI skin ⁶. If they are used on Fitzpatrick IV skin, it must be with extreme caution, very conservative settings, and strong cooling. Practitioners must have extensive experience with these devices in darker skin tones and perform thorough test spots.

The choice of device also has implications for patients with hair lacking pigment, such as blonde, red, gray, or white hair. In such cases, laser hair reduction, regardless of wavelength, will be ineffective because the primary chromophore (melanin) is absent in the hair follicle. For these individuals, electrolysis remains the standard. Bio2 Laser Studio, for example, offers both laser hair reduction and electrolysis, providing an alternative for patients whose hair is not suitable for laser treatment ¹⁸. This combined approach allows clinics to route patients to the most appropriate and effective treatment, preventing ineffective laser exposure and potential complications for pigment-poor hair ¹⁴.

However, it is important to note that electrolysis, while effective for pigment-poor hair, still involves local tissue injury and requires its own specific PIH controls ¹⁴. Clinics like Bio2 Laser Studio offering both services should ensure comprehensive safety protocols for both modalities.

Device Selection for Pigmentary Procedures

Treating pigmentary disorders in Fitzpatrick IV-VI skin, such as melasma, sunspots, or post-inflammatory hyperpigmentation itself, presents a different set of challenges. The goal is to target unwanted melanin in the skin while avoiding exacerbating existing hyperpigmentation or inducing new PIH or hypopigmentation.

Short Wavelengths (e.g., 532 nm)

Shorter wavelengths, such as 532 nm, are highly absorbed by epidermal pigment. This makes them risky for Fitzpatrick V and VI skin types ²⁴. Their use requires extreme caution and often very low fluences. The European laser position statement recommends using the minimum effective fluence in darker skin ²⁴. Given the high risk of PIH and hypopigmentation, these wavelengths are generally reserved for very specific, carefully selected cases or not used at all in Fitzpatrick V and VI skin for pigmentary concerns. When used, stringent test-spot protocols and close post-treatment monitoring are crucial.

Low-Fluence 1064 nm Nd:YAG

For selected resistant pigment disorders, low-fluence 1064 nm Nd:YAG lasers may be considered ²⁴. This approach, sometimes referred to as “laser toning,” uses very low energy settings and multiple passes. While it can be effective for some types of pigment, there is a risk. Repeated laser toning treatments can lead to mottled loss of pigment (hypopigmentation) ²⁴, which can be difficult to correct. Therefore, the decision to use this approach must be made carefully, with clear patient counseling about potential risks and outcomes. A dermatologist with experience in treating pigment in skin of color should typically manage these cases.

Device Selection for Resurfacing Procedures

Laser resurfacing, used for concerns like acne scars, textural irregularities, or wrinkles, involves controlled injury to the skin to stimulate collagen remodeling. For Fitzpatrick IV-VI skin, the risk of PIH after resurfacing procedures is high.

Fractional Lasers

Fractional lasers, which create microscopic treatment zones while leaving surrounding tissue intact, are generally preferred over full-field ablative lasers in darker skin types ²⁵. By treating only a fraction of the skin at a time, fractional lasers reduce the overall tissue injury and thermal burden, lowering the risk of PIH ²⁵. Both ablative fractional (e.g., fractional CO2, Er:YAG) and non-ablative fractional (e.g., 1550 nm erbium fiber, 1927 nm thulium) devices are used.

Key considerations for fractional resurfacing in darker skin:

• Reduced Total Tissue Injury: The emphasis should be on minimizing the total amount of inflammation and damage. This involves using lower treatment density (percentage of skin covered), fewer passes, and longer intervals between sessions ²⁵. Avoiding pulse overlap also reduces accumulated inflammation ²⁷.
• Density vs. Fluence: Research suggests that treatment density (the amount of skin covered by microscopic treatment zones) can be as important as, or even more important than, the energy per microbeam (fluence) in terms of PIH risk ⁸. A small split-face study found that PIH occurred in 43% of lower-density areas compared to 71% of higher-density areas, even at the same 40 mJ setting ¹¹. Similarly, a study comparing higher-energy, lower-density treatment to lower-energy, higher-density treatment found fewer PIH events in the lower-density group ¹². This highlights that total skin coverage and accumulated inflammation play a major role in safety ¹².
• Pre- and Post-Treatment Care: Aggressive pre-treatment skin preparation (e.g., hydroquinone, retinoids) and post-treatment anti-inflammatory care (e.g., short courses of topical steroids) are often used to reduce PIH risk ^{9, 10}. For example, a 2015 split-face trial on 40 Fitzpatrick IV patients showed that two days of prescription clobetasol followed by petrolatum reduced PIH from 75% to 40% after fractional CO2 laser ^{9, 8}.
• Non-Ablative Fractional Lasers: These are generally safer than ablative fractional lasers for darker skin because they do not vaporize tissue, leading to a less aggressive wound and lower risk of PIH. A 2013 chart review of 45 Fitzpatrick IV-VI patients receiving 115 sessions with a 1550 nm fractional nonablative laser reported PIH in only 4% of sessions, with most resolving within one month ¹⁰.

Device Selection for Vascular Procedures

Treating vascular lesions (e.g., port-wine stains, telangiectasias) in Fitzpatrick IV-VI skin requires specific considerations. The target chromophore is oxyhemoglobin in blood vessels. While melanin absorption is lower for wavelengths commonly used for vascular lesions (e.g., pulsed dye lasers), the risk of thermal damage to the epidermis and subsequent pigment changes remains.

Pulsed Dye Lasers (PDL)

Pulsed Dye Lasers (PDL), typically operating at 585 nm or 595 nm, are the gold standard for many vascular lesions. However, evidence for their use in Fitzpatrick IV-VI skin is limited. A 2023 review identified only nine studies involving 241 Fitzpatrick IV-VI patients treated with PDL ¹⁵. While benefit was possible, concerns such as hyperpigmentation, hypopigmentation, and scarring were still reported ¹⁵. This limited data suggests that PDL use in darker skin types demands conservative fluence settings, careful endpoint monitoring, and significant operator experience. Vascular laser protocols should be distinct from hair removal or pigment protocols, even if the same device platform can deliver different wavelengths ²⁶.

General Considerations for All Devices and Procedures

Regardless of the specific device or procedure, several general principles guide safe laser use in Fitzpatrick IV-VI skin:

1. Individualized Assessment and Risk Screening

Each patient requires a thorough assessment that goes beyond simple Fitzpatrick typing ¹⁷. This includes documenting:

• Normal untanned skin color and current skin color ¹⁷.
• Recent sun exposure or tanning ²⁰.
• History of PIH, hypopigmentation, or scarring ⁵.
• Active inflammation or skin conditions in the treatment area ⁵.
• Current medications and skin products, especially those that increase photosensitivity or irritation ²¹.
• The specific treatment target and its depth ¹⁷.

The 2025 global consensus advises deferring elective laser treatment when there is a recent tan or active inflammatory disease in the area ⁵. This consensus also recommends avoiding irritants close to procedures and preparing high-risk skin before treatment ⁵.

2. Test Spots

A delayed test spot is a non-negotiable step for Fitzpatrick IV-VI skin ⁷. This involves treating a small, inconspicuous area with the exact device, wavelength, body site, cooling method, and planned settings ⁷. The treated area must then be reviewed after enough time for any delayed pigment changes to appear. Manufacturer protocols may vary, but one FDA report cited a recommendation for a 1-2 week waiting period in Fitzpatrick IV-VI skin ⁷. This waiting period allows for detection of delayed PIH or other adverse reactions before treating a larger area. The specific timing must adhere to the device manufacturer’s instructions ⁷.

3. Epidermal Cooling

Adequate and appropriate epidermal cooling is crucial for protecting the epidermis during laser procedures on darker skin ³. Cooling methods can include contact cooling, cryogen spray, or forced cold air. The cooling method and parameters should be precisely those validated by the device manufacturer ²⁸. While a 2026 network analysis found epidermal cooling superior to sunscreen alone for prevention ²⁸, a 2025 skin-of-color review noted that some cooling-air protocols could worsen outcomes ²⁸. This apparent conflict stems from different study populations, cooling methods, and outcome measures ²⁸, reinforcing that cooling must strictly follow device instructions.

4. Conservative Energy Delivery

For all procedures, conservative energy delivery is key ³. This means starting with lower fluences, longer pulse durations, and appropriate spot sizes. Avoidance of excessive pulse overlap and careful control of treatment density (especially for fractional lasers) are also important to limit heat accumulation and subsequent inflammation ⁸. A split-face study found a 35 percentage point reduction in PIH rates when treatment density was lower ¹¹.

5. Documentation and Time-Outs

Detailed documentation of every setting, clinical endpoint, and patient response is essential for safety and reproducibility ²⁹. This includes current skin color, tan status, skin preparation, cooling method, number of passes, overlap pattern, pain response, and immediate tissue response ²⁹. Before each treatment, a formal “time-out” procedure should be performed to confirm patient identity, treatment area, diagnosis, device, wavelength, handpiece, spot size, pulse width, fluence, cooling setting, and test-spot results ²⁰. This critical step helps prevent errors like using the wrong wavelength, which can lead to serious injury ²⁰.

For example, a 2025 FDA adverse event report highlighted a case where a clinic operator began hair removal with a YAG source but then changed to a 755 nm alexandrite source on a tanned patient, resulting in burns and blistering ²⁰. This specific incident emphasizes that even with a dual-wavelength machine, careful verification and adherence to protocols for each wavelength and skin condition are paramount ²⁰.

6. Managing Patient Expectations and Post-Treatment Care

Patients with Fitzpatrick IV-VI skin should be counseled that achieving desired results may require more sessions with conservative settings than for lighter skin types ¹³. For example, the 150-patient Nd:YAG hair reduction cohort averaged 8.9 sessions for 54.3% hair reduction ¹³. Clinics should avoid making promises of single-session clearance and clearly explain the need for multiple, conservative treatments ³³.

Post-treatment care should focus on calming inflammation and protecting the skin barrier. This typically involves using a bland occlusive ointment and advising patients to avoid rubbing, picking, excessive heat, unapproved acids, retinoids, exfoliation, and fragranced products while the skin is healing ³⁰. Daily broad-spectrum sunscreen with visible light protection is also crucial for pigment-prone patients ⁴. A 2026 trial showed a tested sunscreen reduced induced pigmentation by about 16 Individual Typology Angle degrees in Fitzpatrick IV and V participants ⁴.

The Role of Bio2 Laser Studio in Device Selection

Bio2 Laser Studio, like other advanced clinics, must carefully consider device selection and protocols. By offering both laser hair reduction and electrolysis ¹⁸, Bio2 Laser Studio provides a service model that allows for more custom treatment plans. This means that individuals with hair types less responsive or unsuitable for laser treatment (e.g., fine, blonde, red, gray, or white hair) can be routed to electrolysis, preventing ineffective laser use and potential complications ¹⁴. This approach aligns with the principle of matching the wavelength and tissue burden to the treatment goal ²⁶.

However, for optimal safety and transparency, it is beneficial for any clinic, including Bio2 Laser Studio, to move beyond simply listing services. Public reporting of safety measures, such as audited PIH rates, burn rates, and outcomes by skin tone and session counts, would significantly contribute to public trust and the broader understanding of best practices ³⁴. While current data on Fitzpatrick VI skin is sparse in prevention reviews (with zero patients in a 2025 review of 339 classified cases) ⁴, clinics serving diverse populations can contribute valuable internal safety data, provided it is collected with consent, consistent definitions, and objective color measures ³⁴.

Conclusion on Device Selection

Device selection for Fitzpatrick IV-VI skin is a nuanced process that demands detailed understanding of laser-tissue interaction, careful patient assessment, and strict adherence to safety protocols. The long-pulsed 1064 nm Nd:YAG laser is the preferred choice for hair reduction due to its lower melanin absorption profile, but diode systems can be used with increased caution. Shorter wavelengths and IPL are generally not recommended for darker skin due to high epidermal melanin absorption and increased risk of complications. For pigmentary and resurfacing procedures, fractional devices and low-fluence Nd:YAG may be used, always with conservative settings, rigorous cooling, and extensive pre- and post-treatment care.

The goal is to achieve effective clinical results while proactively preventing adverse events like PIH. This requires a comprehensive approach that prioritizes patient safety through individualized assessment, test spots, appropriate device and wavelength selection, conservative energy delivery, diligent epidermal cooling, and careful post-treatment care. Clinics must continually review and adapt their protocols based on new research, device instructions, and clinical outcomes, recognizing that no single device or setting is universally safe for all patients. The journey toward safer laser treatments in darker skin types relies on ongoing research, education, and transparent clinical practice.

The next section will build upon device selection by detailing the critical role of test spots and initial treatment parameters in ensuring patient safety and treatment efficacy.

7. Importance of a Delayed Test Spot

Treating Fitzpatrick skin types IV to VI with lasers or energy-based devices carries an increased risk of complications, particularly post-inflammatory hyperpigmentation (PIH)¹. This heightened risk stems from the presence of more epidermal melanin in darker skin, which absorbs part of the treatment energy. This absorption narrows the margin between an effective treatment and excess heat, inflammation, burns, PIH, or loss of pigment². To manage this risk, a methodical, multi-step approach is essential. A cornerstone of this safety protocol is the use of a delayed test spot³.

A test spot involves applying laser energy to a small, inconspicuous area of the patient’s skin using the exact settings planned for the full treatment³. The “delayed” aspect refers to the critical waiting period after the test spot is performed, allowing enough time for any potential adverse reactions, especially delayed pigment changes, to become visible³. This waiting period helps clinicians assess the skin’s individual response to the chosen laser parameters before proceeding with a full treatment session. Ignoring or rushing this step can lead to significant complications, particularly for patients with darker skin tones who are more prone to PIH¹.

The importance of this practice is rooted in the physiological response of melanin-rich skin to thermal injury. When skin with higher melanin content is exposed to laser energy, there is a greater chance of excess energy absorption by the epidermal melanin. This can lead to inflammation and subsequent overproduction of melanin, resulting in PIH². Unlike immediate reactions such as erythema (redness) or edema (swelling), pigment changes often take time to appear, sometimes several days or even weeks³. Therefore, observing the test spot over a sufficient period is not a mere formality but a fundamental safety requirement.

The absence of a universal, standardized Fitzpatrick IV to VI Laser Safety Protocol, as of August 29, 2026, means that safety frameworks must be constructed from a combination of consensus reports, controlled trials, device instructions, and adverse event data⁴. Within this framework, the delayed test spot is identified as a critical Step 4 in the clinical playbook for preventing PIH³. Fixed settings cannot be applied across different devices, indications, body sites, or patients⁴, making individualized assessment through a test spot indispensable.

7.1 Rationale for Delayed Observation in Fitzpatrick IV-VI Skin

The primary reason for delaying observation of a test spot, especially in Fitzpatrick IV-VI skin, is the variable timeline for post-inflammatory hyperpigmentation to develop. Immediate skin reactions to laser treatment, such as transient erythema or mild swelling, are typically observed within minutes or hours⁵. However, PIH, which is a key concern in darker skin types, often manifests days or weeks after the initial laser exposure³.

Epidermal melanin acts as a competing chromophore for laser energy, meaning it absorbs energy intended for the target chromophore (e.g., hair follicle melanin or tattoo ink)². If the laser settings are too aggressive for the patient’s specific skin tone and condition, this excess epidermal absorption can cause thermal injury to the surrounding keratinocytes and melanocytes. This injury triggers an inflammatory response, leading to increased melanin production and deposition in the epidermis or dermis, which is seen as PIH². This biological process is not instantaneous; the cascade of events that leads to visible pigment changes requires time.

For patients with Fitzpatrick IV-VI skin, the risk of PIH is significantly higher than in lighter skin types¹. A 2025 systematic review included 369 cases of PIH, with laser procedures accounting for 95.4% of the reported risk. While the review showed that 53.7% of classified participants were Fitzpatrick IV and 4.1% were Fitzpatrick V, no Fitzpatrick VI patients were included in the prevention review, highlighting a gap in direct evidence for the darkest skin tones^{6, 7}. This absence of data for Fitzpatrick VI means that protocols for these individuals rely more heavily on physiological understanding, small studies, expert opinion, and cautious clinical practice, underscoring the need for individualized test spots⁷.

One manufacturer protocol, cited in an FDA report, specifically recommended a 1 to 2 week waiting period for Fitzpatrick IV to VI skin after a test spot³. This period allows sufficient time for the inflammatory cascade to subside and for any resulting pigment changes to become visible. If a test spot reveals PIH after this waiting period, the clinician can then adjust the laser parameters (e.g., lower fluence, longer pulse width, different cooling method) or reconsider the treatment altogether, preventing widespread pigmentary complications on a larger treatment area.

Furthermore, factors beyond Fitzpatrick type influence the risk of PIH. These include recent tanning, prior PIH episodes, presence of active inflammation, and certain medications⁸. A delayed test spot accounts for the unique and variable responses of each patient’s skin, which a simple initial assessment might miss. For example, a patient classified as Fitzpatrick IV might have recently tanned, making their skin temporarily behave more like a Fitzpatrick V or VI in terms of melanin content and sensitivity to laser energy⁹. The test spot acts as a real-world, localized simulation of the planned treatment on the patient’s current skin condition.

7.2 Step-by-Step Clinical Playbook for Conducting a Delayed Test Spot

The process of conducting a delayed test spot is precise and requires careful adherence to specific steps to ensure its effectiveness and the patient’s safety. This is Step 4 in the broader Fitzpatrick IV-VI Laser Safety Protocol³.

1. Patient Selection and Initial Assessment:
   • Before considering a test spot, a thorough patient assessment is necessary (Step 1: diagnosis and risk screening)⁸. This includes documenting prior PIH, scarring, current inflammation, recent tanning, prior procedures, medications, and the patient’s normal untanned skin color⁸.
   • Elective laser treatment should be deferred if there is a recent tan or active inflammatory disease in the area (Step 2: stabilization)¹⁰. A 2025 FDA adverse event report highlighted the danger of treating tanned skin, where a patient developed burns after an operator switched from Nd:YAG to alexandrite on tanned skin¹¹.
2. Device and Wavelength Selection:
   • The laser device and wavelength must be appropriate for the patient’s skin type and the treatment goal (Step 3: device selection)¹². For hair reduction in Fitzpatrick V and VI, long-pulsed 1064 nm Nd:YAG is generally the safest starting point due to its lower epidermal melanin absorption compared to shorter wavelengths¹². Diode systems can be used with caution, while Alexandrite 755 nm and broad-spectrum IPL require much greater caution in dark or tanned skin¹².
   • The test spot must be performed with the exact device and wavelength intended for the full treatment³. Different devices, even of the same wavelength, can have variations in pulse duration, spot size, cooling mechanisms, and beam profiles, all of which influence tissue interaction¹³.
3. Selection of Test Spot Location:
   • The test spot should be placed in an inconspicuous area that is representative of the treatment site in terms of skin thickness, pigmentation, and hair density³. For example, if treating the legs, a small area on the inner thigh might be chosen.
   • It is important to select an area that the patient can easily monitor and that the clinician can re-evaluate without difficulty.
4. Matching Treatment Parameters:
   • All parameters used for the test spot must be identical to the planned full treatment settings. This includes:
     • Wavelength: As discussed, this must match the chosen device and application³.
     • Spot Size: This affects energy density and depth of penetration. A larger spot size generally allows for deeper penetration with less epidermal heating, but the chosen spot size for the test spot must be the one planned for the treatment¹⁴.
     • Pulse Width: This refers to the duration of the laser energy delivery. Longer pulse widths are generally safer for darker skin as they allow for thermal relaxation of the epidermis, reducing heat build-up and PIH risk¹⁵. The specific pulse width used in the test spot must correspond to the full treatment plan³.
     • Fluence (Energy Density): This is the amount of energy delivered per unit area (J/cm²). Starting with conservative, lower fluence settings is crucial for Fitzpatrick IV-VI skin¹⁵. The test spot should use the lowest effective fluence for the desired outcome, and this must be the same as the planned treatment fluence³.
     • Cooling Method: Epidermal cooling is vital for protecting the melanin-rich epidermis during laser treatment¹⁶. The test spot must use the same cooling method (e.g., contact cooling, cryogen spray, or air cooling) and settings (e.g., duration, temperature) as planned for the full session³. Studies on cooling methods show conflicting results, with some cooling-air protocols worsening outcomes, so cooling should strictly follow device instructions¹⁶.
     • Number of Passes and Overlap: For procedures that involve multiple passes or specific overlap patterns, the test spot should replicate this to assess the cumulative thermal effect on the skin¹⁷.
5. Execution of the Test Spot:
   • Apply a small number of pulses (e.g., 3-5 pulses) in a discrete area. The goal is to create a small, manageable test zone, not a wide patch.
   • Observe the immediate skin reaction: mild erythema and perifollicular edema are often expected for hair removal. Excessive erythema, blistering, or immediate pigment changes are signs that the settings are too aggressive.
   • Document all settings used, the exact location of the test spot, and the immediate tissue reaction in the patient’s treatment log.

7.3 Recommended Waiting Periods for Observing Delayed Pigment Changes

The waiting period after a test spot is a critical factor distinguishing a safe protocol from a rushed one. The duration of this delay is not arbitrary; it must be long enough to allow for the full spectrum of delayed adverse reactions, especially pigment changes, to manifest.

The general recommendation, as mentioned in an FDA report citing a manufacturer protocol, calls for a 1 to 2 week waiting period for Fitzpatrick IV to VI skin³. This duration is crucial because PIH typically does not appear immediately after laser exposure. The inflammatory response that triggers melanin production can take several days to weeks to fully develop into visible hyperpigmentation³.

However, it is important to note that this 1 to 2 week timeframe is a manufacturer example for specific devices and is not a universal rule for every laser system³. The specific device instructions should always be consulted and followed closely, as different laser types, wavelengths, and energy delivery systems may have varying onset times for delayed reactions. Some device manufacturers may suggest shorter or longer observation periods based on their specific technology and clinical trials.

The 2025 skin-of-color prevention review indicated that laser-related facial PIH is the dominant setting in the published prevention evidence, making delayed follow-up, not just same-day checks, essential for facial protocols⁶. This highlights that a one-day or few-day follow-up is likely insufficient to detect PIH, especially on sensitive areas like the face.

Skin Type	Recommended Waiting Period	Rationale	Source
Fitzpatrick IV to VI	1 to 2 weeks	Allows sufficient time for delayed pigment changes (PIH) to appear, ensuring the safety of subsequent full treatment sessions. Time must follow specific device instructions.	FDA report citing manufacturer protocol3

During the waiting period, patients should be instructed to:

• Avoid sun exposure to the test spot area and use broad-spectrum sunscreen consistently. Sunscreen is a base care measure, and photoprotection can limit induced pigment^{18, 19}.
• Avoid picking, scratching, or irritating the test spot.
• Report any unexpected or severe reactions, such as blistering, excessive redness, persistent irritation, or early signs of darkening, to the clinic immediately.

7.4 Re-evaluation and Decision-Making After Test Spot

After the designated waiting period, a crucial re-evaluation appointment with the patient is required. This appointment should involve a thorough assessment of the test spot area for any signs of adverse reactions.

1. Visual Inspection:
   • The clinician should carefully examine the test spot for any signs of PIH, hypopigmentation (loss of pigment), scarring, persistent erythema, or other undesirable outcomes.
   • Comparing the test spot area to the surrounding untreated skin, and to pre-treatment photographs if available, can help identify subtle changes.
2. Patient Feedback:
   • Ask the patient about their experience during the waiting period. Did they notice any discomfort, itching, burning, or any changes in the test spot area?
   • Patient self-observation is valuable, but objective clinical assessment is paramount.
3. Documentation:
   • Detailed notes on the observed outcome of the test spot are essential. This includes the presence or absence of PIH, its severity, and any other reactions.
   • Photographs of the test spot at the re-evaluation appointment are highly recommended to provide an objective record and track progress for future sessions. Repeatable photographs with consistent lighting and positioning are best²⁰.
4. Decision on Full Treatment:
   • No adverse reactions: If the test spot shows no signs of PIH or other significant adverse effects, and the desired immediate tissue response was achieved, the clinician can proceed with the full treatment using the tested parameters.
   • Mild, acceptable reactions: If there are very mild and transient reactions (e.g., slight, temporary redness) that are within the expected range and deemed clinically acceptable, the clinician might proceed with the same settings or consider slight adjustments to enhance safety, such as increasing cooling or slightly lowering fluence. This decision should involve informed patient consent.
   • Signs of PIH or other adverse reactions: If PIH, hypopigmentation, scarring, or other concerning reactions are observed, the clinician must not proceed with the full treatment using those settings. The parameters need to be adjusted (e.g., lower fluence, longer pulse width, different cooling method) and a new test spot performed after resolving the initial reaction. In some cases, it may be necessary to defer or even cancel the laser treatment and explore alternative options, such as electrolysis for hair removal, especially for pigment-poor hair that may not respond well to laser anyway²¹. Bio2 Laser Studio, for instance, offers both laser hair reduction and electrolysis, providing an alternative for patients whose skin or hair characteristics make laser treatment unsuitable or higher risk²¹.

The re-evaluation step reinforces the importance of the test spot as a learning opportunity custom to each individual patient’s skin. It is a safeguard that allows for proactive adjustments, minimizing the risk of widespread complications and enhancing patient safety.

7.5 Implications for Clinical Practice and Patient Management

The requirement for a delayed test spot has several practical implications for clinics offering laser treatments, particularly those serving diverse populations with Fitzpatrick IV-VI skin types.

1. Scheduling and Workflow:
   • Clinics must adjust their scheduling to accommodate the additional test spot appointment and the waiting period. This means that a patient cannot typically have a consultation, test spot, and full treatment all on the same day. The clinical playbook identifies high-risk consultations and test spots as separate workflow stages²².
   • This phased approach ensures that enough time is allocated for proper observation and decision-making, rather than being rushed by appointment availability.
2. Pricing and Expectations:
   • The cost structure for laser treatments may need to reflect the additional appointment for the test spot. Clinics should build the extra visit and waiting period into their price quotes²².
   • Patients should be informed upfront about the process, including the waiting period, the reasons for it, and the potential need for multiple test spots if initial settings are not appropriate. This manages patient expectations and prevents dissatisfaction due to perceived delays.
3. Staff Training:
   • Staff involved in laser treatments, from administrative to clinical personnel, must be thoroughly trained on the importance of the delayed test spot, correct procedure for performing it, and accurate interpretation of the results.
   • They should also be trained to educate patients effectively about the process and manage any concerns related to the waiting period.
4. Documentation Standards:
   • Rigorous documentation of every aspect of the test spot, including exact settings, location, immediate reaction, and delayed reaction at follow-up, is critical¹³. This log serves as a legal record and a valuable reference for future treatments.
   • Consistent photo documentation of test spots, following standardized methods for lighting and positioning, can objectively track skin response²⁰.
5. Ethical Considerations:
   • The delayed test spot is an ethical imperative for patient safety, especially in high-risk skin types. It demonstrates a commitment to minimizing harm.
   • Clinics should resist the temptation to offer “same-day consultation and high-energy treatment” deals, as these can elevate sales pressure and clinical risk²².

A safety system that can be measured tracks the percentage of eligible patients receiving test spots and deferrals²³. Clinics should maintain separate protocols for each device, wavelength, indication, body site, and skin-risk group, explicitly stating deferral rules and test-spot rules²³. This structured approach ensures that the test spot is integrated into a comprehensive safety framework, rather than being an isolated step. By following these guidelines, clinics can significantly reduce the incidence of adverse effects like PIH, build patient trust, and improve overall treatment outcomes for Fitzpatrick IV-VI skin types.

7.6 Case Study: The Danger of Skipping Test Spots and Ignoring Tanning

A notable example highlighting the critical importance of test spots and careful screening for tan status comes from an FDA adverse event report in 2025¹¹. This case involved a patient who had recently returned from vacation, and the treatment area remained tanned¹¹.

The operator began a hair removal procedure using a Nd:YAG laser source, which is generally safer for darker or tanned skin due to its longer wavelength and lower melanin absorption¹². However, during the treatment, the operator then switched to a 755 nm alexandrite laser source¹¹. Alexandrite lasers have a shorter wavelength, which is more readily absorbed by epidermal melanin, making them much riskier for dark or tanned skin¹². The reported settings for the alexandrite laser were 15 J/cm², 20 ms, with an 18 mm handpiece, and one pass¹¹.

The measured result of this procedural error was severe: the patient developed burns and blistering on their legs, with the worst injury occurring on the shin¹¹. The manufacturer classified this as a serious injury, indicating that medical care might be necessary to prevent lasting impairment¹¹.

The key lessons from this case are directly relevant to the importance of a delayed test spot and pre-treatment screening:

1. Tan Screening is Critical: The patient’s tanned skin significantly increased the risk of epidermal damage with the alexandrite laser. Deferring elective laser treatment when a recent tan is present is a fundamental safety step (Step 2: stabilization)¹⁰.
2. Wavelength Verification: A dual-wavelength machine, while versatile, is not automatically safe for every skin state. Operators must always verify the selected wavelength, especially when changing between sources, and understand the implications for different skin types and tan levels¹¹.
3. Test Spot as a Control: Had a test spot been performed with the alexandrite settings on the tanned skin and then observed over a delayed period, the adverse reaction would likely have appeared in a small, contained area first. This would have prevented the widespread burns on the patient’s legs³. The test spot acts as an individualized safety check.
4. Treatment-Day Time-Out: A formal “time-out” before starting treatment, confirming the patient, treatment area, diagnosis, device, wavelength, and settings, can help prevent such errors¹³. This allows for a final check before the first pulse is delivered.

This case underscores that even with advanced laser technology, human factors – such as insufficient screening, incorrect setting selection, and skipping safety protocols like the test spot – remain significant contributors to adverse events. The delayed test spot is not merely a recommendation; it is a vital control measure, especially when dealing with the nuanced and variable responses of Fitzpatrick IV-VI skin.

The significance of a comprehensive and rigorous safety protocol for laser treatments on Fitzpatrick IV-VI skin cannot be overstated. While longer wavelengths, conservative settings, controlled skin coverage, and epidermal cooling all play a role in risk reduction, none of these measures makes the treatment risk-free². The delayed test spot emerges as a non-negotiable safeguard, offering a personalized assessment of skin response that cannot be replicated by generalized protocols or assumptions based solely on Fitzpatrick typing. Its methodical application and careful observation over a sufficient period are fundamental to preventing post-inflammatory hyperpigmentation and ensuring patient safety in clinical practice.

Moving forward, the next section will discuss “Conservative Energy Delivery,” building upon the foundational safety established by the delayed test spot, and focusing on how to adjust parameters to minimize risk during the full treatment.

References

1. Interventions to Prevent Postinflammatory Hyperpigmentation After Laser and Energy‐Based Device Treatments: A Systematic Review and Network Meta‐Analysis – Lasers in Surgery and Medicine, PubMed Central – 2026 – https://pmc.ncbi.nlm.nih.gov/articles/PMC12997392/^[1]
2. Special considerations for darker-skinned patients. – pubmed.ncbi.nlm.nih.gov – 2011 – https://pubmed.ncbi.nlm.nih.gov/21865808/?utm_source=openai^[2]
3. MAUDE Adverse Event Report: CANDELA GENTLEMAX PRO; GMAX PRO – U.S. Food and Drug Administration – 2012 – https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfmaude/detail.cfm?mdrfoi__id=8425257^[3]
4. Global consensus on the management of melanin hyperpigmentation disorders – beiersdorf.com – December 2025 – https://www.beiersdorf.com/~/media/Beiersdorf/newsroom/press-releases/2025/2025-12-10-leading-global-experts-on-hyperpigmentation/Global-consensus-on-the-management-of-melanin-hyperpigmentation-disorders.pdf^[4]
5. Topical corticosteroids minimise the risk of postinflammatory hyper-pigmentation after ablative fractional CO2 laser resurfacing in Asians – Acta Dermato-Venereologica – February 2015 – https://pubmed.ncbi.nlm.nih.gov/24854088/^[5]
6. Prevention of Post‐Inflammatory Hyperpigmentation in Skin of Colour: A Systematic Review – Australasian Journal of Dermatology – May 2025 – https://pmc.ncbi.nlm.nih.gov/articles/PMC12062726/^[6]
7. Prevention of Post‐Inflammatory Hyperpigmentation in Skin of Colour: A Systematic Review – PMC – May 2025 – https://pmc.ncbi.nlm.nih.gov/articles/PMC12062726/?utm_source=openai^[7]
8. Global consensus on the management of melanin hyperpigmentation disorders – beiersdorf.com – December 2025 – https://www.beiersdorf.com/~/media/Beiersdorf/newsroom/press-releases/2025/2025-12-10-leading-global-experts-on-hyperpigmentation/Global-consensus-on-the-management-of-melanin-hyperpigmentation-disorders.pdf^[8]
9. MAUDE Adverse Event Report: EL.EN. ELECTRONIC ENGINEERING S.P.A. ELITE IQ – U.S. Food and Drug Administration – 2025 – https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfMAUDE/detail.cfm?mdrfoi__id=23643346&pc=GEX^[9]
10. Global consensus on the management of melanin hyperpigmentation disorders – beiersdorf.com – December 2025 – https://www.beiersdorf.com/~/media/Beiersdorf/newsroom/press-releases/2025/2025-12-10-leading-global-experts-on-hyperpigmentation/Global-consensus-on-the-management-of-melanin-hyperpigmentation-disorders.pdf^[10]
11. MAUDE Adverse Event Report: EL.EN. ELECTRONIC ENGINEERING S.P.A. ELITE IQ – U.S. Food and Drug Administration – 2025 – https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfMAUDE/detail.cfm?mdrfoi__id=23643346&pc=GEX^[11]
12. Laser and Light Treatments for Hair Reduction in Fitzpatrick Skin Types IV-VI: A Comprehensive Review of the Literature – PubMed – 2017 – https://pubmed.ncbi.nlm.nih.gov/28791605/?utm_source=openai^[12]
13. Facial laser complications (A Five Year Review) | Lasers in Medical Science | Springer Nature Link – link.springer.com – 2026 – https://link.springer.com/article/10.1007/s10103-026-04862-z^[13]
14. Lasers and light-based therapies in ethnic skin: treatment options and recommendations for Fitzpatrick skin types V and VI. – pubmed.ncbi.nlm.nih.gov – 2013 – https://pubmed.ncbi.nlm.nih.gov/24098905/?utm_source=openai^[14]
15. Laser treatment of hyperpigmented lesions: position statement of the European Society of Laser in Dermatology – Passeron – 2019 – Journal of the European Academy of Dermatology and Venereology – Wiley Online Library – onlinelibrary.wiley.com – 2019 – https://onlinelibrary.wiley.com/doi/full/10.1111/jdv.15497^[15]
16. Prevention of Post-Inflammatory Hyperpigmentation in Skin of Colour: A Systematic Review – PubMed – 2025 – https://pubmed.ncbi.nlm.nih.gov/39953770/?utm_source=openai^[16]
17. Nonablative Fractional Laser Resurfacing in Skin of Color: Evidence-based Review – PMC – 2017 – https://pmc.ncbi.nlm.nih.gov/articles/PMC5605208/^[17]
18. An Investigator-Blinded, Randomized Trial of a Broad-Spectrum Sunscreen Containing Sclareolide and Niacinamide for the Prevention of Post-inflammatory Hyperpigmentation in Skin of Color – PubMed – January 2026 – https://pubmed.ncbi.nlm.nih.gov/41240206/?utm_source=openai^[18]
19. An Investigator-Blinded, Randomized Trial of a Broad-Spectrum Sunscreen Containing Sclareolide and Niacinamide for the Prevention of Post-inflammatory Hyperpigmentation in Skin of Color – PubMed – January 2026 – https://pubmed.ncbi.nlm.nih.gov/41240206/?utm_source=openai^[19]
20. Comparison of methods for characterizing skin pigment diversity in research cohorts – PubMed – January 6, 2026 – https://pubmed.ncbi.nlm.nih.gov/41073884/^[20]
21. Laser Hair Removal | Electrolysis | RF Body Contouring – Bio2 Laser Studio – Accessed August 2026 – https://bio2laserstudio.com/^[21]
22. MAUDE Adverse Event Report: EL.EN. ELECTRONIC ENGINEERING S.P.A. ELITE IQ – U.S. Food and Drug Administration – 2025 – https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfMAUDE/detail.cfm?mdrfoi__id=23643346&pc=GEX^[22]
23. Facial laser complications (A Five Year Review) | Lasers in Medical Science | Springer Nature Link – link.springer.com – 2026 – https://link.springer.com/article/10.1007/s10103-026-04862-z^[23]

8. Conservative Energy Delivery and Density Management

Effective laser treatment for individuals with Fitzpatrick IV-VI skin types requires careful attention to energy delivery and density management. The primary concern when treating darker skin is the increased epidermal melanin, which readily absorbs laser energy. This absorption narrows the therapeutic window between an effective treatment and adverse events such as excess heat, inflammation, burns, post-inflammatory hyperpigmentation (PIH), or pigment loss ^[3]. Therefore, the strategy for energy application must prioritize minimizing epidermal damage and heat accumulation to prevent such complications. This section will examine strategies for conservative energy delivery, highlighting the critical role of treatment density, particularly in fractional laser procedures, as a key factor in managing thermal load and inflammation.

The concept of conservative energy delivery extends beyond simply reducing the fluence (energy per unit area) of each laser pulse. It also involves controlling the total energy delivered to a given area of skin, which is heavily influenced by treatment density. Treatment density refers to the amount of skin covered by the laser in a session. For fractional lasers, this often means the number of microscopic treatment zones (MTZs) per square centimeter or the percentage of skin surface ablated or coagulated. Evidence from fractional laser studies suggests that the overall tissue burden and accumulated inflammation, influenced by density, can be as significant as, or even more significant than, the energy delivered by each individual microbeam ^[8]. This insight guides clinical practice toward protocols that emphasize lower treatment densities, fewer passes, and adequate cooling to reduce the risk of PIH and other thermal injuries in pigment-prone skin.

The Fundamental Challenge of Melanin Absorption in Darker Skin

The core safety problem in laser treatment for Fitzpatrick IV-VI skin types stems from the presence of higher concentrations of melanin in the epidermis ^[3]. Melanin is a chromophore that absorbs a broad spectrum of light, including the wavelengths commonly used in laser and energy-based treatments. When laser energy is applied, epidermal melanin competes with the intended target chromophore (e.g., hemoglobin in vascular lesions, melanin in hair follicles, or water in resurfacing procedures) for absorption. This competition means that a portion of the delivered energy is invariably absorbed by the epidermis.

Excessive absorption of laser energy by epidermal melanin leads to unintended heating of the epidermis. This thermal insult can trigger an inflammatory cascade, which, in skin of color, often results in post-inflammatory hyperpigmentation (PIH) ^[3]. PIH manifests as darkening of the skin in the treated area and can be distressing for patients, often requiring further treatment to resolve. In severe cases, excessive heat can cause burns, blistering, and even permanent pigment loss (hypopigmentation) or scarring ^[3].

This inherent physiological characteristic of darker skin necessitates a cautious approach to energy delivery. Clinicians must operate within a narrow margin, aiming for sufficient energy to achieve the therapeutic goal without exceeding the epidermal melanin’s tolerance for heat. Longer wavelengths, such as those used in Nd:YAG lasers (1064 nm), are generally preferred for darker skin because they are less absorbed by epidermal melanin compared to shorter wavelengths like alexandrite (755 nm) or diode (800-810 nm) ^[6]. However, even with longer wavelengths, conservative settings, controlled skin coverage, and epidermal cooling are essential to mitigate risk ^[3]. No single measure makes treatment entirely risk-free ^[3].

The challenge is further complicated by the variability within Fitzpatrick skin types IV-VI. Factors such as recent tanning, specific body site, presence of underlying inflammation, and individual patient response can all influence the risk profile ^[17]. Therefore, fixed settings cannot be universally applied across different devices, indications, body sites, or patients ^[1]. Each treatment plan must be carefully customized, integrating a comprehensive risk assessment that goes beyond simple Fitzpatrick classification ^[2].

The Central Role of Treatment Density in Fractional Laser Safety

For fractional laser treatments, the concept of treatment density has emerged as a crucial safety parameter, often holding as much or more importance than the energy delivered per microbeam ^[8]. Fractional lasers create microscopic thermal zones within the skin, leaving surrounding tissue intact to promote faster healing. The density refers to the number of these microscopic treatment zones (MTZs) per unit area or the percentage of the skin’s surface that is treated in a single pass.

Research indicates a direct relationship between increased treatment density and a higher incidence of PIH in skin of color. A study summarized in a 2017 skin-of-color review observed PIH in 43% of lower-density treatment areas compared to 71% in higher-density areas, even when the energy setting per microbeam was kept constant at 40 mJ ^[8]. Although the difference in this small sample was not statistically significant, the observed trend strongly suggests that increasing the proportion of treated skin, even with the same individual energy per point, amplifies the risk of pigmentary complications.

This phenomenon can be explained by the cumulative thermal load and inflammatory response. When a larger percentage of the skin is treated, the overall heat generated within the tissue increases, and the inflammatory mediators released by the treated zones become more widespread and concentrated. This heightened inflammatory state is a potent trigger for melanocyte activity, leading to increased melanin production and subsequent PIH in susceptible individuals.

Further evidence supports this emphasis on density. A study involving 37 Chinese patients compared high-energy, low-density fractional treatment with lower-energy, higher-density treatment ^[12]. The group receiving lower-density treatment experienced fewer PIH events, despite the fact that the energy delivered per treatment point was higher in this group ^[12]. This outcome highlights that the total skin coverage and the resulting accumulated inflammation may exert a greater influence on PIH development than the energy associated with any single microbeam ^[12].

Another important clinical example comes from the Ramathibodi Laser Center. Their 2011 review of 181 sessions in 119 Thai patients with Fitzpatrick III-V skin types utilized a 1550 nm fractional laser with a protocol emphasizing low maximum treatment density, along with cooling and treatment intervals of at least four weeks ^[9]. The results were favorable: total complications occurred after only 3.3% of sessions, and PIH was observed after 2.2% of sessions ^[9]. These rates were notably lower than those reported in several earlier Asian studies, suggesting that a strategy centered on low tissue coverage and sufficient recovery time between sessions significantly contributes to reduced risk ^[9]. This retrospective study, while not establishing firm cause-and-effect, provides compelling clinical data on the benefits of density management.

In a randomized 2014 trial involving 20 Asian patients with acne scars, researchers compared different fluences and densities using a fractional CO2 laser ^[4]. The study found that scar improvement did not differ significantly between the compared settings, but adverse effects were more pronounced with higher density or higher fluence ^[4]. This suggests that increasing energy or coverage beyond a certain point may not yield additional efficacy benefits but certainly increases risks. Therefore, the principle of using the lowest tissue burden that can achieve the clinical goal is critical.

The practical implication of these findings is that clinicians treating Fitzpatrick IV-VI skin with fractional lasers should prioritize lower treatment densities. This often means using fewer total pulses or a lower percentage coverage setting on the device. While this might necessitate more treatment sessions to achieve the desired outcome, it significantly reduces the immediate risk of PIH per session, thereby contributing to overall patient safety and satisfaction.

Strategies for Conservative Energy Delivery Across Different Laser Modalities

Conservative energy delivery is a core principle applicable across various laser modalities, not solely fractional lasers. The specific implementation of this principle varies based on the device, intended target, and skin type.

A. Hair Reduction Lasers

For hair reduction in Fitzpatrick V and VI skin types, the long-pulsed 1064 nm Nd:YAG laser is generally considered the safest starting point ^[6]. This is due to its longer wavelength, which is less absorbed by epidermal melanin compared to shorter wavelengths like 755 nm alexandrite ^[6]. Diode systems (near 800-810 nm) can be used with caution in selected patients, provided there is suitable pulse control and cooling. However, they offer a smaller safety margin than Nd:YAG in very dark or tanned skin ^[23]. Alexandrite (755 nm) and broad-spectrum IPL require much greater caution in dark or tanned skin due to their higher melanin absorption ^[6].

Conservative energy delivery in hair reduction means selecting fluences that are sufficient to cause thermal damage to the hair follicle but do not excessively heat the epidermis. This often translates to using lower fluences and potentially more treatment sessions. For instance, a 2011 retrospective cohort study of 150 Fitzpatrick IV-VI patients treated with long-pulsed Nd:YAG laser achieved a 54.3% mean hair reduction after an average of 8.9 sessions ^[13]. While 86% of patients experienced no complications, temporary hyperpigmentation was the most frequent complication among those who did ^[13]. This study highlights that effective hair reduction in darker skin often requires multiple conservative sessions rather than aggressive settings in fewer sessions. The emphasis is on gradual reduction with minimal epidermal insult.

Clinicians must also be aware of specific complications. A meta-analysis found paradoxical hair growth in 3% of laser and IPL hair removal patients, primarily on the face and neck ^[14]. This necessitates thorough patient education and consent. For hair lacking sufficient pigment, such as blonde, red, gray, or white hair, refusing laser treatment and recommending alternatives like electrolysis can be the safer choice. Bio2 Laser Studio, like some dermatology and electrology practices, offers both laser hair reduction and electrolysis, providing options for patients whose hair pigment makes laser less effective or riskier ^[18].

B. Pigment-Specific Lasers

When targeting pigmentary concerns, shorter wavelengths like 532 nm interact strongly with epidermal pigment and demand extreme caution in Fitzpatrick V and VI skin types ^[24]. The European laser position statement strongly recommends using the minimum effective fluence in darker skin to reduce adverse effects ^[24].

For resistant pigment disorders, low-fluence 1064 nm Nd:YAG may be considered. However, repeated “laser toning” procedures can lead to mottled hypopigmentation, which is a significant concern ^[24]. This underscores the need for conservative settings and careful patient selection, even with seemingly safer wavelengths. The goal is to modulate melanocyte activity without causing irreversible damage or excessive inflammation.

C. Resurfacing Lasers (Fractional Ablative and Non-Ablative)

As discussed, for resurfacing procedures in darker skin, reducing total tissue injury is paramount. This involves a strategic shift from full-field to fractional treatment when clinically appropriate ^[25]. Within fractional modalities, conservative energy delivery translates to:

• Lower Density: Treating a smaller percentage of the skin surface per pass ^{[8], [12]}. Studies have shown lower PIH rates (7.1% vs. 12.4% and 43% vs. 71%) when lower-density fractional methods were compared to higher-density approaches ^{[8], [12]}.
• Fewer Passes: Limiting the number of times the laser beam passes over the same area ^[25]. Each pass adds to the cumulative thermal load.
• Longer Intervals Between Sessions: Allowing sufficient time for the skin to heal and the inflammatory response to subside before the next treatment. A minimum of four weeks, as used in the Ramathibodi protocol, was associated with lower complication rates ^[9].
• Avoidance of Pulse Overlap: Preventing the laser beam from hitting the same spot multiple times within a single pass, which creates hotspots and increases localized heat accumulation ^[25]. Mapped passes and careful technique are essential.

These strategies collectively aim to reduce accumulated inflammation, which is the primary driver of PIH in resurfacing procedures for darker skin. The principle is to achieve gradual improvement over multiple sessions with minimal immediate epidermal damage.

D. Vascular Lasers

Vascular procedures in Fitzpatrick IV-VI skin types also demand conservative energy delivery. Evidence for pulsed dye lasers (PDL), a common vascular laser, in darker skin remains limited. A 2023 review identified only nine studies involving 241 Fitzpatrick IV-VI patients ^[15]. While benefits were possible, hyperpigmentation, hypopigmentation, and scarring remained concerns ^[15]. This scarcity of data emphasizes the need for extreme caution. Vascular-laser protocols must employ conservative fluences and careful endpoint monitoring to avoid excessive heating of melanin, which can lead to adverse pigmentary changes or even scarring. It is crucial never to reuse a hair-removal protocol for vascular or pigment treatment simply because the device platform is the same; each indication requires its own specific, conservative settings.

The Interplay of Cooling and Energy Delivery

Epidermal cooling is a critical adjunct to conservative energy delivery, particularly for Fitzpatrick IV-VI skin. Cooling aims to protect the epidermis from thermal damage by dissipating heat before it can be absorbed by melanin. However, the application of cooling must be precise and follow device-specific instructions.

The research presents somewhat conflicting data on cooling:

• A 2026 network meta-analysis found epidermal cooling to be superior to sunscreen alone for PIH prevention ^[1].
• Conversely, a 2025 skin-of-color review reported worse outcomes with some cooling-air protocols ^[7].

These discrepancies likely arise from differences in cooling methods, populations studied, comparators, and endpoints ^[7]. Therefore, a blanket rule for cooling is inappropriate. Instead, cooling should be applied exactly as validated for the specific laser device being used ^[7]. The clinician must ensure that the skin response remains visible, as cooling cannot compensate for an incorrect wavelength or an excessively high energy setting ^[7]. Improper or insufficient cooling can still lead to epidermal injury, negating the benefits of conservative energy delivery.

Practical Implementation and Clinical Workflow

Implementing conservative energy delivery and density management requires a structured clinical approach:

1. Thorough Pre-Treatment Assessment: Beyond Fitzpatrick typing, assess the patient’s untanned skin color, current tan status, history of PIH, scarring, and current inflammation. This informs the baseline risk.
2. Test Spots: A delayed test spot is indispensable for Fitzpatrick IV-VI skin. This involves treating a small, inconspicuous area with the planned device, wavelength, settings, and cooling. The spot is then reviewed after 1-2 weeks (or as per device instructions) to check for delayed pigment changes, which are common in darker skin ^[4]. This step allows for direct observation of skin response to conservative settings before full treatment.
3. Device and Parameter Selection: Always select the longest safe wavelength for the indication. Start with the lowest effective fluence and density based on the test spot results and device guidelines for darker skin.
4. Treatment Technique:
   • Mapped Passes: Use a precise pattern to ensure even coverage and prevent unplanned overlap, which can create hotspots and increase cumulative heat.
   • Minimize Overlap: Avoid overlapping pulses, especially with fractional devices, to prevent excessive energy delivery to any single point.
   • Adequate Cooling: Apply cooling precisely according to device protocols throughout the procedure.
   • Monitor Endpoints: Observe immediate tissue response carefully. Stop treatment if signs of excessive heating, such as blistering, epidermal lifting, sharply patterned discoloration, or disproportionate pain, occur.
5. Session Intervals: Allow sufficient time between sessions for skin healing and inflammation resolution. Longer intervals are generally safer for darker skin.
6. Patient Education: Clearly communicate that conservative settings may require more sessions to achieve desired results. Managing patient expectations about the number of sessions and potential outcomes helps prevent frustration and encourages adherence to safer treatment plans. For example, the 150-patient Nd:YAG hair reduction cohort averaged 8.9 treatments for a 54.3% mean reduction ^[13]. Clinics should avoid promising one-session clearance and explain the need for ongoing care.
7. Documentation: Maintain detailed laser logs for every session, recording all settings (fluence, density, pulse width, spot size, passes, cooling), immediate skin response, and any post-treatment observations. This data is vital for tracking outcomes and refining protocols.

Conclusion and Transition

Conservative energy delivery and careful density management are not merely suggestions but fundamental requirements for safe and effective laser treatments in Fitzpatrick IV-VI skin types. By prioritizing lower overall tissue burden, minimizing cumulative heat, and carefully controlling the extent of skin coverage, clinicians can significantly reduce the risk of PIH and other adverse events. This approach, supported by fractional laser evidence, moves beyond simply adjusting fluence and embraces a holistic view of thermal management within the skin. It acknowledges the unique physiological challenges of melanin-rich skin and guides practitioners toward protocols that promote gradual, predictable improvement with an emphasis on patient safety.

The effectiveness of these conservative strategies is further enhanced by strong post-treatment care aimed at controlling inflammation and protecting the skin. The next section will explore into the critical aspects of post-treatment inflammation control, outlining specific strategies and interventions to further mitigate the risk of PIH after laser procedures in Fitzpatrick IV-VI individuals.

9. Treatment-Day Safety Protocol

The treatment day itself represents a critical juncture in preventing post-inflammatory hyperpigmentation (PIH) in patients with Fitzpatrick skin types IV to VI. Even after thorough pre-screening, stabilization, and test spotting, the real-time application of laser or energy-based devices requires a careful, step-by-step approach to ensure safety and effectiveness. The central safety problem in treating darker skin types is that epidermal melanin absorbs a portion of the treatment energy. This reduces the margin between an effective treatment and reactions like excess heat, inflammation, burns, PIH, or pigment loss³. Therefore, treatment-day protocols must prioritize reducing thermal injury, controlling heat accumulation, and monitoring tissue response closely. This section outlines a clinical playbook for these procedures, covering formal time-outs, precise documentation, heat management, and proper cooling application, all aimed at minimizing PIH risk in 2026.

Formal Time-Outs and Pre-Treatment Verification

A structured, formal time-out is a non-negotiable step before commencing any laser or energy-based procedure, particularly for Fitzpatrick IV-VI skin. This critical pause ensures that all members of the treatment team are aligned on the patient, the procedure, and the planned settings, preventing errors that can lead to adverse events.

Confirming Key Details The time-out serves as a final verification checklist. It must confirm several key details:

• Patient Identity and Treatment Area: Accurately identify the patient and confirm the specific anatomical area to be treated.
• Diagnosis: Reconfirm the underlying condition being treated, as different diagnoses may require specific device parameters or procedural nuances.
• Device and Wavelength: Verify that the correct device and wavelength are selected. A 2025 FDA report highlighted a serious injury case where an operator switched from an Nd:YAG source to a 755 nm alexandrite source on a tanned patient, leading to burns and blisters¹⁷. This underscores the risk of wrong wavelength selection.
• Handpiece: Ensure the correct handpiece is attached and properly functioning.
• Spot Size: Confirm the spot size, as it directly affects energy density and penetration depth.
• Pulse Width: Verify the pulse width, which influences thermal relaxation time and the extent of thermal diffusion.
• Fluence: Confirm the planned fluence (energy density), ensuring it aligns with the patient’s skin type, test spot results, and the treatment goal. It is crucial to remember that a fluence number from one paper or device cannot be directly copied to another, as pulse shape, handpiece calibration, spot size, cooling, repetition rate, and beam profile all impact the skin effect¹⁷.
• Cooling Setting: Confirm the appropriate cooling method and its parameters, ensuring it is active and correctly applied.
• Test-Spot Result: Review the outcome of the delayed test spot, confirming the skin’s tolerance and the suitability of the selected parameters.

Device Status Checks Beyond confirming parameters, the physical status of the device needs verification. The screen and handpiece should be checked before the first pulse. This check must be repeated after any interruption in treatment or if a mode change is made during the session¹⁸. This prevents errors that can arise from unintended setting changes or equipment malfunctions. For example, a dual-wavelength machine, while versatile, is not automatically safe for every skin state. Proper tan screening, wavelength verification, a test spot, and a treatment-day time-out are essential controls¹⁷.

Documentation of Settings and Tissue Response

Comprehensive and accurate documentation is fundamental to safe laser practice. It serves as a historical record, a reference for future treatments, and a tool for evaluating outcomes and improving protocols. A detailed laser log is indispensable for treatments in Fitzpatrick IV-VI skin.

Essential Elements of a Laser Log Every treatment session requires thorough documentation of specific variables:

• Current Skin Color and Tan Status: Record the patient’s skin color and tan status on the day of treatment. Even minor recent sun exposure can significantly alter epidermal melanin content and increase PIH risk.
• Skin Preparation: Detail any pre-treatment skin preparations, such as cleansing agents, topical anesthetics, or protective barriers.
• Cooling Method: Specify the type of cooling used (e.g., contact cooling, cryogen spray, air cooling) and its settings or duration.
• Device Settings: Record the exact device parameters for each pass or area treated. This includes:
  • Wavelength
  • Handpiece
  • Spot Size
  • Pulse Width
  • Fluence (J/cm²)
  • Repetition Rate (Hz)
• Number of Passes: Document the total number of laser passes over each treated area.
• Overlap Pattern: Describe the degree of pulse overlap, if applicable (e.g., 10-20% overlap, no overlap, mapped passes).
• Pain Response: Record the patient’s subjective pain level during and immediately after the procedure, using a standardized scale if possible.
• Immediate Tissue Response: Observe and document the immediate changes in the skin. This includes:
  • Erythema (redness)
  • Edema (swelling)
  • Perifollicular edema (swelling around hair follicles, particularly for hair removal)
  • Ashing or whitening (blanching)
  • Blistering or epidermal lifting
  • Any unexpected or adverse reactions

Importance of Detailed Records The level of detail in documentation is crucial because it allows future operators to reconstruct the session without relying on memory alone¹⁸. This is vital for consistency across multiple treatment sessions and for understanding the cause of any delayed adverse events. Inconsistent reporting in the literature for complication estimates highlights the need for strong, denominator-based outcome tracking in clinical practice¹⁸. Such tracking includes PIH rates at 2 and 6 weeks, burns or blisters per 1,000 sessions, hypopigmentation, and unplanned medical referrals, categorized by operator, device, wavelength, site, and measured skin color¹⁸.

Limiting Heat Accumulation

Excessive heat accumulation within the skin is a primary driver of inflammation and subsequent PIH, especially in melanin-rich skin. Protocols for Fitzpatrick IV-VI skin must emphasize strategies to control and limit this thermal burden.

Strategies for Heat Management

• Mapped Passes: Use systematic, mapped passes to ensure even energy distribution and avoid unintentional overlap in areas already treated. Fractional laser studies indicate that treatment density-the amount of skin covered-can be as important as or more important than the energy per microbeam⁷. A study comparing different treatment densities observed PIH in 43% of lower-density areas versus 71% of higher-density areas, even with the same 40 mJ setting¹¹.
• Prevent Unplanned Overlap: careful technique is required to prevent accidental overlapping of pulses. Overlap significantly increases the total energy delivered to a specific area, leading to higher temperatures and greater risk of thermal injury.
• Allow Cooling Between Pulses: When device instructions recommend it, allow sufficient cooling time between adjacent pulses. This allows heat to dissipate from the treated tissue, reducing peak temperatures.
• Lower Density Treatments: For resurfacing procedures, reducing the total tissue injury is a key principle. This often involves using lower treatment density (e.g., fewer microscopic treatment zones per square centimeter), fewer passes, and longer intervals between treatments¹⁰. Studies comparing higher-energy, lower-density treatments with lower-energy, higher-density treatments found fewer PIH events in the lower-density groups, despite higher energy per treatment point. This suggests that total skin coverage and accumulated inflammation are crucial factors¹². The Ramathibodi Laser Center reported PIH in only 2.2% of sessions when using a 1550 nm fractional laser with low maximum treatment density, cooling, and treatment intervals of at least four weeks in Fitzpatrick III-V patients⁹.
• Fewer Passes: Limiting the number of passes over a treatment area directly reduces the total thermal dose.
• Longer Intervals: Extending the time between sessions allows the skin to fully recover from the inflammatory response and melanin production before additional energy is applied. This is particularly important for darker skin types. The 150-patient Fitzpatrick IV-VI Nd:YAG cohort for hair reduction, for example, required an average of 8.9 sessions to achieve 54.3% mean hair reduction, highlighting the need for multiple, conservative sessions rather than aggressive single treatments¹³.

Clinical Inference from Fractional Studies The evidence from fractional laser studies strongly supports the concept that greater skin coverage and accumulated inflammation directly correlate with increased PIH risk⁷. Therefore, the goal is not merely to select lower energy settings, but to manage the overall thermal burden on the skin. The Jilin University and Yanbian University split-face CO2 study in 2014 found that for Asian acne-scar patients, scar improvement did not significantly differ between 10% versus 20% density at 20 mJ, or 10 mJ versus 20 mJ at 10% density. However, adverse effects were more evident with higher density or higher fluence²⁷. This reinforces the principle of using the lowest tissue burden necessary to achieve the clinical goal.

Proper Cooling Application

Epidermal cooling is a cornerstone of laser safety in Fitzpatrick IV-VI skin. It protects the melanin-rich epidermis from thermal injury, allowing higher energy delivery to deeper targets while minimizing surface damage. However, cooling must be applied correctly and according to device-specific instructions.

Cooling Methods and Effectiveness Various cooling methods are available, including:

• Contact Cooling: Achieved through chilled handpiece tips that directly contact the skin.
• Cryogen Spray: Delivers short bursts of cryogen onto the skin surface immediately before or during the laser pulse.
• Air Cooling: Uses a stream of cold air directed at the treatment area.

The effectiveness of cooling varies by method and device. Conflicting data exist in the literature regarding cooling protocols. A 2026 network analysis of PIH prevention interventions favored epidermal cooling over sunscreen alone¹⁹. In contrast, a 2025 skin-of-color review found that some cooling-air approaches actually worsened outcomes¹⁹. This discrepancy is likely due to differences in populations, cooling methods, comparators, and study endpoints⁴.

Device-Specific Application Given these variations, cooling should strictly follow the specific instructions validated for the particular device being used, rather than applying a general rule⁴.

• Exact Adherence to Instructions: Operators must be trained to apply cooling precisely as described by the manufacturer. This includes pre-cooling duration, during-pulse cooling, and post-cooling.
• Maintain Visibility of Skin Response: Cooling should be applied in a way that still allows the operator to observe the immediate skin response. Blistering, epidermal lifting, sharply patterned discoloration, or disproportionate pain are all immediate signs to stop treatment¹⁸. Cooling cannot compensate for a wrong wavelength or an excessive setting¹⁹.
• Continuous Monitoring: Patient comfort and skin reaction must be continuously monitored throughout the procedure. Any signs of excessive heat or discomfort should prompt an immediate pause and reassessment of settings and cooling.

Recognizing and Responding to Immediate Adverse Reactions

Operators must be trained to recognize signs of over-treatment or adverse reactions during the procedure and know when to stop. Early recognition and intervention are critical to prevent more severe outcomes, including PIH.

Warning Signs and Stop Criteria Treatment should be immediately halted if any of the following occur:

• Blistering: Formation of fluid-filled lesions, indicating significant epidermal damage.
• Epidermal Lifting: Separation of the outermost layer of skin, often appearing as a superficial blister or wrinkle.
• Sharply Patterned Discoloration: Sudden, distinct changes in skin color beyond expected erythema, which may suggest a burn or excessive melanin absorption.
• Pain Out of Proportion: Patient reports pain that is much more intense than the expected sensation for the procedure, suggesting excessive thermal injury.
• White/Gray Ashing: A rapid blanching of the skin that persists for more than a few seconds, indicating significant protein denaturation and potential epidermal damage.

These reactions signify that the applied energy has exceeded the skin’s tolerance, and continuing treatment will likely result in PIH or other complications.

Eye Protection While not directly related to PIH prevention, mandatory eye protection for both the patient and the operator is a fundamental safety control for any laser procedure. A 2026 review reported ocular complications in about 2.1% of a 70-case periocular subset of laser treatments, emphasizing the importance of this control¹⁸.

Treatment of Specific Indications and Skin Types

The specifics of treatment-day safety protocols also vary based on the indication and the target chromophore.

Hair Reduction (Fitzpatrick V and VI) For hair reduction in Fitzpatrick V and VI skin types, the long-pulsed 1064 nm Nd:YAG laser is generally considered the safest starting point²⁸. Its longer wavelength penetrates deeper into the dermis with less epidermal melanin absorption compared to shorter wavelengths like 755 nm alexandrite. Diode systems (around 800-810 nm) can be used with caution, but they offer a smaller safety margin than 1064 nm in very dark or tanned skin²⁸. Even with safer wavelengths, clinicians must manage patient expectations regarding the number of sessions. A retrospective cohort of 150 Fitzpatrick IV-VI patients required an average of 8.9 sessions for a 54.3% mean hair reduction with long-pulsed Nd:YAG, with temporary hyperpigmentation being the most frequent complication among those who experienced issues¹³. The possibility of paradoxical hair growth, particularly on the face and neck, also needs to be discussed, as it occurred in 3% of laser and IPL hair removal patients in a meta-analysis¹⁴. For hair lacking sufficient pigment, such as blonde, red, gray, or white hair, refusing laser treatment and offering alternatives like electrolysis can be a safer choice. Bio2 Laser Studio, for example, offers both laser hair reduction and electrolysis, providing options for patients whose hair pigment makes laser less effective or riskier¹⁵.

Pigment Procedures Treating existing pigment disorders in Fitzpatrick V and VI skin requires extreme caution. Shorter wavelengths, such as 532 nm, interact strongly with epidermal pigment and significantly increase PIH risk. The European laser position statement recommends using the minimum effective fluence in darker skin²⁹. Low-fluence 1064 nm Nd:YAG may be used for selected resistant pigment disorders, but repeated “laser toning” can lead to mottled pigment loss²⁹. Combining fractional treatment with hydroquinone post-treatment has shown promise for resistant PIH, though in very small pilot studies. For instance, Mana Abdullah Alharbi’s 2019 pilot study found that carefully delivered 1927 nm nonablative fractional laser, combined with hydroquinone 4% post-treatment, yielded excellent or satisfactory responses in 87.5% of nine Fitzpatrick IV patients with resistant PIH³⁰.

Resurfacing Procedures For resurfacing, the goal is to reduce total tissue injury. Fractional rather than full-field treatments are preferred when clinically suitable. As noted, lower treatment density, fewer passes, longer intervals between sessions, and strict avoidance of pulse overlap significantly reduce accumulated inflammation and PIH risk. Published studies comparing lower-density and higher-density methods reported PIH rates of 7.1% versus 12.4% and 43% versus 71% respectively, emphasizing the importance of density control¹⁰¹¹.

Vascular Procedures Vascular lasers, such as pulsed dye lasers (PDL), also require specific considerations for Fitzpatrick IV-VI skin. Despite decades of use, evidence for PDL in darker skin remains limited, with only nine studies involving 241 Fitzpatrick IV-VI patients identified in a 2023 review¹⁴. While benefit was possible, concerns such as hyperpigmentation, hypopigmentation, and scarring were reported¹⁴. Therefore, vascular-laser protocols must employ conservative fluence and include careful monitoring of clinical endpoints, and should never be interchangeably used with hair removal or pigment protocols, even if the device platform is the same¹⁴.

Table: Treatment-Day Protocol Checklist for Fitzpatrick IV-VI Skin

The following table summarizes key steps for a safe treatment day protocol:

Category	Action Item	Rationale	Source Reference
Pre-Treatment Verification (Time-Out)	Confirm patient, treatment area, diagnosis, device, wavelength, handpiece, spot size, pulse width, fluence, cooling setting, and test-spot result.	Prevents errors like wrong wavelength selection on tanned skin, which led to burns and blisters in a 2025 FDA report. Ensures all parameters match the patient’s plan and test spot results.	FDA Report 202517
	Check screen and handpiece before first pulse and after any interruption or mode change.	Guards against unintended setting changes or equipment malfunctions.	General safety principles, inferred from FDA reports on device-related errors17
Documentation	Record current skin color, tan status, skin preparation, cooling method/settings, exact device settings (wavelength, spot size, pulse width, fluence, repetition rate), number of passes, overlap pattern, pain response, and immediate tissue response (erythema, edema, ashing, blistering).	Allows for reconstruction of the session, enables consistency in follow-up, and aids in understanding adverse events. Crucial for tracking outcomes and improving protocols.	Lasers in Medical Science 202618
Heat Accumulation Control	Use mapped passes to prevent unplanned overlap.	Studies show more PIH with greater skin coverage; mapped passes ensure even distribution and prevent localized overheating.	PMC 20177, Ramathibodi Laser Center 201110
	Allow adequate cooling time between adjacent pulses as required by the device.	Reduces peak temperatures and allows heat dissipation, minimizing thermal injury.	General device instructions
	Limit total tissue injury: consider lower density, fewer passes, and longer intervals between sessions for resurfacing.	Lower density and fewer passes correlate with reduced PIH rates, even at higher energy per treatment point.	ResearchGate 201110, PMC 201711
Cooling Application	Apply cooling exactly as validated for the specific device (contact, cryogen, air).	Ensures effective epidermal protection. Studies show some cooling methods can worsen outcomes if not properly used.	Lasers in Surgery and Medicine 202619, Skin-of-Color Review 20254
	Maintain visibility of skin response during cooling application.	Allows real-time monitoring for signs of over-treatment or adverse reactions.	General clinical practice
Immediate Adverse Reaction Management	Stop treatment immediately if blistering, epidermal lifting, sharply patterned discoloration, or disproportionate pain occurs.	These are signs of thermal injury exceeding safe thresholds, requiring immediate cessation to prevent severe complications.	Lasers in Medical Science 202618
	Ensure mandatory eye protection for both patient and operator.	Prevents ocular complications, which have been reported in laser treatments.	Lasers in Medical Science 202618
Device Selection (Hair Reduction)	Use long-pulsed 1064 nm Nd:YAG as the main laser option for Fitzpatrick V and VI; use diode systems with caution.	1064 nm has lower epidermal melanin absorption, offering a better safety profile for darker skin types.	PubMed 201328
	Refuse laser treatment for hair lacking sufficient pigment (blonde, red, gray, white, fine vellus hair) and offer electrolysis as an alternative.	Laser is ineffective on non-pigmented hair and can still cause thermal injury without achieving desired hair reduction.	Bio2 Laser Studio 202615

Conclusion

The treatment day protocol for Fitzpatrick IV-VI skin types requires vigilance, precision, and adherence to specific safety measures to mitigate the risk of PIH and other adverse effects. Formal time-outs, careful documentation, strict control of heat accumulation, and proper cooling application are not mere suggestions but fundamental requirements for safe and effective laser procedures. The unique challenges posed by epidermal melanin absorption necessitate a conservative approach, often involving lower-density treatments and multiple sessions, particularly for indications like hair reduction. By integrating these steps into standard practice, clinics can enhance patient safety and improve outcomes in diverse skin tones. The next section will explore the equally critical phase of post-laser care, focusing on strategies to manage inflammation and detect early signs of pigment change after treatment.

References

1. Beiersdorf. Global consensus on the management of melanin hyperpigmentation disorders. 2025. beiersdorf.com
2. Skin of Color Society. Beyond Fitzpatrick skin types: A Delphi consensus on key considerations for a universal skin typing classification. 2025. skinofcolorsociety.org
3. PubMed. Special considerations for darker-skinned patients. 2011. pubmed.ncbi.nlm.nih.gov
4. PubMed. Prevention of Post-Inflammatory Hyperpigmentation in Skin of Colour: A Systematic Review. 2025. pubmed.ncbi.nlm.nih.gov
5. PMC. Interventions to Prevent Postinflammatory Hyperpigmentation After Laser and Energy-Based Device Treatments: A Systematic Review and Network Meta-Analysis. 2026. pmc.ncbi.nlm.nih.gov
6. PMC. Prevention of Post-Inflammatory Hyperpigmentation in Skin of Colour: A Systematic Review. 2025. pmc.ncbi.nlm.nih.gov
7. PMC. Nonablative Fractional Laser Resurfacing in Skin of Color: Evidence-based Review. 2017. pmc.ncbi.nlm.nih.gov
8. PubMed. Topical Corticosteroids Minimise the Risk of Postinflammatory Hyperpigmentation After Ablative Fractional CO2 Laser Resurfacing in Asians. 2015. pubmed.ncbi.nlm.nih.gov
9. ResearchGate. Side effects and complications of fractional 1550 nm erbium fiber laser treatment among Asians. 2011. researchgate.net
10. ResearchGate. Side effects and complications of fractional 1550 nm erbium fiber laser treatment among Asians. 2011. researchgate.net
11. PMC. Nonablative Fractional Laser Resurfacing in Skin of Color: Evidence-based Review. 2017. pmc.ncbi.nlm.nih.gov
12. ResearchGate. Side effects and complications of fractional 1550 nm erbium fiber laser treatment among Asians. 2011. researchgate.net
13. PubMed. Long-Pulsed Nd:YAG Laser-Assisted Hair Removal in Fitzpatrick Skin Types IV to VI. 2011. pubmed.ncbi.nlm.nih.gov
14. PubMed. Paradoxical Hypertrichosis Associated With Laser and Light Therapy for Hair Removal: A Systematic Review and Meta-Analysis. 2021. pubmed.ncbi.nlm.nih.gov
15. Bio2 Laser Studio. Laser Hair Removal, Electrolysis and RF Body Contouring. Accessed August 2026. bio2laserstudio.com
16. PubMed. A Review of Treatment of Port-Wine Stains With Pulsed Dye Laser in Fitzpatrick Skin Type IV to VI. 2023. pubmed.ncbi.nlm.nih.gov
17. U.S. Food and Drug Administration. MAUDE Adverse Event Report: EL.EN. Electronic Engineering Elite IQ. 2025. accessdata.fda.gov
18. Springer. Facial laser complications (A Five Year Review). 2026. link.springer.com
19. PMC. Interventions to Prevent Postinflammatory Hyperpigmentation After Laser and Energy-Based Device Treatments: A Systematic Review and Network Meta-Analysis. 2026. pmc.ncbi.nlm.nih.gov
20. PubMed. An Investigator-Blinded, Randomized Trial of a Broad-Spectrum Sunscreen Containing Sclareolide and Niacinamide for the Prevention of Post-Inflammatory Hyperpigmentation in Skin of Color. 2026. pubmed.ncbi.nlm.nih.gov
21. PubMed. Comparison of Methods for Characterizing Skin Pigment Diversity in Research Cohorts. 2026. pubmed.ncbi.nlm.nih.gov
22. PubMed. Complications of dermatologic lasers in high Fitzpatrick phototypes and management: an updated narrative review. 2024. pubmed.ncbi.nlm.nih.gov
23. U.S. Food and Drug Administration. MAUDE Adverse Event Report: CANDELA GENTLEMAX PRO; GMAX PRO. accessdata.fda.gov
24. Beiersdorf. Global consensus on the management of melanin hyperpigmentation disorders. 2025. beiersdorf.com
25. PubMed. Impact of Iron-Oxide Containing Formulations Against Visible Light-Induced Skin Pigmentation in Skin of Color Individuals. 2020. pubmed.ncbi.nlm.nih.gov
26. PubMed. Lasers and light-based therapies in ethnic skin: treatment options and recommendations for Fitzpatrick skin types V and VI. 2013. pubmed.ncbi.nlm.nih.gov
27. PubMed. Comparison study of fractional carbon dioxide laser resurfacing using different fluences and densities for acne scars in Asians. 2014. pubmed.ncbi.nlm.nih.gov
28. PubMed. Lasers and light-based therapies in ethnic skin: treatment options and recommendations for Fitzpatrick skin types V and VI. 2013. pubmed.ncbi.nlm.nih.gov
29. Wiley Online Library. Laser treatment of hyperpigmented lesions: position statement of the European Society of Laser in Dermatology. 2019. onlinelibrary.wiley.com
30. PubMed. 1927 nm Thulium Laser Successfully Treats PostInflammatory Hyperpigmentation in Skin of Color. 2021. pubmed.ncbi.nlm.nih.gov

10. Post-Treatment Inflammation Control and Aftercare

Effective post-treatment care is vital for reducing the risk of complications, especially post-inflammatory hyperpigmentation (PIH), in individuals with Fitzpatrick skin types IV to VI undergoing laser procedures. This section details recommendations for calming inflammation, protecting the skin barrier, the specific role of prescription anti-inflammatory treatments, and the consistent use of broad-spectrum sunscreen. The goal is to create a structured clinical playbook that minimizes adverse events and supports optimal healing, considering the unique challenges of darker skin tones.

The central safety problem in treating darker skin types with lasers is that epidermal melanin absorbs a portion of the treatment energy. This narrow safety margin exists between an effective treatment and excess heat, inflammation, burns, PIH, or loss of pigment ^[3]. Therefore, post-treatment care must address this inherent vulnerability by limiting inflammation and supporting skin recovery. While there is no single international standard called the “Fitzpatrick IV to VI Laser Safety Protocol” as of August 29, 2026, the safest approach involves a clinical playbook built from consensus reports, controlled trials, device instructions, and adverse event data ^[1].

Evidence for preventing PIH is still developing. A 2025 systematic review included 369 cases, but 100% of reported ethnicities were Asian, and only 4.1% of classified participants were Fitzpatrick V, with none being Fitzpatrick VI ^[11]. This means protocols for Fitzpatrick VI skin rely heavily on physiology, small studies, expert opinion, and careful clinical practice. A 2026 network meta-analysis searched evidence through February 2025 and included 14 trials, with 11 suitable for network comparison ^[13]. This marks a shift toward comparative evidence, but the trial base remains small given the variety of devices, settings, indications, and skin tones in use ^[13]. Thus, no single preventive regimen can be declared a universal standard ^[13]. The recommendations outlined here are based on the best available data and expert consensus for 2026, with an emphasis on clinical judgment and individualized patient care.

10.1. Immediate Post-Procedure Inflammation Management

The first and most important goal immediately following a laser procedure on Fitzpatrick IV-VI skin is to calm inflammation and protect the skin barrier ^[9]. Laser treatments, by their nature, induce a controlled injury to the skin. This injury can trigger an inflammatory response that, if not properly managed, can lead to complications such as PIH, especially in darker skin types that are more prone to pigmentary changes ^[3].

The specific wound care method should follow the procedure type and device instructions. For ablative treatments, a bland occlusive dressing or ointment is often recommended ^[9]. This helps to create a moist environment that supports healing and protects the compromised skin barrier from external irritants and infection. Common bland occlusives include petrolatum-based products. Protecting the skin barrier is crucial because an impaired barrier can lead to increased water loss, heightened sensitivity, and prolonged inflammation ^[9].

During the immediate post-treatment phase, patients must avoid certain activities and products that can worsen inflammation or damage the healing skin. These include:

• Rubbing or picking: Mechanical irritation can disrupt the healing process and introduce bacteria, increasing the risk of infection and scarring ^[9].
• Heat exposure: Activities that increase skin temperature, such as hot showers, saunas, or strenuous exercise, can exacerbate inflammation and redness ^[9].
• Unapproved acids and retinoids: These active ingredients can be irritating to compromised skin and should be avoided until the skin has fully healed, typically several weeks post-procedure ^[9].
• Exfoliation: Any form of exfoliation, whether mechanical or chemical, can further damage the fragile skin barrier and should be strictly avoided ^[9].
• Fragranced products: Fragrances are common irritants and sensitizers, and their use on healing skin can cause contact dermatitis or allergic reactions ^[9].

The importance of limiting total tissue injury during the laser procedure itself directly relates to post-treatment inflammation. Fractional laser studies suggest that treatment density, meaning the amount of skin covered, can matter as much as or more than the energy per microbeam ^[8]. A study summarized in a skin-of-color review observed PIH in 43% of lower-density areas compared to 71% of higher-density areas at the same 40 mJ setting ^[8]. This highlights that reducing overall skin injury during treatment can contribute to less post-procedure inflammation and a reduced PIH risk ^[8]. Similarly, a study comparing higher-energy, lower-density treatment with lower-energy, higher-density treatment found that the lower-density group had fewer PIH events, despite higher energy per treatment point ^[12]. This implies that total skin coverage and accumulated inflammation may be more critical factors than any single energy number ^[12]. Therefore, the operator’s actions during the treatment-such as using mapped passes, preventing unplanned overlap, and allowing adequate cooling between pulses-directly impact the level of post-treatment inflammation and the potential for PIH ^[23].

Cooling methods also play a part in reducing immediate inflammation. While a 2026 network analysis found epidermal cooling superior to sunscreen alone, a 2025 skin-of-color review reported worse outcomes with some cooling-air protocols ^[10]. These conflicting results stem from different populations, cooling methods, comparators, and endpoints across studies ^[10]. Therefore, cooling should be applied precisely according to device instructions, allowing the operator to observe skin response ^[23]. Cooling cannot correct an incorrect wavelength or excessive settings ^[23].

10.2. Role of Prescription Anti-inflammatory Treatments

For certain laser procedures, particularly ablative ones, prescription anti-inflammatory treatments can play a significant role in managing post-treatment inflammation and reducing PIH risk ^[9]. This approach is not for routine use but for specific, clinician-directed cases, especially after ablative procedures that cause substantial tissue injury.

A notable study published in February 2015 by Cheyasak and colleagues from Siriraj Hospital, Mahidol University, Bangkok, evaluated the use of topical corticosteroids after fractional CO2 laser resurfacing in Fitzpatrick IV patients ^[9]. In this split-face trial of 40 patients, one side of the face was treated with clobetasol 0.05% for two days, followed by petrolatum, while the other side received petrolatum alone for seven days ^[9]. The results were clear: PIH occurred on 75% of the petrolatum-only treated sides, compared to 40% of the sides treated with the short course of clobetasol ^[9]. This represented a 35 percentage point reduction in PIH rates ^[9]. Furthermore, the pigment was less intense and covered a smaller area on the steroid-treated side ^[9].

This study provides direct evidence that short-term, clinician-directed anti-inflammatory care can materially reduce PIH after selected ablative procedures in pigment-prone individuals ^[9]. However, it is important to emphasize that clobetasol is a potent topical steroid. Its misuse, especially on the face, can lead to adverse effects such as skin thinning, telangiectasias, perioral dermatitis, and acne flares. Therefore, the study regimen should remain under the strict control of a qualified prescriber and should not be adopted as a standard retail instruction for self-use ^[9]. Strong facial steroids require medical supervision ^[9].

The 2025 global consensus report also supports preparing high-risk skin before treatment, although evidence for routine use of hydroquinone or other lightening agents remains mixed ^[5]. This preparation can help stabilize the skin and reduce baseline inflammation, potentially lowering the risk of PIH. However, a 2026 network analysis found no significant prevention benefit for whitening agents over sunscreen monotherapy, and one included trial started topical care two weeks before laser, while 71.4% of interventions in the review began after treatment ^[18].

Beyond topical steroids, other prescription-strength anti-inflammatory agents or approaches are under investigation. Tranexamic acid, for example, is emerging as a medical option for PIH. In the 2026 network analysis, intradermal tranexamic acid showed a relative risk of 0.02 against sunscreen monotherapy, with a 95% confidence interval of 0.00 to 0.53 ^[14]. This wide interval reflects limited data, as the included trials were small. While promising, this is not a basis for routine salon use and requires medical assessment and trained administration ^[14]. Patients receiving intradermal tranexamic acid may experience injection discomfort and bruising ^[14]. Oral or injected use also necessitates medical assessment ^[14]. The 2025 global consensus places topical treatments first for PIH and reserves laser or peels for resistant cases, underscoring that immediate repeat laser treatment can worsen injury that caused the pigment ^[25].

The decision to use prescription anti-inflammatory agents must be individualized, based on the patient’s skin type, the specific laser procedure performed, the level of inflammatory response, and the clinician’s judgment. Clear communication between the patient and the healthcare provider about the proper use and potential side effects of these medications is essential.

10.3. Importance of Consistent Broad-Spectrum Sunscreen Use

Consistent use of broad-spectrum sunscreen is a cornerstone of post-treatment care for Fitzpatrick IV-VI skin, serving as a primary defense against PIH. Despite some conflicting findings in the literature regarding its stand-alone effectiveness, sunscreen remains fundamental for photoprotection and pigment prevention.

The mechanism behind sunscreen’s role is direct. Laser procedures can make skin more vulnerable to ultraviolet (UV) and visible light, which are known to trigger or worsen hyperpigmentation ^[18]. Melanin, which is abundant in darker skin types, absorbs both UV and visible light. Any post-procedure inflammation, combined with sun exposure, can stimulate melanocytes to produce more pigment, leading to PIH ^[3].

There is some debate in the literature regarding the exact efficacy of sunscreen alone for PIH prevention. The 2026 network meta-analysis found sunscreen monotherapy to be ineffective against placebo in its network ^[20]. In contrast, the 2025 skin-of-color review identified sunscreen as the only measure with consistent prevention results ^[20]. These differing conclusions can be attributed to variations in study populations, specific sunscreen formulations tested, and endpoints measured ^[10].

However, controlled light-exposure studies consistently show that both ultraviolet and visible light can deepen pigment ^[20]. A 2026 trial involving 20 Fitzpatrick IV and V participants demonstrated significant photoprotection. A tested broad-spectrum sunscreen reduced induced pigmentation by about 16 Individual Typology Angle (ITA) degrees and improved secondary color measures by 48% to 87% ^[16]. This study, while small and product-specific, supports the idea that photoprotection can materially limit induced pigment ^[16]. The trial found that protected, barrier-disrupted skin improved by 5.96 ITA degrees, while unprotected skin worsened by 9.88 degrees ^[18].

The type of sunscreen also matters. For pigment-prone patients, especially those with darker skin, sunscreen providing visible-light protection is crucial ^[6]. Iron-oxide formulas, for instance, have shown better performance against visible-light pigmentation compared to non-tinted mineral SPF 50 products in Fitzpatrick IV skin ^[19]. This is because iron oxides help block visible light, which can contribute to pigmentation independent of UV radiation. Therefore, recommending sunscreens that contain ingredients like iron oxides, or tinted formulations, can offer enhanced protection for these patients.

Consistent application of broad-spectrum sunscreen (SPF 30 or higher, with UVA and UVB protection) should begin even before the laser procedure. This helps stabilize the skin’s pigmentary response and creates a foundation of protection. Post-treatment, daily application, often multiple times a day, is necessary, especially if the patient is exposed to sunlight ^[6]. Sunscreen should be considered base care, forming an essential part of the patient’s daily skin care regimen, regardless of whether other active treatments are used ^[20].

Patient education is also key. Patients must understand that sunscreen is not merely for preventing sunburn but is a critical tool for preventing PIH, a long-term aesthetic concern for many with darker skin. They should be advised on proper application techniques and frequency, especially during the initial healing phase and for several months afterward.

10.4. Comprehensive Aftercare Playbook and Delayed Follow-Up

An effective aftercare playbook extends beyond immediate inflammation control and sunscreen use. It includes ongoing skin barrier protection, detailed patient instructions, and a structured delayed follow-up schedule to monitor for complications and guide subsequent treatment decisions. The goal is to detect and manage any signs of PIH or other adverse events early, preventing them from becoming more severe or permanent.

10.4.1. Patient Instructions for Home Care

Patients should receive clear, written instructions detailing:

• Cleansing: Gentle cleansing with a mild, non-foaming cleanser to avoid stripping the skin’s natural oils.
• Moisturizing: Continued use of bland occlusives or rich moisturizers to support the skin barrier, especially after ablative procedures ^[9].
• Medication application: Specific instructions for any prescribed topical anti-inflammatory agents, including frequency, duration, and areas of application.
• Sunscreen: Daily application of broad-spectrum SPF 30+ sunscreen, with visible-light protection (e.g., iron oxides) for pigment-prone individuals, reapplied every two hours when outdoors ^[6].
• Activities to avoid: Reiterating the importance of avoiding rubbing, picking, intense heat, strenuous exercise, swimming (especially chlorinated water), and harsh skin products (e.g., retinoids, alpha-hydroxy acids) until cleared by the practitioner ^[9].
• Warning signs: Information on what symptoms warrant immediate contact with the clinic (e.g., excessive pain, blistering beyond expected, signs of infection like pus or spreading redness, or unexpected pigment changes).

10.4.2. Delayed Follow-Up Schedule

Delayed follow-up is critical because PIH can manifest days to weeks after treatment ^[24]. A practical service schedule for follow-up includes multiple touchpoints:

• 48 to 72 hours post-treatment: A photo check or quick virtual consultation to assess immediate healing, look for early signs of excessive inflammation or unexpected reactions, and confirm proper aftercare adherence. This timing is an operational inference from studies that followed patients at days 3, 5, 7, and later ^[24].
• 7 to 14 days post-treatment: A follow-up visit, either in-person or virtual, to evaluate skin recovery, assess for any developing pigmentary changes, and address patient concerns. This allows enough time for delayed pigment changes to appear, which is especially important for test spots ^[7].
• Before the next session (if applicable): A comprehensive reassessment of the treated area to ensure all inflammation has subsided and no PIH has developed. Future treatment should not proceed if inflammation or new pigment is still developing ^[24].

This structured follow-up allows for early detection of PIH, which is crucial for effective intervention. The 2025 skin-of-color prevention review indicated that laser-related facial PIH is the dominant setting in published prevention evidence ^[15]. Therefore, facial protocols specifically need delayed follow-up, not just same-day checks ^[15]. If PIH appears, further energy treatment must be stopped. The active inflammation or any underlying acne should be treated, photoprotection should be strengthened, and appropriate topical care should be initiated according to local clinical guidelines ^[25]. The global consensus emphasizes that topical treatments should be used first, with laser or chemical peels reserved for resistant cases. Immediate repeat laser treatment on existing PIH can worsen the injury that caused the pigment ^[25].

10.4.3. Data Collection and Tracking

Clinics should integrate detailed tracking of outcomes into their aftercare protocols. This includes documenting any PIH development, its severity, duration, and the interventions used. For example, Bio2 Laser Studio and other clinics could improve public trust by reporting clear, denominator-based safety measures without making them promotional claims ^[28]. This data is invaluable for refining protocols, identifying areas for improvement, and providing evidence-based care.

The collection of objective pigment data and consistent definitions in reporting adverse events are important for closing the evidence gap, especially for Fitzpatrick VI skin ^[27]. For example, no Fitzpatrick VI patients were included in the 2025 prevention review, and only 6% of classified participants in the broader 2024 treatment review were Fitzpatrick VI ^[27]. Clinics serving diverse populations have a chance to collect valuable safety data, provided it is gathered with consent, consistent definitions, and objective color measurements ^[27].

10.5. Aftercare Considerations for Specific Procedures and Skin Conditions

Aftercare protocols must be custom to the specific laser procedure performed, the individual patient’s skin response, and any pre-existing conditions. Different treatments will elicit varied inflammatory responses and healing timelines, necessitating flexible yet structured aftercare.

10.5.1. Hair Reduction Treatments

For hair reduction in Fitzpatrick V and VI skin, long-pulsed 1064 nm Nd:YAG is generally the safest laser starting point due to its lower epidermal melanin absorption compared to shorter wavelengths ^[29]. Diode systems can be used with caution ^[29]. Despite being safer, Nd:YAG laser hair reduction still carries a risk of temporary hyperpigmentation ^[30]. In a 2011 retrospective cohort of 150 Fitzpatrick IV to VI patients, hyperpigmentation was the most frequent complication among those who experienced issues, though these events were temporary ^[30].

After hair reduction, the skin may be red and swollen, and perifollicular edema might be present. Aftercare focuses on:

• Cooling: Application of cool compresses or ice packs to reduce swelling and discomfort.
• Emollients: Bland emollients to soothe the skin and maintain barrier function.
• Sun avoidance: Strict sun avoidance and broad-spectrum sunscreen are crucial to prevent PIH ^[6].
• Avoidance of irritants: Patients should be advised to avoid harsh scrubs, perfumed lotions, and tight clothing that could irritate the treated area.

Clinics like Bio2 Laser Studio offer both laser hair reduction and electrolysis, which is beneficial for patients with hair that lacks enough pigment for laser treatment ^[33]. Electrolysis creates local tissue injury and therefore requires its own specific PIH control measures ^[33].

10.5.2. Pigment Procedures

When treating pigment disorders, especially in darker skin, the risk of PIH is inherently higher due to the primary target being melanin. Shorter wavelengths, such as 532 nm, interact strongly with epidermal pigment and require greater caution in Fitzpatrick V and VI skin ^[31]. The European laser position statement recommends using the minimum effective fluence in darker skin ^[31]. Low-fluence 1064 nm Nd:YAG might be considered for some resistant pigment disorders, but repeated “laser toning” can cause mottled loss of pigment ^[31].

Aftercare for pigment procedures often involves:

• Gentle healing: A focus on promoting gentle healing without further stimulating melanocytes.
• Anti-inflammatory agents: Judicious use of prescription anti-inflammatory agents may be considered under strict medical guidance ^[9].
• Sun protection: Intense and continuous broad-spectrum sunscreen use, with visible light protection, is non-negotiable ^[6].
• Topical depigmenting agents: Once the initial inflammatory phase has passed, and under medical supervision, topical depigmenting agents (e.g., hydroquinone, retinoids, azelaic acid) may be introduced to prevent or treat PIH ^[25]. However, the 2025 global consensus recommends topicals first, reserving laser or peels for resistant cases ^[25].

10.5.3. Resurfacing Procedures

Fractional resurfacing, whether ablative or non-ablative, creates controlled micro-injuries. The goal is to reduce total tissue injury during the procedure by using lower density, fewer passes, longer intervals, and avoiding pulse overlap ^[32]. This reduces accumulated inflammation ^[32]. For instance, published fractional studies reported PIH rates of 7.1% versus 12.4% and 43% versus 71% when comparing lower-density and higher-density methods ^[32].

Aftercare for resurfacing includes:

• Occlusion and barrier support: Liberal application of bland occlusive ointments (e.g., petrolatum) to protect the compromised skin barrier and promote moist wound healing ^[9].
• Strict sun protection: Essential to prevent PIH, as resurfaced skin is highly vulnerable to UV and visible light.
• Prescription anti-inflammatory treatments: Short courses of topical corticosteroids, as demonstrated by the Cheyasak study, can reduce PIH after ablative fractional CO2 laser resurfacing in Fitzpatrick IV patients ^[9]. This must be clinician-directed due to the potency of these medications ^[9].

10.5.4. Vascular Procedures

Vascular procedures using lasers, such as pulsed dye lasers (PDL), also carry risks of pigmentary changes, including hyperpigmentation, hypopigmentation, and scarring, in Fitzpatrick IV to VI skin ^[34]. A 2023 review found only nine PDL studies involving 241 Fitzpatrick IV to VI patients, indicating limited evidence ^[34]. Vascular-laser protocols require conservative fluence and careful endpoint monitoring ^[34].

Aftercare focuses on:

• Bruising management: Cool compresses and elevation to reduce bruising and swelling.
• Gentle skin care: Avoidance of harsh products.
• Sun protection: Critical to prevent PIH in areas that have experienced vascular injury and inflammation ^[6].

It is important to remember that a hair removal protocol should never be reused for vascular or pigment treatment, even if the device platform is the same ^[34].

10.6. General Principles for Aftercare in Darker Skin Tones

Regardless of the specific procedure, several general principles should guide aftercare for Fitzpatrick IV-VI skin to minimize PIH risk and promote healthy healing:

• Individualized Approach: Each patient’s skin response can differ. Aftercare protocols should be individualized based on the patient’s history, the specific laser parameters used, and observed immediate post-treatment reactions ^[17].
• Patient Education and Compliance: Thorough patient education is paramount. Patients must understand the importance of strict adherence to aftercare instructions, particularly regarding sun protection and avoiding irritants. Clear, written instructions and opportunities for questions can enhance compliance.
• Early Intervention: Any signs of worsening inflammation, infection, or early pigmentary changes should be addressed promptly by a healthcare professional. Delayed intervention can lead to more persistent PIH.
• Holistic Skin Health: Encourage patients to maintain overall skin health through a gentle, consistent skincare routine, adequate hydration, and a balanced diet.
• Realistic Expectations: Patients should be informed that PIH is a potential, though manageable, complication in darker skin types. Setting realistic expectations about healing timelines and the potential need for additional treatments for PIH management is essential.

The 2025 global consensus on melanin hyperpigmentation disorders places topical treatments first and reserves laser or chemical peels for resistant cases ^[25]. This indicates that a conservative, multi-modal approach is often best for managing PIH, with aftercare forming a crucial preventive and early-treatment component.

For clinics like Bio2 Laser Studio, maintaining separate protocols for each device, wavelength, indication, body site, and skin-risk group is essential ^[26]. Each protocol should specify deferral rules, test-spot rules, permitted starting ranges, cooling requirements, acceptable endpoints, stop criteria, follow-up timing, and escalation steps ^[26]. There should not be a single Fitzpatrick IV to VI parameter chart ^[26]. Tracking outcomes, such as the percentage of eligible patients receiving test spots, recent-tan deferrals, PIH at 2 and 6 weeks, and unplanned medical referrals, can help clinics measure and improve safety ^[26].

In summary, strong post-treatment inflammation control and aftercare are non-negotiable components of safe laser practice for Fitzpatrick IV-VI skin. These measures, combined with careful patient selection, appropriate device and setting choices, and careful treatment execution, form a comprehensive strategy to minimize PIH and achieve good clinical outcomes.

10.7. Conclusion and Transition to Next Section

Effective post-treatment inflammation control and aftercare are fundamental to achieving successful and safe outcomes for Fitzpatrick IV-VI patients undergoing laser procedures. These steps are a direct extension of the careful pre-treatment assessment and precise energy delivery discussed in previous sections. By calming inflammation, protecting the skin barrier, using prescription anti-inflammatory treatments when indicated, and rigorously applying broad-spectrum sunscreen, clinics can significantly reduce the incidence and severity of PIH. The importance of delayed follow-up and structured patient education cannot be overstated, as PIH often develops after the initial treatment visit. The commitment to careful aftercare, combined with detailed tracking of outcomes, fosters a culture of safety and continuous improvement within laser practices.

This comprehensive approach to aftercare sets the stage for managing complications should they arise, and for ensuring patient satisfaction. The next section will build upon these principles by detailing [SECTION_11_TITLE], focusing on protocols for identifying, treating, and preventing long-term pigmentary changes.

---

Sources

1. Global consensus on the management of melanin hyperpigmentation disorders – Journal of the European Academy of Dermatology and Venereology – December 2025 – https://www.beiersdorf.com/~/media/Beiersdorf/newsroom/press-releases/2025/2025-12-10-leading-global-experts-on-hyperpigmentation/Global-consensus-on-the-management-of-melanin-hyperpigmentation-disorders.pdf ^[1]
2. Beyond Fitzpatrick Skin Types: A Delphi Consensus on Key Considerations for a Universal Skin Typing Classification – Journal of the American Academy of Dermatology and Skin of Color Society – 2025 – https://skinofcolorsociety.org/images/2025/10/29/Delphi%202025_JAAD_1-s2.0-S0190962225027318-main.pdf ^[2]
3. Special considerations for darker-skinned patients. – pubmed.ncbi.nlm.nih.gov – 2011 – https://pubmed.ncbi.nlm.nih.gov/21865808/?utm_source=openai ^[3]
4. Global consensus on the management of melanin hyperpigmentation disorders – Journal of the European Academy of Dermatology and Venereology – December 2025 – https://www.beiersdorf.com/~/media/Beiersdorf/newsroom/press-releases/2025/2025-12-10-leading-global-experts-on-hyperpigmentation/Global-consensus-on-the-management-of-melanin-hyperpigmentation-disorders.pdf ^[4]
5. Global consensus on the management of melanin hyperpigmentation disorders – Journal of the European Academy of Dermatology and Venereology – December 2025 – https://www.beiersdorf.com/~/media/Beiersdorf/newsroom/press-releases/2025/2025-12-10-leading-global-experts-on-hyperpigmentation/Global-consensus-on-the-management-of-melanin-hyperpigmentation-disorders.pdf ^[5]
6. An Investigator-Blinded, Randomized Trial of a Broad-Spectrum Sunscreen Containing Sclareolide and Niacinamide for the Prevention of Post-inflammatory Hyperpigmentation in Skin of Color – PubMed – January 2026 – https://pubmed.ncbi.nlm.nih.gov/41240206/?utm_source=openai ^[6]
7. MAUDE Adverse Event Report: CANDELA GENTLEMAX PRO; GMAX PRO – U.S. Food and Drug Administration – Report concerning a 2015 event – https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfmaude/detail.cfm?mdrfoi__id=8425257 ^[7]
8. Nonablative Fractional Laser Resurfacing in Skin of Color: Evidence-based Review – PubMed Central – 2017 – https://pmc.ncbi.nlm.nih.gov/articles/PMC5605208/ ^[8]
9. Topical Corticosteroids Minimise the Risk of Postinflammatory Hyperpigmentation After Ablative Fractional CO2 Laser Resurfacing in Asians – Acta Dermato-Venereologica – February 2015 – https://pubmed.ncbi.nlm.nih.gov/24854088/ ^[9]
10. Prevention of Post-Inflammatory Hyperpigmentation in Skin of Colour: A Systematic Review – PubMed – 2025 – https://pubmed.ncbi.nlm.nih.gov/39953770/?utm_source=openai ^[10]
11. Prevention of Post-Inflammatory Hyperpigmentation in Skin of Colour: A Systematic Review – Australasian Journal of Dermatology – May 2025 – https://pmc.ncbi.nlm.nih.gov/articles/PMC12062726/ ^[11]
12. Side Effects and Complications of Fractional 1550 nm Erbium Fiber Laser Treatment Among Asians – Journal of Cosmetic Dermatology – 2011 – https://www.researchgate.net/profile/Penpun-Wattanakrai/publication/51862192_Side_effects_and_complications_of_fractional_1550-nm_erbium_fiber_laser_treatment_among_Asians/links/5ac878ff4585151e80a560b5/Side-effects-and-complications-of_fractional_1550-nm_erbium_fiber_laser_treatment_among_Asians.pdf ^[12]
13. Interventions to Prevent Postinflammatory Hyperpigmentation After Laser and Energy-Based Device Treatments: A Systematic Review and Network Meta-Analysis – Lasers in Surgery and Medicine, PubMed Central – 2026 – https://pmc.ncbi.nlm.nih.gov/articles/PMC12997392/ ^[13]
14. Interventions to Prevent Postinflammatory Hyperpigmentation After Laser and Energy-Based Device Treatments: A Systematic Review and Network Meta-Analysis – Lasers in Surgery and Medicine, PubMed Central – 2026 – https://pmc.ncbi.nlm.nih.gov/articles/PMC12997392/ ^[14]
15. Prevention of Post-Inflammatory Hyperpigmentation in Skin of Colour: A Systematic Review – Australasian Journal of Dermatology – May 2025 – https://pmc.ncbi.nlm.nih.gov/articles/PMC12062726/ ^[15]
16. An Investigator-Blinded, Randomized Trial of a Broad-Spectrum Sunscreen Containing Sclareolide and Niacinamide for the Prevention of Post-inflammatory Hyperpigmentation in Skin of Color – PubMed – January 2026 – https://pubmed.ncbi.nlm.nih.gov/41240206/?utm_source=openai ^[16]
17. Comparison of Methods for Characterizing Skin Pigment Diversity in Research Cohorts – British Journal of Dermatology – January 6, 2026 – https://pubmed.ncbi.nlm.nih.gov/41073884/ ^[17]
18. Global consensus on the management of melanin hyperpigmentation disorders – Journal of the European Academy of Dermatology and Venereology – December 2025 – https://www.beiersdorf.com/~/media/Beiersdorf/newsroom/press-releases/2025/2025-12-10-leading-global-experts-on-hyperpigmentation/Global-consensus-on-the-management-of-melanin-hyperpigmentation-disorders.pdf ^[18]
19. Impact of Iron-Oxide Containing Formulations Against Visible Light-Induced Skin Pigmentation in Skin of Color Individuals – Journal of Drugs in Dermatology – July 1, 2020 – https://pubmed.ncbi.nlm.nih.gov/32726103/?utm_source=openai ^[19]
20. Interventions to Prevent Postinflammatory Hyperpigmentation After Laser and Energy-Based Device Treatments: A Systematic Review and Network Meta-Analysis – Lasers in Surgery and Medicine, PubMed Central – 2026 – https://pmc.ncbi.nlm.nih.gov/articles/PMC12997392/ ^[20]
21. MAUDE Adverse Event Report: EL.EN. Electronic Engineering Elite IQ – U.S. Food and Drug Administration – Report concerning a 2025 event – https://www.accessdata.fda.gov/scripts/cdrh/cfMAUDE/detail.cfm?mdrfoi__id=23643346&pc=GEX ^[21]
22. Facial laser complications (A Five Year Review) – Lasers in Medical Science – 2026 – https://link.springer.com/article/10.1007/s10103-026-04862-z ^[22]
23. MAUDE Adverse Event Report: EL.EN. ELECTRONIC ENGINEERING S.P.A. ELITE IQ – U.S. Food and Drug Administration – Report concerning a 2025 event – https://www.accessdata.fda.gov/scripts/cdrh/cfMAUDE/detail.cfm?mdrfoi__id=23643346&pc=GEX ^[23]
24. Topical Corticosteroids Minimise the Risk of Postinflammatory Hyperpigmentation After Ablative Fractional CO2 Laser Resurfacing in Asians – Acta Dermato-Venereologica – February 2015 – https://pubmed.ncbi.nlm.nih.gov/24854088/ ^[24]
25. Global consensus on the management of melanin hyperpigmentation disorders – Journal of the European Academy of Dermatology and Venereology – December 2025 – https://www.beiersdorf.com/~/media/Beiersdorf/newsroom/press-releases/2025/2025-12-10-leading-global-experts-on-hyperpigmentation/Global-consensus-on-the-management-of-melanin-hyperpigmentation-disorders.pdf ^[25]
26. Facial laser complications (A Five Year Review) – Lasers in Medical Science – 2026 – https://link.springer.com/article/10.1007/s10103-026-04862-z ^[26]
27. Prevention of Post-Inflammatory Hyperpigmentation in Skin of Colour: A Systematic Review – Australasian Journal of Dermatology – May 2025 – https://pmc.ncbi.nlm.nih.gov/articles/PMC12062726/ ^[27]
28. Laser Hair Removal, Electrolysis and RF Body Contouring – Bio2 Laser Studio – Accessed August 2026 – https://bio2laserstudio.com/ ^[28]
29. Lasers and light-based therapies in ethnic skin: treatment options and recommendations for Fitzpatrick skin types V and VI. – pubmed.ncbi.nlm.nih.gov – 2013 – https://pubmed.ncbi.nlm.nih.gov/24098905/?utm_source=openai ^[29]
30. Long-Pulsed Nd:YAG Laser-Assisted Hair Removal in Fitzpatrick Skin Types IV to VI – Journal of Cutaneous and Aesthetic Surgery – 2011 – https://pubmed.ncbi.nlm.nih.gov/21519944/?utm_source=openai ^[30]
31. Laser treatment of hyperpigmented lesions: position statement of the European Society of Laser in Dermatology – Journal of the European Academy of Dermatology and Venereology – 2019 – https://onlinelibrary.wiley.com/doi/full/10.1111/jdv.15497 ^[31]
32. Side Effects and Complications of Fractional 1550 nm Erbium Fiber Laser Treatment Among Asians – Journal of Cosmetic Dermatology – 2011 – https://www.researchgate.net/profile/Penpun-Wattanakrai/publication/51862192_Side_effects_and_complications_of_fractional_1550-nm_erbium_fiber_laser_treatment_among_Asians/links/5ac878ff4585151e80a560b5/Side-effects-and-complications_of_fractional_1550-nm_erbium_fiber_laser_treatment_among_Asians.pdf ^[32]
33. Laser Hair Removal, Electrolysis and RF Body Contouring – Bio2 Laser Studio – Accessed August 2026 – https://bio2laserstudio.com/ ^[33]
34. A Review of Treatment of Port-Wine Stains With Pulsed Dye Laser in Fitzpatrick Skin Type IV to VI – Journal of Cutaneous Medicine and Surgery – 2023 – https://pubmed.ncbi.nlm.nih.gov/37253863/?utm_source=openai ^[34]

11. Role of Sunscreen and Emerging Interventions

Preventing post-inflammatory hyperpigmentation (PIH) after laser and energy-based procedures, especially in individuals with Fitzpatrick skin types IV to VI, requires a comprehensive approach. This includes careful patient selection, appropriate device and setting choices, and careful post-procedure care. Among these critical steps, the consistent use of sunscreen has long been a cornerstone of photoprotection. However, recent research in 2026 presents a more nuanced view, evaluating also the effectiveness of traditional broad-spectrum sunscreens but also exploring the role of protection against visible light and the potential of newer medical interventions like intradermal tranexamic acid. This section analyzes the current state of evidence for sunscreen use, examines the evolving understanding of visible-light protection, and discusses the status of emerging medical strategies designed to reduce PIH risk in pigment-prone skin.

The core challenge in treating darker skin types with lasers stems from the higher concentration of epidermal melanin. This melanin absorbs laser energy, narrowing the margin between effective treatment and unwanted side effects such as excess heat, inflammation, burns, and PIH, or even loss of pigment ^[3]. Given this physiological reality, strategies aimed at reducing inflammation and protecting against subsequent pigment production are very important. While the evidence base for PIH prevention in Fitzpatrick VI skin remains limited, largely relying on physiological principles, small studies, expert opinions, and cautious clinical practice ^[10], new data are beginning to provide comparative insights into different preventive measures.

A significant development in 2026 is a network meta-analysis that systematically compared various interventions for preventing PIH after laser and energy-based treatments ^[1]. This analysis included 14 randomized controlled trials, with 11 suitable for network comparison ^[1]. This marks a shift from solely narrative advice to more comparative evidence, although the trial base is still small considering the range of devices, settings, indications, and skin tones in use ^[1]. This limited evidence base means no single preventive regimen can be declared a universal standard ^[1]. The findings from this and other recent studies offer clearer guidance on the role of sunscreen and the potential of advanced medical treatments.

The Foundational Role of Sunscreen in PIH Prevention

Sunscreen has been a long-standing recommendation for preventing PIH, primarily by blocking ultraviolet (UV) radiation. Daily broad-spectrum sunscreen remains a base care recommendation ^[8]. However, recent data offer conflicting views on its effectiveness as a stand-alone measure. A 2025 skin-of-color review identified sunscreen as the most consistent preventive measure ^[11]. In contrast, the 2026 network meta-analysis found sunscreen monotherapy to be no more effective than placebo in its network comparison ^[19]. These seemingly contradictory findings highlight the challenges of clinical research, where differences in study populations, methodologies, comparators, and endpoints can lead to varying conclusions ^[11].

Despite these differences, controlled light-exposure studies consistently show that both ultraviolet and visible light can worsen pigment ^[19]. This reinforces the importance of photoprotection as a general principle. A 2026 trial involving 20 Fitzpatrick IV and V participants provided specific evidence for sunscreen’s benefit. This study demonstrated that a tested sunscreen formulation reduced induced pigmentation by approximately 16 Individual Typology Angle (ITA) degrees and improved secondary color measures by 48% to 87% ^[8]. Specifically, protected, barrier-disrupted skin showed an improvement of 5.96 ITA degrees, while unprotected skin worsened by 9.88 degrees ^[15]. This study, while small and product-specific, suggests that effective photoprotection can significantly limit induced pigment ^[8].

Beyond its direct protective effects, initiating photoprotection before a laser procedure is important, rather than waiting for pigment changes to appear ^[16]. The goal is to minimize overall sun exposure and reduce the baseline risk for PIH. For clinics like Bio2 Laser Studio, advising patients to consistently use broad-spectrum sunscreen well before any laser treatment aligns with best practices for minimizing PIH risk. This emphasizes that photoprotection is not just a post-treatment concern but an integral part of pre-procedure skin preparation.

The role of sunscreen in PIH prevention is summarized by its consistent recommendation in clinical guidelines, even as the specific comparative efficacy data evolve. Its widespread availability and ease of use make it a fundamental component of any PIH prevention strategy. The key is to choose products that offer broad-spectrum protection and to ensure patient adherence to daily application.

Visible-Light Protection and Its Growing Importance

The understanding of PIH prevention has expanded beyond just UV radiation to include visible light. Visible light, which makes up about 50% of the solar spectrum, can also trigger pigment production, especially in individuals with darker skin tones ^[44]. This has led to an increased focus on sunscreens that offer protection against the entire light spectrum, not just UV. Iron-oxide containing formulations, for example, have demonstrated better performance against visible-light pigmentation in Fitzpatrick IV skin compared to non-tinted mineral SPF 50 products ^[16]. This indicates that the type of sunscreen and its ingredients can influence its effectiveness against PIH, particularly when visible light exposure is a factor.

The 2026 sunscreen study, which tested a broad-spectrum formula, confirmed its ability to provide about 16 ITA degrees of net protection after combined inflammation and light exposure ^[15]. This suggests that comprehensive photoprotection, extending to visible light, can play a material role in limiting induced pigment ^[15]. The inclusion of ingredients like sclareolide and niacinamide in the tested formulation may contribute to these improved outcomes by addressing both pigment production and inflammation.

For patients prone to PIH, visible-light protection should be considered as a critical addition to their daily skin care regimen ^[8]. Clinics should educate patients on the importance of selecting sunscreens that specifically mention visible light protection or contain ingredients known to block visible light, such as iron oxides or tinted formulations. This shift in understanding means that “broad-spectrum” in sunscreen recommendations should increasingly imply protection against both UV and visible light, especially for Fitzpatrick skin types IV to VI.

Emerging Medical Interventions: Tranexamic Acid

Beyond external protection, medical interventions are also gaining attention for their potential to prevent PIH. Among these, intradermal tranexamic acid stands out as a promising option. Tranexamic acid, a synthetic derivative of the amino acid lysine, is known for its anti-fibrinolytic properties and has been used in various medical contexts. In dermatology, it has shown benefit in treating melasma and other hyperpigmentation disorders by inhibiting plasminogen activator, which can reduce melanin synthesis ^[45].

The 2026 network meta-analysis provided compelling, though preliminary, data on intradermal tranexamic acid. It ranked highest against sunscreen monotherapy, showing a relative risk of 0.02 with a 95% confidence interval of 0.00 to 0.53 ^[2]. This suggests a very strong preventive effect compared to sunscreen alone. However, the wide confidence interval reflects the limited data available, indicating that while promising, this result is not yet a basis for routine use in all clinical settings, especially outside of medical supervision ^[2]. The study noted that trials included were small, and patients reported injection discomfort and bruising ^[20].

The use of intradermal tranexamic acid requires medical assessment and trained administration ^[2]. This is not a treatment that can be adopted in a standard spa protocol due to the need for injections and potential side effects. For clinics offering advanced laser treatments, such as Bio2 Laser Studio, referring patients to medical professionals for consideration of intradermal tranexamic acid could be a valuable part of a comprehensive PIH prevention strategy for high-risk individuals. It represents a medical option that can be integrated into the care plan for resistant cases or patients with a history of severe PIH.

Oral tranexamic acid is another route of administration, commonly used for melasma. While it offers systemic benefits, its use requires careful medical supervision due to potential systemic side effects, including thrombotic risks. The specific evidence for oral tranexamic acid in preventing post-laser PIH, as compared to intradermal application, was not detailed in the provided research, but its existence as a medical option for pigmentation disorders suggests its potential in a broader PIH management strategy.

Other Emerging Interventions and Conflicting Data

The 2026 network meta-analysis also shed light on other interventions. While it found epidermal cooling and several medical interventions superior to sunscreen alone ^[11], this contrasts with a 2025 skin-of-color review that reported worse outcomes with some cooling-air protocols ^[11]. This highlights the importance of specific cooling methods and device instructions. The effectiveness of cooling is not a blanket rule; it depends on the population, cooling method, comparators, and endpoints used in studies ^[11]. Therefore, cooling protocols must strictly adhere to device instructions ^[11].

Skin priming with lightening agents, such as hydroquinone, is another area with mixed evidence. The 2025 global consensus supports lightening-agent priming for higher-risk procedures and advises avoiding irritants close to treatment ^[16]. However, the 2026 network analysis found no significant prevention benefit for whitening agents over sunscreen monotherapy ^[16]. One trial included in the review started topical care two weeks before laser, while most interventions in the review began after treatment ^[16]. This difference in timing could influence outcomes, suggesting that pre-treatment priming might be more beneficial than post-treatment application of lightening agents for prevention. The general advice is to prepare high-risk skin before treatment, although routine use of hydroquinone or other lightening agents still has mixed evidence ^[5].

Another intervention for post-treatment inflammation control involves prescription anti-inflammatory agents. A split-face trial in 40 Fitzpatrick IV patients demonstrated that two days of prescription clobetasol, followed by petrolatum, reduced PIH rates from 75% to 40% compared to petrolatum alone ^[9]. This supports short, clinician-directed anti-inflammatory care after selected ablative procedures. However, the use of strong steroids like clobetasol, especially on the face, requires medical control and should not be a routine self-administered treatment ^[18].

The complex interplay between different interventions means that a holistic approach is often necessary. Individual patient risk factors, the specific laser procedure, and the practitioner’s expertise all influence the choice and combination of preventive strategies.

Current Evidence Limitations and Future Directions

Despite the advancements, several limitations in the current evidence base affect the generalization of findings. The prevention evidence remains thin, particularly for Fitzpatrick VI individuals. A 2025 systematic review included 369 cases of PIH, but 100% of the reported ethnicity was Asian. Only 4.1% of classified participants were Fitzpatrick V, and none were Fitzpatrick VI ^[10]. This means protocols for Fitzpatrick VI skin still rely heavily on expert opinion and cautious clinical practice rather than strong trial data ^[10]. Claims of proven Fitzpatrick VI safety should be viewed with caution ^[10].

The studies included in the 2026 network meta-analysis, while providing comparative data, still constitute a small trial base for the breadth of devices, settings, indications, and skin tones encountered in clinical practice ^[1]. This underscores that no single preventive regimen can be considered a universal standard ^[1]. There is a clear need for more research, especially randomized controlled trials, focused on diverse populations and Fitzpatrick skin types IV to VI. Future research should also standardize methodologies and endpoints to allow for more direct comparisons between interventions.

The understanding of skin measurement is also evolving. A 2026 study of 789 adults highlighted significant differences between subjective skin ratings and objective color measurements ^[4]. Depending on the method, 7%, 14%, 16%, 23%, or 26% of the same cohort could be classified as dark ^[14]. This means subjective scales can materially change who is placed in a high-risk group ^[14]. Clinics should integrate objective pigment data, such as colorimetry or spectrophotometry, alongside Fitzpatrick typing and patient history to improve risk assessment ^[14].

Furthermore, the focus has historically been on PIH treatment rather than prevention. A 2024 systematic review on PIH treatment included 1,356 patients with skin of color, showing a more diverse representation of Fitzpatrick types (40% IV, 34% V, 6% VI) and ethnicities (70% Black, 27% Asian, 3% Hispanic or Latin) ^[6]. While this data is useful, treatment results cannot be assumed to answer prevention questions ^[6]. More studies specifically designed to prevent PIH in diverse skin types are needed.

Table 11.1 summarizes the key findings regarding sunscreen and emerging interventions:

Intervention	Key Findings and Data Points	Implications for Clinical Practice	Citation
Broad-Spectrum Sunscreen (UV protection)	2025 skin-of-color review: most consistent preventive measure. 2026 network meta-analysis: ineffective against placebo for prevention in its network. Controlled light-exposure studies: UV and visible light deepen pigment.	Base care for daily use. Essential component of post-procedure instructions. Discrepancies in efficacy data suggest its role may be more foundational than sole preventive.	[11], [19]
Visible-Light Protection (e.g., iron oxide sunscreens)	2026 trial (20 Fitzpatrick IV/V participants): tested sunscreen reduced induced pigmentation by 16 ITA degrees, improved secondary color measures by 48-87%. Iron-oxide formulations outperformed non-tinted mineral SPF 50 against visible-light pigmentation in Fitzpatrick IV skin.	Crucial for pigment-prone patients, especially Fitzpatrick IV-VI. Recommend sunscreens with visible-light blocking ingredients (e.g., iron oxides, tints). Start before procedures.	[8], [15], [16]
Intradermal Tranexamic Acid	2026 network meta-analysis: ranked highest against sunscreen monotherapy with a relative risk of 0.02 (95% CI 0.00-0.53). Trials were small, with reported injection discomfort and bruising.	Promising medical option, but not for routine salon use. Requires medical assessment and trained administration. Consider for high-risk or resistant cases under medical supervision.	[2], [20]
Topical Lightening Agents (e.g., hydroquinone)	2025 global consensus: supports priming for higher-risk procedures. 2026 network meta-analysis: no significant benefit over sunscreen monotherapy. Evidence for routine use remains mixed.	May be used for skin preparation in high-risk cases, but evidence for routine preventative use is not strong. Use under clinical guidance.	[5], [16]
Prescription Topical Anti-inflammatories (e.g., clobetasol)	2015 trial (40 Fitzpatrick IV patients): 2 days of clobetasol reduced PIH from 75% to 40% after fractional CO2 laser.	May be useful for short-term, post-ablative procedure inflammation control under medical supervision. Not for routine self-use due to potency and side effects.	[9], [18]
Epidermal Cooling	2026 network analysis: favored epidermal cooling over sunscreen alone. 2025 skin-of-color review: some cooling-air approaches worsened outcomes. Effectiveness depends on population, methods, and endpoints.	Follow device-specific instructions exactly. Not a universal solution. Must allow skin response to remain visible.	[11]

Conclusion

The prevention of PIH in Fitzpatrick IV-VI skin remains a significant concern in laser and energy-based procedures. While daily broad-spectrum sunscreen is a fundamental aspect of care, the data on its sole effectiveness are mixed. The importance of visible-light protection is increasingly recognized, pushing toward more comprehensive photoprotection strategies. Emerging medical interventions, such as intradermal tranexamic acid, show promise but require further research and medical oversight before widespread adoption. For clinics, combining stringent pre-treatment assessment, conservative treatment parameters, and strong post-procedure care with custom photoprotection and medical interventions, where appropriate, is essential. The lack of extensive data for Fitzpatrick VI skin types emphasizes the need for caution and individualized treatment plans. Continued research and standardized reporting will further refine these protocols, improving safety and outcomes for all patients.

The next section will discuss the importance of patient education and informed consent, particularly for patients with darker skin tones considering laser procedures.

12. Measuring and Improving Clinic Safety

Safe laser and energy-based device treatment for individuals with Fitzpatrick IV-VI skin types requires more than just adherence to device guidelines. It demands a systematic approach to clinic safety, encompassing strong protocols, continuous measurement of outcomes, thorough training audits, transparent patient communication, and a commitment to addressing gaps in clinical evidence, especially for Fitzpatrick VI skin. This section details practical strategies for clinics to establish and maintain a high standard of safety, focusing on preventing post-inflammatory hyperpigmentation (PIH) and other adverse events.

The current state of laser safety protocols for darker skin tones, as of August 29, 2026, lacks a single, universally accepted “Fitzpatrick IV to VI Laser Safety Protocol” ^[1]. Instead, safe clinical practice relies on a “playbook” built from consensus reports, controlled trials, specific device instructions, and data on adverse events ^[1]. A critical insight is that fixed settings for laser treatment cannot be applied universally across different devices, indications, body sites, or individual patients ^[1]. This underscores the need for clinics to implement adaptable and evidence-based safety frameworks.

The primary safety concern in treating darker skin types is the presence of epidermal melanin ^[3]. This melanin absorbs a portion of the laser’s treatment energy, narrowing the difference between effective treatment and unwanted effects ^[3]. Excess energy absorption can lead to overheating, inflammation, burns, PIH, or even permanent loss of pigment ^[3]. While techniques such as using longer wavelengths, applying conservative settings, controlling skin coverage, and epidermal cooling can reduce these risks, no treatment is entirely risk-free ^[3].

The Imperative for custom Protocols and Continuous Improvement

Clinic safety is not a static state but an ongoing process of assessment, adjustment, and education. Clinics must recognize that the specific challenges of treating Fitzpatrick IV-VI skin require a heightened level of detail and customization in their safety procedures. This includes moving beyond generic guidelines to establish specific, measurable, and auditable protocols for every aspect of laser treatment.

The guidance presented here is built upon the understanding that while the science behind laser-skin interaction is complex, the operational safety measures can be structured and consistently applied. It emphasizes the need for a data-driven approach, where outcomes are not just observed but formally tracked and analyzed to identify areas for improvement. This proactive stance is important for minimizing adverse events and promoting superior patient care.

Beyond Fitzpatrick Type: Comprehensive Risk Assessment

One of the most fundamental aspects of improving clinic safety involves re-evaluating how patient risk is assessed. The Fitzpatrick skin typing system, while widely used, has recognized limitations, especially for guiding laser parameters ^[6]. A 2025 Delphi study involving 22 skin-of-color experts showed that 95% agreed the Fitzpatrick system has clinical and research limitations ^[2]. A 2026 study of 789 adults further highlighted this, finding substantial differences between subjective skin ratings and objective color measurements ^[2].

Therefore, Fitzpatrick type should be only one input in a broader risk assessment, not the sole determinant of safety protocols ^[2]. Clinics should adopt a structured intake process that captures a wider array of risk factors. This includes:

• Documenting prior PIH and scarring: A patient’s history of PIH or scarring indicates their skin’s propensity to react adversely to injury ^[4].
• Assessing current inflammation: Active inflammation in the treatment area can increase the risk of adverse outcomes ^[4].
• Identifying recent tanning: Tanned skin has increased epidermal melanin, making it more prone to absorbing laser energy and causing burns or PIH ^[4]. An FDA adverse event report from 2025 described a tanned patient who developed burns after an operator changed from Nd:YAG to alexandrite laser ^[19].
• Recording prior procedures and medications: These can affect skin sensitivity, healing, and overall response to laser treatment ^[20].
• Measuring normal untanned skin color: This provides a baseline pigment level, which is more reliable than subjective Fitzpatrick classification ^[4].
• Evaluating treatment target and depth: Understanding the specific target (e.g., hair follicle, pigment, vascular lesion) and its depth influences device selection and settings ^[17].

Objective measurements, such as colorimetry or spectrophotometry, can supplement subjective assessments, offering more precise data on skin pigment ^[17]. The 2026 Lipnick study showed that five different assessment methods applied to 789 individuals yielded materially different estimates of the proportion of participants with dark skin ^[17]. This highlights how subjective scales can significantly alter who is categorized as high-risk ^[17]. Therefore, clinics should use repeatable photographs taken with consistent camera settings, distance, lighting, and patient positioning to track changes and provide objective data ^[17].

Moreover, the specific diagnosis matters as much as skin tone. For example, brown epidermal PIH and blue-gray dermal PIH respond differently to treatment ^[18]. The 2025 global consensus advises against laser or intense pulsed light (IPL) treatment during active inflammatory stages of acquired dermal pigment disorders because it can worsen pigmentation ^[18].

Stakeholder Implication: Providers need a structured intake form that moves beyond a single Fitzpatrick dropdown menu ^[19]. Patients should be prepared for the possibility that a safe consultation may result in deferral of treatment, topical pre-treatment, a test spot, selection of a different device, or even a recommendation against laser altogether ^[19]. Device manufacturers and researchers should be encouraged to report objective pigment data alongside Fitzpatrick types in their studies ^[19].

Maintaining Separate, Detailed Protocols for Every Scenario

A key strategy for reducing PIH rates and improving overall safety is to maintain separate, specific protocols for each device, wavelength, indication, body site, and skin-risk group ^[40]. This directly addresses the problem that no single set of fixed settings can be universally applied ^[1].

Each protocol should be a clear, step-by-step guide that includes:

• Deferral rules: Specific criteria that necessitate postponing or refusing treatment, such as recent tanning, active dermatitis, or uncontrolled acne inflammation ^[40].
• Test-spot rules: Detailed instructions for performing test spots, including area, settings, cooling, and the required waiting period for evaluation ^[40].
• Permitted starting ranges: Clearly defined initial parameters for fluence, pulse width, and spot size based on patient and skin characteristics ^[40].
• Cooling requirements: Device-specific cooling methods and settings, emphasizing that cooling should follow manufacturer instructions rather than a blanket rule ^[10].
• Acceptable endpoints: Visual and tactile responses during treatment that indicate effective energy delivery without causing excessive injury ^[40].
• Stop criteria: Clear indicators (e.g., blistering, sharp discoloration, excessive pain) that mandate immediate cessation of treatment ^[34].
• Follow-up timing: Schedule for post-treatment checks and re-evaluations ^[40].
• Escalation steps: Procedures for managing adverse events, including when to refer to a medical professional ^[40].

The absence of a “single Fitzpatrick IV to VI parameter chart” ^[40] means that clinics must internalize this nuance. This approach helps ensure that operators make informed decisions custom to each patient’s specific needs and reduces the risk of errors that can arise from applying general guidelines to complex situations. The 2025 FDA case where a tanned patient suffered burns after an operator used an incorrect wavelength and settings underscores the importance of such detailed, device-specific protocols ^[30].

Tracking Denominator-Based Outcomes

For clinic safety to truly improve, it must be measured. Tracking denominator-based outcomes allows clinics to move beyond anecdotal experience and gain quantitative insight into their safety performance ^[41]. This means recording not just adverse events, but also the total number of procedures performed, enabling the calculation of rates rather than just raw counts. The literature’s inconsistent reporting methods contribute to widely varying complication estimates, highlighting the need for standardized internal tracking ^[41].

Useful measures for clinics include:

• Percentage of eligible patients receiving test spots: This tracks adherence to a critical safety step.
• Recent-tan deferrals: The number or percentage of treatments postponed due to recent sun exposure.
• PIH rates at specific time points (e.g., 2 and 6 weeks): This provides a concrete measure of a common complication.
• Burns or blisters per 1,000 sessions: A critical indicator of immediate tissue damage.
• Hypopigmentation rates: Tracking this rarer but potentially permanent complication.
• Unplanned medical referrals: An indicator of the severity and frequency of complications requiring external medical intervention.
• Adverse events broken down by operator, device, wavelength, body site, and measured skin color: This granular data helps identify specific risk factors and areas needing attention ^[41].

By collecting and analyzing this data, clinics can identify trends, evaluate the effectiveness of their protocols, and pinpoint specific areas where additional training or protocol adjustments are needed. For instance, if a particular operator consistently has higher PIH rates for a specific device, it might indicate a need for retraining or closer supervision. If a certain body site shows higher complication rates, the protocol for that site might need revision. This systematic data collection transforms safety from a subjective goal into an objective, manageable process.

Auditing Training and Preventing Mode-Selection Errors

Even the most advanced laser equipment is only as safe as the operator using it. Training audits are essential for ensuring that all personnel are competent in operating devices, adhering to protocols, and responding appropriately to adverse events. FDA reports highlight that even machines cleared for darker skin can cause injury if an operator selects the wrong wavelength, treats tanned skin, skips a test spot, or fails to follow instructions ^[42]. Device clearance means the device can be used safely, but it does not guarantee safe operation ^[42].

Key aspects of training audits should include:

• Regular competency assessments: Operators should periodically demonstrate their proficiency in device operation and protocol adherence.
• Review of adverse event reports: Analysis of past incidents can reveal common errors or knowledge gaps that need to be addressed in training programs ^[42].
• Simulation of emergency procedures: Ensuring staff know how to respond to unexpected events, such as burns or eye exposure ^[34].
• Focus on critical safety checks: Reinforcing the importance of pre-treatment time-outs, wavelength verification, and test spot evaluations. The “time-out” procedure, a formal pause before treatment to confirm critical parameters like patient identity, treatment area, device settings, and test-spot results, is a direct lesson from FDA reports on wrong wavelength selection ^[31].
• Education on heat accumulation: Training on limiting heat accumulation through mapped passes, preventing unplanned overlap, and allowing adequate cooling between pulses ^[33].

Audits should also confirm initial training but also verify ongoing education and adaptation to updated protocols or new device features. This continuous learning model ensures that the human element of safety keeps pace with technological advancements and evolving best practices.

Transparent Pricing and Informed Consent

Patient education and transparent communication are central to safety. This begins with clear pricing models and comprehensive informed consent processes. Laser treatments, especially for darker skin types, often require multiple, conservative sessions to achieve desired results safely ^[13]. For example, a study of 150 Fitzpatrick IV to VI patients treated with long-pulsed Nd:YAG for hair reduction found an average of 8.9 sessions were needed for a 54.3% mean hair reduction ^[13].

Clinics must avoid making “one-session promises” and instead educate patients about the probable need for multiple treatments ^[43]. This honesty manages patient expectations and reduces pressure on operators to use aggressive settings in an attempt to achieve rapid results, which can increase risk. The consent process should thoroughly explain:

• Potential complications: Clearly outlining risks such as PIH, burns, hypopigmentation, and scarring.
• The need for conservative settings: Explaining why lower energy and more sessions are used for safety in darker skin.
• Paradoxical hair growth: Specifically for hair removal, patients should be informed about the 3% pooled prevalence of paradoxical hypertrichosis, particularly for facial and neck areas ^[14].
• Post-treatment care requirements: Emphasizing the importance of sun protection and adherence to aftercare instructions.
• The possibility of additional treatments: Such as maintenance sessions, adjunctive electrolysis (as offered by Bio2 Laser Studio) for pigment-poor hair, topical care, or specialist referral ^[43].
• Test spot rationale: Explaining why a test spot is necessary and the waiting period involved ^[22].

Transparent communication builds trust and empowers patients to make informed decisions. It also removes the perceived need for a clinic to rush a procedure or use aggressive settings to satisfy a patient’s unrealistic expectations, thereby reducing clinical risk ^[22].

Addressing the Fitzpatrick VI Evidence Gap

A significant challenge in advancing safety protocols for darker skin types is the limited clinical evidence, particularly for Fitzpatrick VI individuals. The 2025 prevention review included 369 cases, but 100% of the reported ethnicity was Asian, only 4.1% were Fitzpatrick V, and zero were Fitzpatrick VI ^[9]. Similarly, a 2024 review on PIH treatment found that only 6% of classified participants were Fitzpatrick VI ^[5]. This means protocols for Fitzpatrick VI skin largely rely on understanding physiology, small studies, expert opinion, and conservative clinical practice ^[9].

Clinics serving diverse populations have a role in closing this evidence gap through systematic internal reporting ^[44]. By collecting data on Fitzpatrick VI patients with consistent definitions and objective color measurements, clinics can contribute valuable real-world safety data. This requires:

• Standardized data collection: Using consistent intake forms and follow-up procedures to ensure data comparability.
• Objective color measures: Incorporating tools like colorimeters to supplement subjective Fitzpatrick typing ^[44].
• Patient consent for data use: Obtaining informed consent from patients for their de-identified data to be used for research and safety analysis.
• Collaboration: Sharing aggregated, de-identified data with researchers or industry groups to contribute to a larger evidence base.

Currently, many clinics, like Bio2 Laser Studio, provide valuable services but do not publicly report detailed safety metrics such as session counts, PIH rates, burn rates, outcomes by skin tone, or follow-up completion ^[45]. While this is common practice, greater transparency from clinics can improve public trust and contribute to a richer understanding of safety outcomes across diverse populations ^[45]. This would involve reporting clear, denominator-based safety measures without turning the data into promotional claims ^[45].

The Pre-Treatment Checklist: Steps to Stabilize and Screen

Before any laser energy is delivered, a series of crucial steps must be completed to stabilize the skin and screen for risks. This pre-laser checklist is designed to defer elective treatments when risk is high and to prepare the skin for optimal safety and efficacy.

1. Diagnosis and Risk Screening

The first step in any safe laser protocol is a precise diagnosis and thorough risk screening ^[4]. The target of treatment must be confirmed, whether it is unwanted hair, pigment, or a vascular lesion ^[4]. This forms the foundation for device selection and setting parameters. Clinics must also document a comprehensive history, including:

• History of PIH: Previous incidents of PIH strongly indicate a patient’s susceptibility.
• Scarring: History of hypertrophic scars or keloids can impact healing.
• Current inflammation: Active inflammatory conditions in the treatment area are contraindications.
• Recent tanning: Sun exposure increases epidermal melanin, raising the risk of adverse reactions.
• Prior procedures and medications: These can influence skin sensitivity and healing.
• Patient’s normal untanned skin color: This provides a baseline for objective skin typing.

If existing PIH is present, laser treatment should generally follow topical treatment rather than being the initial approach ^[4].

2. Skin Stabilization and Deferral

Deferral of elective laser treatment is paramount when risk factors are present ^[5]. Key conditions that should trigger deferral include:

• Recent tan or active inflammatory disease: Visible tanning, recent sunburn, active dermatitis, or uncontrolled acne inflammation in the treatment area significantly increase the risk of burns and PIH ^[5].
• Avoidance of irritants: The 2025 global consensus recommends avoiding irritants close to procedures to reduce skin reactivity ^[5].

Skin priming with lightening agents for high-risk procedures is an area with mixed evidence ^[5]. While the 2025 global consensus supports it, a 2026 network analysis found no significant prevention benefit for whitening agents over sunscreen monotherapy ^[21]. If used, topical treatment should start weeks before laser treatment ^[21].

Broad-spectrum sunscreen should be considered base care and started before any procedure, especially for pigment-prone patients ^[21]. A 2026 trial of 20 Fitzpatrick IV and V participants showed that a tested sunscreen provided about 16 Individual Typology Angle (ITA) degrees of net protection against induced pigmentation ^[21]. Iron-oxide formulas also perform better against visible light-induced pigmentation in Fitzpatrick IV skin ^[16].

Stakeholder Implication: High-risk consultations and test spots should be separate workflow stages, with clinics factoring in the extra visit and waiting period into pricing and scheduling ^[22]. Rushing into same-day consultation and high-energy treatment due to sales pressure creates unnecessary clinical risk ^[22].

3. Device Selection Based on Wavelength and Tissue Burden

Matching the appropriate device and wavelength to the treatment goal and skin type is a critical safety control. Epidermal melanin absorbs part of the laser energy, making longer wavelengths generally safer for darker skin ^[3].

• Hair reduction in Fitzpatrick V and VI: Long-pulsed 1064 nm Nd:YAG is the preferred starting point because of its lower epidermal melanin absorption ^[7]. Diode systems (near 800-810 nm) can be used with caution, but they offer less safety margin than Nd:YAG in very dark or tanned skin ^[23]. Alexandrite (755 nm) and broad-spectrum IPL require significantly more caution ^[7]. Even with Nd:YAG, safer does not mean risk-free; a 2011 study showed 54.3% hair reduction after 8.9 sessions in Fitzpatrick IV-VI patients, with temporary hyperpigmentation as the most common complication ^[13].
• Pigment procedures: Shorter wavelengths, like 532 nm, interact strongly with epidermal pigment and demand extreme caution in Fitzpatrick V and VI ^[24]. The European laser position statement advises using the minimum effective fluence in darker skin ^[24]. Low-fluence 1064 nm Nd:YAG may treat resistant pigment disorders, but repeated “laser toning” can cause mottled pigment loss ^[24].
• Resurfacing: Reducing total tissue injury is key. Fractional treatment is generally preferred over full-field where clinically suitable ^[25]. Lower treatment density, fewer passes, longer intervals between sessions, and avoiding pulse overlap help reduce accumulated inflammation ^[25]. Studies show that lower density leads to significantly less PIH, even at the same energy settings ^[11], emphasizing that total skin coverage and accumulated inflammation are crucial safety controls ^[12].
• Vascular procedures: These require specific protocols. A 2023 review found only nine pulsed dye laser studies involving Fitzpatrick IV to VI patients, highlighting limited evidence and ongoing concerns about hyperpigmentation, hypopigmentation, and scarring ^[15]. A hair removal protocol should never be reused for vascular or pigment treatment ^[15].

When hair lacks sufficient pigment, such as blonde, red, gray, or white hair, refusing laser treatment can be the safer choice. Clinics like Bio2 Laser Studio offer both laser hair reduction and electrolysis ^[26], providing alternative options that do not depend on hair pigment for energy absorption. While electrolysis also creates local tissue injury, it has its own PIH controls ^[26].

4. Test Spots: A Critical Evaluation Step

A delayed test spot is a non-negotiable safety measure for darker skin types ^[8]. It involves treating a small, inconspicuous area with the exact device, wavelength, body site, cooling method, and planned settings to observe the skin’s reaction ^[8]. The crucial element is delaying the full treatment until enough time has passed for delayed pigment changes to appear ^[8]. One manufacturer protocol cited in an FDA report recommended a 1-2 week wait for Fitzpatrick IV to VI or tanned skin ^[8], though specific timing must align with device instructions ^[8].

The Treatment-Day Protocol: Execution and Monitoring

The treatment day itself requires strict adherence to safety protocols, careful energy delivery, and real-time monitoring of the patient’s response.

1. Formal Time-Out Before Treatment

Every treatment session should begin with a formal “time-out” ^[27]. This is a critical pause to confirm all essential parameters:

• Patient identity
• Correct treatment area
• Diagnosis and treatment goal
• Specific device, wavelength, and handpiece
• Spot size, pulse width, and fluence settings
• Cooling settings
• Result of the delayed test spot

The screen and handpiece settings should be re-checked before the first pulse and after any interruption or change in treatment mode ^[27]. This procedure directly addresses risks identified in FDA reports concerning wrong wavelength selection, where operator errors led to serious injuries ^[27].

2. Conservative Energy Delivery and Heat Management

Given the risk of epidermal melanin absorption, conservative energy delivery is key ^[3]. This means selecting settings that are effective but minimize excess heat. In fractional laser treatments, the amount of skin covered (treatment density) can be as important as the energy per microbeam ^[37]. A study showed PIH rates of 43% in lower-density areas compared to 71% in higher-density areas at the same energy setting ^[37]. Therefore, operators must:

• Limit heat accumulation: Use mapped passes, avoid unplanned overlap of laser pulses, and allow adequate cooling time between adjacent pulses if required by the device ^[29]. This clinical inference comes from studies linking greater skin coverage and thermal injury to increased PIH ^[29].
• Do not copy fluence numbers: Fluence values from literature or other devices are not directly transferable due to variations in pulse shape, handpiece calibration, spot size, cooling, repetition rate, and beam profile, all of which affect the actual skin effect ^[28].
• Apply cooling as validated: Cooling methods should strictly follow the device manufacturer’s instructions ^[10]. While some research shows epidermal cooling is superior to sunscreen alone in preventing PIH, other reviews suggest certain cooling-air protocols can worsen outcomes ^[10]. This discrepancy highlights the importance of device-specific validation for cooling techniques ^[10]. Cooling cannot compensate for inappropriate wavelengths or excessive settings ^[35].

3. Real-Time Monitoring and Stop Criteria

During treatment, continuous monitoring of the patient’s skin response and subjective feedback is critical. Operators must be trained to recognize and act upon specific stop criteria ^[34]:

• Blistering: Immediate cessation is required if blisters appear.
• Epidermal lifting: This indicates excessive energy delivery.
• Sharply patterned discoloration: Suggests uneven energy distribution or burn.
• Pain disproportionate to expected response: Unusually severe pain can be an indicator of injury.

Eye protection for both the patient and the operator is a mandatory control. A 2026 review reported ocular complications in about 2.1% of periocular laser cases, underscoring the risk ^[34].

4. Detailed Laser Log Documentation

Every detail of the treatment session must be recorded in a laser log ^[28]. This includes:

• Current skin color and tan status
• Skin preparation methods
• Cooling parameters used
• Number of passes and overlap pattern
• Patient’s pain response
• Immediate tissue response
• Device settings (wavelength, spot size, pulse width, fluence)

A comprehensive log ensures that a future operator can reconstruct the session accurately without relying on memory, which is vital for follow-up treatments and adverse event analysis ^[28].

Post-Treatment Care and Early Detection of PIH

Effective aftercare plays a pivotal role in limiting inflammation and detecting early signs of PIH, helping to mitigate its severity or prevent its progression.

1. Controlling Inflammation and Protecting the Skin Barrier

The immediate goal post-treatment is to calm inflammation and protect the compromised skin barrier ^[36]. Clinics should provide specific wound-care instructions, often involving a bland occlusive agent for ablative procedures ^[36]. Patients must be advised to avoid:

• Rubbing or picking the treated area
• Exposure to excessive heat
• Using unapproved acids, retinoids, or exfoliants
• Applying fragranced products while the barrier is impaired

2. Judicious Use of Prescription Anti-Inflammatories

For selected ablative procedures, short-term prescription anti-inflammatory treatment can reduce PIH. In a 2015 split-face trial of 40 Fitzpatrick IV patients, a two-day regimen of clobetasol 0.05% followed by petrolatum reduced PIH from 75% to 40%, compared to petrolatum alone ^[8]. However, clobetasol is a strong steroid, and its misuse can cause harm, particularly on the face ^[8]. Therefore, such regimens should remain under the supervision of a qualified medical prescriber and not be issued as a standard retail instruction ^[8].

3. Consistent Photoprotection

Sunscreen remains a fundamental component of post-treatment care ^[38]. Despite some conflicting data in prevention reviews – a 2026 network analysis found sunscreen monotherapy ineffective against placebo in its network, while a 2025 skin-of-color review identified sunscreen as the most consistent preventive measure ^[38] – controlled light-exposure studies confirm that ultraviolet and visible light can deepen pigmentation ^[38]. Therefore, broad-spectrum sunscreen with visible-light protection (e.g., iron oxide formulations) should be consistently used, particularly by pigment-prone patients.

4. Emerging Medical Options: Tranexamic Acid

Intradermal tranexamic acid shows promise as an emerging medical option for PIH prevention, with a relative risk of 0.02 against sunscreen in a 2026 analysis ^[39]. However, the supporting trials are small, and the procedure involves injection discomfort and bruising ^[39]. Oral or injected tranexamic acid requires medical assessment and trained administration; it is not suitable for routine salon use ^[39].

5. Delayed Follow-Up for Early Detection

Delayed follow-up is essential to detect PIH as it develops, rather than relying on same-day checks ^[39]. A practical schedule could include:

• A photo check at 48 to 72 hours
• Another check at 7 to 14 days
• A thorough reassessment before any subsequent treatment session

This timing is inferred from studies that track patients over several days, weeks, and months ^[39]. It is crucial never to repeat treatment while inflammation or new pigment is still developing, as this can worsen the injury ^[39]. If PIH appears, further energy-based treatment should be stopped, active inflammation or acne treated, photoprotection strengthened, and appropriate topical care initiated under local clinical guidance ^[39]. The global consensus positions topicals as the first line of treatment for PIH, reserving laser or peels for resistant cases ^[39].

Summary Table of Clinic Safety Measures

The following table provides a consolidated overview of key safety measures for clinics treating Fitzpatrick IV-VI skin, drawing from the comprehensive guidelines discussed.

Category	Specific Safety Measure	Rationale / Impact	Key Data / Source
Risk Assessment	Use structured intake forms beyond Fitzpatrick type.	Fitzpatrick alone has limits; objective measures and history are more accurate.	95% of experts agree Fitzpatrick has limits [2]; 789-adult study shows subjective-objective mismatch [2].
	Document normal untanned skin color, PIH history, current inflammation, recent tan, medications.	These factors directly influence treatment risk and outcome.	Risk screening is Step 1 [4].
Protocol Design	Maintain separate, detailed protocols for each device, wavelength, indication, body site, skin-risk group.	Fixed settings do not apply universally; customization reduces errors.	No single “Fitzpatrick IV-VI Laser Safety Protocol” exists [1].
	Protocols must specify deferral rules, test-spot rules, permitted ranges, cooling, endpoints, stop criteria, follow-up, and escalation.	Provides clear operational guidance for operators.	Ensures consistent and safe practice [40].
Pre-Treatment	Implement clear deferral gates for active inflammation or recent tan.	Tanned or inflamed skin significantly increases burn and PIH risk.	FDA adverse event: tanned patient burns from wrong wavelength [19].
	Perform delayed test spots, waiting 1-2 weeks for Fitzpatrick IV-VI skin.	Allows time for delayed pigment changes to appear, confirming safe settings.	Manufacturer protocol cited in FDA report for 1-2 week wait [8].
	Begin photoprotection before procedures; consider visible-light protection.	Sunscreen can materially limit induced pigment; active pigment needs early protection.	2026 sunscreen trial: 16 ITA degrees net protection [15]; iron-oxide effective against visible light [16].
Device Selection	For hair reduction in Fitzpatrick V-VI, prioritize long-pulsed 1064 nm Nd:YAG.	Lower epidermal melanin absorption for 1064 nm reduces PIH risk.	1064 nm Nd:YAG generally safest for hair reduction [7].
	For fractional resurfacing, emphasize low density and reduced total tissue injury.	Lower density and fewer passes decrease accumulated inflammation and PIH risk.	43% PIH at lower density vs. 71% at higher density [11].
	Offer electrolysis for pigment-poor hair where laser is ineffective or unsafe.	Provides a safer alternative when laser relies on melanin absorption.	Bio2 Laser Studio offers both options [26].
Treatment Day	Conduct a formal time-out to confirm all parameters before starting.	Prevents errors like wrong wavelength selection, a cause of serious injury.	FDA report on wrong wavelength causing burns [30].
	Limit heat accumulation through mapped passes and no unplanned overlap.	Prevents excessive thermal injury and subsequent inflammation/PIH.	Inference from fractional studies linking PIH to skin coverage and thermal injury [33].
	Document every setting, response, and clinical endpoint in a laser log.	Allows for accurate reconstruction of session and aids in follow-up.	Ensures future operators can understand prior treatments [28].
Post-Treatment	Calm inflammation and protect the skin barrier (e.g., bland occlusive).	Minimizes secondary injury and supports proper healing.	First goal is to calm inflammation [36].
	Consider prescription anti-inflammatory treatment after selected ablative procedures, under medical control.	Short-term use of agents like clobetasol can significantly reduce PIH incidence.	Clobetasol reduced PIH from 75% to 40% in Fitzpatrick IV trial [8].
	Ensure consistent, daily broad-spectrum sunscreen use.	Essential for preventing and managing pigment changes.	Controlled light-exposure studies show UV/visible light deepens pigment [38].
	Implement delayed follow-up (e.g., 48-72 hrs, 7-14 days, pre-session).	Allows detection of delayed PIH and prevents treatment while inflammation persists.	Operational inference from studies with multi-day follow-ups [39].
Clinic Operations	Track denominator-based outcomes (e.g., PIH rates per 1,000 sessions, deferral rates).	Provides quantitative data for evaluating safety performance and identifying trends.	Literature’s inconsistent reporting leads to wide complication estimates [41].
	Audit training events and mode-selection errors regularly.	Ensures operator competency and prevents human errors.	FDA cases show injury from wrong wavelength, skipped test spots [42].
	Use careful pricing and consent, explaining multi-session needs and potential adjunctive care.	Manages patient expectations and reduces pressure for aggressive settings.	Nd:YAG cohort averaged 8.9 treatments for 54.3% hair reduction [13].
	Internally report Fitzpatrick VI safety data with objective color measures and consent.	Helps close the evidence gap for the darkest skin types.	Zero Fitzpatrick VI in 2025 prevention review [9].

Implementing these measures requires a commitment to continuous improvement and a culture of safety throughout the clinic. It moves clinics from a reactive stance, responding to adverse events, to a proactive one, actively preventing them.

Conclusion

Measuring and improving clinic safety for Fitzpatrick IV-VI skin types is a comprehensive undertaking that goes beyond generic protocols. It necessitates detailed, device-specific procedures, rigorous patient assessment, careful documentation, and an ongoing commitment to training and outcome tracking. By embracing a data-driven approach and fostering transparency, clinics can significantly reduce the incidence of PIH and other adverse events, thereby elevating the standard of care for diverse patient populations. The goal is to ensure that every laser treatment is also effective but also delivered with the highest possible degree of safety.

The next section will expand on the topic of operator training and certification, detailing the specific competencies required for safe and effective laser procedures on Fitzpatrick IV-VI skin.

Sources

^[1] As of August 29, 2026, there is no single international standard called the “Fitzpatrick IV to VI Laser Safety Protocol.” The safest framing is a 2026 clinical playbook built from consensus reports, controlled trials, device instructions, and adverse event data. Fixed settings cannot be applied across devices, indications, body sites, or patients. (beiersdorf.com)

^[2] Fitzpatrick type should be one input, not the full risk assessment. In a 2025 Delphi study, 95% of 22 skin-of-color experts agreed that the current Fitzpatrick system has clinical and research limits. A 2026 study of 789 adults also found large differences between subjective skin ratings and objective color measurements. (skinofcolorsociety.org)

^[3] The central safety problem is that epidermal melanin absorbs part of the treatment energy. That narrows the margin between an effective treatment and excess heat, inflammation, burns, PIH, or loss of pigment. Longer wavelengths, conservative settings, controlled skin coverage, and epidermal cooling can reduce this risk, but none makes treatment risk-free. (pubmed.ncbi.nlm.nih.gov)

^[4] Step 1 is diagnosis and risk screening. Confirm the treatment target. Document prior PIH, scarring, current inflammation, recent tanning, prior procedures, medications, and the patient’s normal untanned skin color. Laser treatment of existing PIH should usually follow topical treatment rather than serve as the first treatment. (beiersdorf.com)

^[5] Step 2 is stabilization. Defer elective laser treatment when there is a recent tan or active inflammatory disease in the area. The 2025 global consensus also recommends avoiding irritants close to procedures and preparing high-risk skin before treatment, although evidence for routine hydroquinone or other lightening agents remains mixed. (beiersdorf.com)

^[6] Expert agreement on Fitzpatrick limits: 95%. In the 2025 Delphi report, 76% of 22 experts strongly agreed and 19% agreed that the Fitzpatrick system has important clinical and research limits. Significance: 2026 clinics should add baseline color measurement, pigment history, and environmental change to the intake process. (skinofcolorsociety.org)

^[7] Step 3 is device selection. For hair reduction in Fitzpatrick V and VI, long-pulsed 1064 nm Nd:YAG is generally the safest laser starting point because it has lower epidermal melanin absorption than shorter wavelengths. Diode systems may be used with caution. Alexandrite 755 nm and broad-spectrum IPL require much greater caution in dark or tanned skin. (pubmed.ncbi.nlm.nih.gov)

^[8] Step 4 is a delayed test spot. Use the same device, wavelength, body site, cooling method, and planned settings. Review the spot after enough time for delayed pigment change to appear. One manufacturer protocol cited in an FDA report called for a 1 to 2 week wait in Fitzpatrick IV to VI skin, but timing must follow the specific device instructions. (accessdata.fda.gov)

^[9] Prevention evidence is still thin. A 2025 systematic review included 369 cases, but reported ethnicity was 100% Asian, only 4.1% of classified participants were Fitzpatrick V, and none were Fitzpatrick VI. Protocols for Fitzpatrick VI therefore rely heavily on physiology, small studies, expert opinion, and cautious clinical practice. (pmc.ncbi.nlm.nih.gov)

^[10] Sunscreen and cooling data appear to conflict. A 2025 skin-of-color review found sunscreen to be the most consistent preventive measure and reported worse outcomes with some cooling-air protocols. A 2026 network analysis found epidermal cooling and several medical interventions superior to sunscreen alone. The studies used different populations, cooling methods, comparators, and endpoints, so cooling should follow the device instructions rather than a blanket rule. (pubmed.ncbi.nlm.nih.gov)

^[11] Same energy, different density: 43% versus 71% PIH. In a small 2016 split-face study summarized in a 2017 evidence review, 40 mJ was delivered at roughly 200 versus 393 microscopic treatment zones per square centimeter. Observed PIH was 43% at lower density and 71% at higher density. The difference was not statistically significant in the small sample. Significance: treatment density should be treated as a major safety control. (pmc.ncbi.nlm.nih.gov)

^[12] High-energy, low-density fractional treatment: 7.1% PIH versus 12.4%. A study of 37 Chinese patients compared higher-energy, lower-density treatment with lower-energy, higher-density treatment. The lower-density group had fewer PIH events, despite higher energy per treatment point. Significance: total skin coverage and accumulated inflammation may matter more than any single energy number. Source: Chan et al., 2007, summarized by Vaiyavatjamai and Wattanakrai in 2011. (researchgate.net)

^[13] Long-pulsed Nd:YAG hair reduction: 54.3% mean reduction. In a 2011 retrospective cohort of 150 Fitzpatrick IV to VI patients, the average treatment count was 8.9. Mean hair reduction was 54.3%, 78.7% rated treatment good or satisfactory, and 86% had no complications. Hyperpigmentation was the most common complication, but reported events were temporary. Significance: 1064 nm can work in darker skin, but safe care often requires multiple conservative sessions. (pubmed.ncbi.nlm.nih.gov)

^[14] Paradoxical hair growth: 3% pooled prevalence. A 2021 meta-analysis included 9,733 laser or IPL hair-removal patients. Paradoxical hypertrichosis occurred in 3% overall but in only 0.08% of nonfacial and non-neck cases. Significance: women receiving face or neck treatment need specific consent about the possibility of increased hair growth. (pubmed.ncbi.nlm.nih.gov)

^[15] Pulsed dye laser evidence in Fitzpatrick IV to VI: nine studies and 241 patients. A 2023 review searched evidence through December 2022 and found only nine eligible studies. Despite decades of pulsed dye laser use, darker skin evidence remains limited and includes hyperpigmentation, hypopigmentation, and scarring. Significance: vascular-laser protocols need conservative fluence and careful endpoint monitoring. (pubmed.ncbi.nlm.nih.gov)

^[16] Impact of Iron-Oxide Containing Formulations Against Visible Light-Induced Skin Pigmentation in Skin of Color Individuals. (pubmed.ncbi.nlm.nih.gov)

^[17] Use repeatable photographs with the same room, camera, distance, lighting, and patient position. Colorimetry or spectrophotometry can add useful data where available. In the 2026 Lipnick study, five assessment methods applied to 789 people produced materially different estimates of how many participants had dark skin. (pubmed.ncbi.nlm.nih.gov)

^[18] The diagnosis matters as much as skin tone. Brown epidermal PIH and blue-gray dermal PIH do not respond in the same way. Active inflammatory conditions should be controlled first. The 2025 global consensus advises avoiding laser or IPL during active inflammatory stages of acquired dermal pigment disorders because treatment may worsen pigmentation. (beiersdorf.com)

^[19] Create a clear deferral gate. Visible tanning, recent sunburn, active dermatitis, uncontrolled acne inflammation, or unresolved irritation should pause elective treatment. In a 2025 FDA adverse event, a tanned patient developed burns after an operator switched from Nd:YAG to alexandrite. (accessdata.fda.gov)

^[20] Review previous PIH, hypopigmentation, blistering, keloids, infection, and poor wound healing. Review medicines and skin products, but do not instruct patients to stop prescription drugs without the prescriber. The purpose is to find factors that may raise light sensitivity, irritation, bleeding, infection, or delayed healing risk. (pubmed.ncbi.nlm.nih.gov)

^[21] Skin priming is an area of disagreement. The 2025 global consensus supports lightening-agent priming for higher-risk procedures and avoidance of irritants close to treatment. The 2026 network analysis found no significant prevention benefit for whitening agents over sunscreen monotherapy. One included trial started topical care two weeks before laser, while 71.4% of interventions in the review began after treatment. (beiersdorf.com)

^[22] Stakeholder implication: high-risk consultations and test spots should be separate workflow stages. Clinics should build the extra visit and waiting period into price quotes and scheduling. Same-day consultation and high-energy treatment can turn sales pressure into clinical risk. (accessdata.fda.gov)

^[23] For hair reduction, long-pulsed 1064 nm Nd:YAG is the main laser option for Fitzpatrick V and VI. Its longer wavelength is absorbed less by epidermal melanin than 755 nm alexandrite. Diode systems near 800 to 810 nm can be used in selected patients with suitable pulse control and cooling, but they leave less safety margin than 1064 nm in very dark or tanned skin. (pubmed.ncbi.nlm.nih.gov)

^[24] For pigment procedures, shorter wavelengths such as 532 nm interact strongly with epidermal pigment and require added caution in Fitzpatrick V and VI. The European laser position statement recommends using the minimum effective fluence in darker skin. Low-fluence 1064 nm Nd:YAG may be considered for selected resistant pigment disorders, but repeated “laser toning” can also cause mottled loss of pigment. (onlinelibrary.wiley.com)

^[25] For resurfacing, reduce total tissue injury. Use fractional rather than full-field treatment where clinically suitable. Lower density, fewer passes, longer intervals, and avoidance of pulse overlap reduce accumulated inflammation. Published fractional studies reported 7.1% versus 12.4% PIH and 43% versus 71% PIH when lower-density and higher-density methods were compared. (researchgate.net)

^[26] When the hair lacks enough pigment, refusing laser can be the safer choice. Bio2 Laser Studio lists both laser hair reduction and electrolysis, as do some dermatology and electrology practices. This gives patients with blonde, red, gray, white, or very fine hair an option that does not depend on light absorption by hair pigment. Electrolysis still creates local tissue injury and needs its own PIH controls. (bio2laserstudio.com)

^[27] Begin with a formal time-out. Confirm patient, treatment area, diagnosis, device, wavelength, handpiece, spot size, pulse width, fluence, cooling setting, and test-spot result. The screen and handpiece should be checked before the first pulse and after any interruption or mode change. This is a direct process lesson from FDA reports involving wrong wavelength selection. (accessdata.fda.gov)

^[28] Record every setting and clinical endpoint in a laser log. Include current skin color, tan status, skin preparation, cooling, number of passes, overlap pattern, pain response, and immediate tissue response. A future operator should be able to reconstruct the session without relying on memory. (link.springer.com)

^[29] Limit heat accumulation. Use mapped passes, prevent unplanned overlap, and allow cooling between adjacent pulses when required by the device. This is a clinical inference from fractional studies showing more PIH with greater skin coverage and from reviews linking PIH to thermal injury and inflammation. (pmc.ncbi.nlm.nih.gov)

^[30] Do not copy a fluence number from a paper or another device. Pulse shape, handpiece calibration, spot size, cooling, repetition rate, and beam profile can change the skin effect. In the 2025 FDA case, a tanned patient was treated with a 755 nm alexandrite setting of 15 J/cm², 20 ms, and an 18 mm handpiece after treatment began with Nd:YAG. Burns and blisters were classified as a serious injury. (accessdata.fda.gov)

^[31] Begin with a formal time-out. Confirm patient, treatment area, diagnosis, device, wavelength, handpiece, spot size, pulse width, fluence, cooling setting, and test-spot result. The screen and handpiece should be checked before the first pulse and after any interruption or mode change. This is a direct process lesson from FDA reports involving wrong wavelength selection. (accessdata.fda.gov)

^[32] Record every setting and clinical endpoint in a laser log. Include current skin color, tan status, skin preparation, cooling, number of passes, overlap pattern, pain response, and immediate tissue response. A future operator should be able to reconstruct the session without relying on memory. (link.springer.com)

^[33] Limit heat accumulation. Use mapped passes, prevent unplanned overlap, and allow cooling between adjacent pulses when required by the device. This is a clinical inference from fractional studies showing more PIH with greater skin coverage and from reviews linking PIH to thermal injury and inflammation. (pmc.ncbi.nlm.nih.gov)

^[34] Stop for blistering, epidermal lifting, sharply patterned discoloration, or pain that is out of proportion to the expected response. Eye protection is a separate mandatory control. A 2026 descriptive review reported ocular complications in about 2.1% of a 70-case periocular subset, although the data were too mixed to provide a true incidence estimate. (link.springer.com)

^[35] Cooling evidence must be read by method. The 2026 network analysis favored epidermal cooling over sunscreen alone, but the 2025 skin-of-color review found that some cooling-air approaches worsened outcomes. Cooling should be applied exactly as validated for the device, while skin response remains visible to the operator. It cannot correct a wrong wavelength or an excessive setting. (pmc.ncbi.nlm.nih.gov)

^[36] The first goal is to calm inflammation and protect the barrier. Use the wound-care method specified for the procedure, often a bland occlusive for ablative treatment. Avoid rubbing, picking, heat, unapproved acids, retinoids, exfoliation, and fragranced products while the barrier is impaired. (pubmed.ncbi.nlm.nih.gov)

^[37] Step 5 is conservative energy delivery. Fractional laser evidence suggests that treatment density, meaning the amount of skin covered, can matter as much as or more than energy per microbeam. A study summarized in a skin-of-color review observed PIH in 43% of lower-density areas and 71% of higher-density areas at the same 40 mJ setting. (pmc.ncbi.nlm.nih.gov)

^[38] Sunscreen should be treated as base care, even though prevention reviews disagree about sunscreen alone. The 2026 network analysis found sunscreen monotherapy ineffective against placebo in its network, while the 2025 skin-of-color review found sunscreen to be the only measure with consistent prevention results. Controlled light-exposure studies also show that ultraviolet and visible light can deepen pigment. (pmc.ncbi.nlm.nih.gov)

^[39] Tranexamic acid should be presented as an emerging medical option, not a standard spa protocol. Intradermal treatment produced a relative risk of 0.02 against sunscreen in the 2026 analysis, but included trials were small. Injection discomfort and bruising were reported. Oral or injected use needs medical assessment. (pmc.ncbi.nlm.nih.gov)

^[40] Maintain separate protocols for each device, wavelength, indication, body site, and skin-risk group. Each protocol should state deferral rules, test-spot rules, permitted starting ranges, cooling requirements, acceptable endpoints, stop criteria, follow-up timing, and escalation steps. There should be no single Fitzpatrick IV to VI parameter chart. (link.springer.com)

^[41] Track denominator-based outcomes. Useful measures include the percentage of eligible patients receiving test spots, recent-tan deferrals, PIH at 2 and 6 weeks, burns or blisters per 1,000 sessions, hypopigmentation, unplanned medical referrals, and adverse events by operator, device, wavelength, site, and measured skin color. The literature’s inconsistent reporting is one reason current complication estimates vary so widely. (link.springer.com)

^[42] Audit training events and mode-selection errors. The FDA cases show that a machine cleared for darker skin can still cause injury when the operator selects the wrong wavelength, treats a tan, skips a test spot, or fails to follow instructions. Device clearance is a condition of safe use, not a guarantee of safe operation. (accessdata.fda.gov)

^[43] Use careful pricing and consent. Conservative settings may require more sessions. The 150-patient Nd:YAG cohort averaged 8.9 treatments for 54.3% mean reduction. Clinics should avoid one-session promises and should explain the possible need for maintenance, electrolysis, topical care, or specialist referral. (pubmed.ncbi.nlm.nih.gov)

^[44] Close the Fitzpatrick VI evidence gap through internal reporting. No Fitzpatrick VI patients appeared in the 2025 prevention review, while only 6% of classified participants in the broader 2024 treatment review were Fitzpatrick VI. Clinics serving diverse populations may hold valuable safety data, but it must be collected with consent, consistent definitions, and objective color measures. (pmc.ncbi.nlm.nih.gov)

^[45] Bio2 Laser Studio’s public site describes laser and electrolysis services but does not report session counts, PIH rates, burn rates, outcomes by skin tone, or follow-up completion. That is a useful example of the wider disclosure gap. Bio2 and its peers could improve public trust by reporting clear denominator-based safety measures without turning the data into promotional claims. (bio2laserstudio.com)

13. Key Data and Clinical Evidence Summary

Understanding the foundational data and clinical evidence is essential for developing strong laser safety protocols, especially for Fitzpatrick IV-VI skin types. This section consolidates critical findings from recent research, including systematic reviews, clinical trials, and expert consensus reports, to provide a detailed overview of the current state of knowledge. It focuses on specific Post-Inflammatory Hyperpigmentation (PIH) rates, the limitations of existing classification systems, and the efficacy of various preventive measures.

The Evolving Standard: No Single Universal Protocol

As of August 29, 2026, there is no single international standard designated as the “Fitzpatrick IV to VI Laser Safety Protocol”^[1]. Instead, safe clinical practice for these skin types is built from a combination of consensus reports, controlled trials, specific device instructions, and data derived from adverse events^[1]. A critical insight is that fixed laser settings cannot be universally applied across different devices, specific indications, body sites, or individual patients^[1]. This highlights the need for individualized assessment and protocol adjustment rather than a rigid, one-size-fits-all approach.

The complexity of melanin absorption in the epidermis is at the core of this challenge^[2]. Epidermal melanin absorbs a portion of the treatment energy, which significantly narrows the therapeutic window between an effective treatment and the risk of adverse events such as excess heat, inflammation, burns, PIH, or even loss of pigment^[2]. While strategies like using longer wavelengths, conservative settings, controlled skin coverage, and epidermal cooling can help reduce these risks, no single measure makes laser treatment entirely risk-free for darker skin types^[2].

The absence of a universal protocol underscores the importance of a comprehensive, step-by-step clinical playbook. This playbook should guide practitioners through diagnosis, stabilization, device selection, test spotting, energy delivery, and post-treatment care to minimize PIH. The evidence base for preventing PIH in darker skin, particularly Fitzpatrick VI, is still considered thin^[3]. A 2025 systematic review, for instance, included 369 cases, but 100% of the reported ethnicity was Asian, only 4.1% of classified participants were Fitzpatrick V, and none were Fitzpatrick VI^[3]. This data gap means that protocols for Fitzpatrick VI skin heavily rely on physiological principles, small-scale studies, expert opinion, and conservative clinical judgment^[3].

Limitations of the Fitzpatrick System and the Need for Better Risk Assessment

The Fitzpatrick skin phototype (FST) system, while widely used, has significant clinical and research limitations, especially when used as the sole basis for laser risk assessment^[4]. A 2025 Delphi study involving 22 skin-of-color experts revealed that 95% agreed on these limitations^[4]. The system was designed to classify how skin reacts to sun exposure (burning and tanning), not as a direct measure of epidermal melanin content or specific laser injury risk^[5].

A 2026 study involving 789 adults further highlighted discrepancies between subjective skin ratings and objective color measurements^[6]. The study compared five assessment methods: three subjective and two objective. It found that depending on the method used, the proportion of participants classified as “dark” could range from 7% to 26% within the same cohort^[6]. Specifically, 14% were classified as dark using one objective threshold, 26% using perceived Fitzpatrick type, 16% using Monk Skin Tone, and only 7% with a stricter objective threshold^[6]. This demonstrates that subjective scales can greatly change how many individuals are placed in a high-risk group, impacting safety protocols and treatment accessibility^[6].

Therefore, Fitzpatrick type should be considered one input among many, not the full basis for risk assessment^[4]. A thorough assessment must include documenting prior PIH, scarring, current inflammation, recent tanning, previous procedures, current medications, and the patient’s normal untanned skin color^[1]. Objective measurements, such as colorimetry or spectrophotometry, can provide valuable supplementary data where available^[5]. Clinics should use a structured intake form that captures these factors, along with repeatable photographs taken under consistent conditions (same room, camera, distance, lighting, and patient position)^[5].

The diagnosis itself is as important as the skin tone^[5]. For example, brown epidermal PIH and blue-gray dermal PIH respond differently to treatments^[5]. Active inflammatory conditions in the treatment area should be controlled before elective laser treatment^[1]. The 2025 global consensus advises against laser or IPL during active inflammatory stages of acquired dermal pigment disorders because treatment may worsen pigmentation^[5].

Key Data on PIH Rates and Treatment Outcomes

Several studies provide specific data points regarding PIH rates and the effectiveness of various interventions:

• Clinical prevention evidence: A 2026 network meta-analysis, searching evidence through February 2025, identified 14 randomized controlled trials relevant to PIH prevention after laser and energy-based device treatments^[7]. Eleven of these trials were suitable for network comparison^[7]. This marks a shift from mainly narrative advice to comparative evidence, but the trial base remains small given the wide range of devices, settings, indications, and skin tones in use^[7]. This means no single preventive regimen can be declared a universal standard^[7].
• Procedure-linked prevention cases: The 2025 skin-of-color prevention review included 369 cases^[8]. Laser procedures were responsible for 95.4% of the studied PIH risk, and the face accounted for 85.3% of reported sites^[8]. This highlights that laser-related facial PIH is the dominant context in the published prevention evidence^[8]. This finding implies that facial protocols require delayed follow-up, not just same-day checks, to detect delayed pigment changes effectively^[8].
• Fitzpatrick VI representation: A critical gap in the prevention literature is the lack of data for Fitzpatrick VI skin types^[9]. In the 2025 prevention review, among 339 classified cases, 42.2% were Fitzpatrick III, 53.7% were IV, 4.1% were V, and 0% were VI^[9]. All reported ethnicity was Asian^[9]. This indicates that evidence becomes thinner as skin pigmentation increases, making claims of proven Fitzpatrick VI safety questionable^[9].
• PIH treatment evidence: A 2024 systematic review on PIH treatment reported data from 1,356 patients with skin of color^[10]. Among cases with phototype data, 40% were Fitzpatrick IV, 34% V, and 6% VI^[10]. Of participants with reported race or ethnicity, 70% were Black, 27% Asian, and 3% Hispanic or Latin^[10]. While this review showed greater diversity than the prevention literature, Fitzpatrick VI still constituted a small proportion^[10]. It is important to note that treatment results cannot be assumed to address prevention questions directly^[10].
• Laser outcomes in one review: The 2024 skin-of-color treatment review found partial improvement in 66% of laser-treated participants^[11]. Laser was the only intervention associated with complete resolution in a subgroup, reported at 26%^[11]. However, cases of worsening PIH also occurred^[11]. This implies that while laser can help resistant PIH, outcomes are variable, and risks must be clearly communicated during consent^[11].
• Laser outcomes in a second review: A separate 2024 systematic review included 877 patients overall and 309 treated with laser or energy devices^[12]. This review reported an 18.1% complete response rate, 61.2% partial response, and 2.6% worsening of PIH^[12]. The lower complete-response figure here conflicts with the 26% subgroup figure from the skin-of-color review^[12]. This discrepancy likely arises from different inclusion rules and patient mixes^[12]. For marketing purposes, it is important to emphasize probable improvement rather than guaranteed clearance^[12].

Efficacy of Specific Interventions

Clinical evidence provides insight into the effectiveness of various interventions for preventing or managing PIH:

Topical Corticosteroids

A 2015 split-face trial involving 40 Fitzpatrick IV patients demonstrated the benefit of short-term topical corticosteroids after ablative fractional CO2 laser treatment^[13]. PIH occurred on 75% of facial sides treated with petrolatum alone, compared to 40% of sides treated with two days of prescription clobetasol followed by petrolatum^[13]. This 35 percentage point reduction supports the use of short, clinician-directed anti-inflammatory care after selected ablative procedures^[13]. However, it does not endorse routine self-use of strong steroids, as facial misuse can cause harm and such regimens require medical control^[13].

Treatment Density and Energy Delivery

Evidence from fractional laser studies suggests that treatment density, or the amount of skin covered by the laser, can be as important as, or even more important than, the energy delivered per microbeam^[14].

• A study summarized in a 2017 skin-of-color review observed PIH in 43% of lower-density areas compared to 71% of higher-density areas, even when using the same 40 mJ setting^[14]. Although the difference was not statistically significant in the small sample, it suggests that treatment density is a major safety control^[14].
• A 2011 review from Ramathibodi Laser Center covered 181 sessions in 119 Thai patients with Fitzpatrick III to V skin undergoing 1550 nm fractional laser treatment^[15]. PIH occurred after 2.2% of sessions, and total complications after 3.3%^[15]. These rates were lower than several earlier reports from Asia, suggesting that low treatment density, longer treatment intervals, and careful cooling can reduce risk^[15]. This was a retrospective study, limiting definitive cause-and-effect conclusions^[15].
• A 2013 chart review of 45 Fitzpatrick IV to VI patients receiving 115 sessions with a 1550 nm fractional nonablative laser reported PIH in 4% of sessions^[16]. Only one episode lasted longer than one month^[16]. This indicates that fractional nonablative resurfacing can be used in darker skin, but the study also used pre- and post-treatment hydroquinone and lacked an untreated control group^[16].
• A study of 37 Chinese patients compared higher-energy, lower-density treatment with lower-energy, higher-density treatment^[17]. The lower-density group experienced fewer PIH events, despite higher energy per treatment point^[17]. This supports the idea that total skin coverage and accumulated inflammation may be more important than a single energy number^[17].
• A 2014 randomized split-face trial involving 20 Asian acne-scar patients compared 10% versus 20% density at 20 mJ, and 10 mJ versus 20 mJ at 10% density for fractional CO2 laser^[18]. Scar improvement did not differ significantly between settings, but adverse effects were more common with higher density or higher fluence^[18]. This reinforces the principle of using the lowest tissue burden that achieves the clinical goal^[18].

Sunscreen and Photoprotection

Daily broad-spectrum sunscreen is considered base care, with visible-light protection being important for pigment-prone patients^[19].

• A 2026 trial of 20 Fitzpatrick IV and V participants found that a tested sunscreen reduced induced pigmentation by approximately 16 Individual Typology Angle (ITA) degrees and improved secondary color measures by 48% to 87%^[19]. This study, though small and product-specific, suggests that photoprotection can materially limit induced pigment^[19].
• There is some conflict in the data regarding sunscreen and cooling. A 2025 skin-of-color review found sunscreen to be the most consistent preventive measure, and reported worse outcomes with some cooling-air protocols^[20]. In contrast, a 2026 network analysis found epidermal cooling and several medical interventions superior to sunscreen alone^[20]. These discrepancies are likely due to different study populations, cooling methods, comparators, and endpoints^[20]. Therefore, cooling methods should strictly follow device instructions rather than a blanket rule^[20].

Tranexamic Acid

Intradermal tranexamic acid shows promise for PIH prevention, ranking highest against sunscreen monotherapy in the 2026 network meta-analysis, with a relative risk of 0.02 and a 95% confidence interval of 0.00 to 0.53^[21]. However, the wide confidence interval reflects limited data, and the result is not a basis for routine salon use due to the need for medical assessment and trained administration^[21]. Oral or injected use also requires medical oversight^[22].

Device Selection and Wavelength Considerations

Appropriate device and wavelength selection are critical for safety in Fitzpatrick IV-VI skin:

• Hair Reduction: For hair reduction in Fitzpatrick V and VI, long-pulsed 1064 nm Nd:YAG is generally the safest laser starting point^[23]. Its longer wavelength is absorbed less by epidermal melanin than shorter wavelengths like 755 nm alexandrite^[23]. Diode systems (e.g., 800-810 nm) can be used with caution in selected patients with good pulse control and cooling, but they offer less safety margin than 1064 nm in very dark or tanned skin^[23]. Alexandrite 755 nm and broad-spectrum IPL require much greater caution in dark or tanned skin^[24].
  • A 2011 retrospective cohort study of 150 Fitzpatrick IV-VI patients treated with long-pulsed Nd:YAG for hair reduction reported a 54.3% mean hair reduction after an average of 8.9 sessions^[25]. While 86% had no complications, temporary hyperpigmentation was the most frequent complication among those who did^[25]. This shows that 1064 nm can be effective in darker skin, but safe care often demands multiple, conservative sessions^[25].
  • A 2021 meta-analysis of 9,733 laser or IPL hair-removal patients found a 3% pooled prevalence of paradoxical hypertrichosis (increased hair growth), but this was only 0.08% for nonfacial and non-neck cases^[26]. This highlights the need for specific consent for women undergoing face or neck treatment about the possibility of increased hair growth^[26].
  • When hair lacks sufficient pigment, refusing laser can be the safer option. Clinics like Bio2 Laser Studio offer both laser hair reduction and electrolysis^[27]. This dual-modality approach allows patients with blonde, red, gray, white, or very fine hair to receive effective treatment that does not rely on light absorption by hair pigment^[27]. Electrolysis, however, also causes local tissue injury and requires its own PIH controls^[27].
• Pigment Procedures: For pigment disorders, shorter wavelengths such as 532 nm interact strongly with epidermal pigment, necessitating extra caution in Fitzpatrick V and VI skin^[28]. The European laser position statement recommends using the minimum effective fluence in darker skin^[28]. Low-fluence 1064 nm Nd:YAG may be considered for selected resistant pigment disorders, but repeated “laser toning” can lead to mottled loss of pigment^[28].
• Vascular Procedures: Vascular lasers require specific protocols. A 2023 review identified only nine pulsed dye laser studies involving 241 Fitzpatrick IV to VI patients^[29]. While benefits were possible, concerns regarding hyperpigmentation, hypopigmentation, and scarring persisted^[29]. This underscores that a hair-removal protocol should never be applied to vascular or pigment treatment simply because the device platform is the same^[29].

Importance of Pre-Treatment Screening and Test Spots

Rigorous pre-treatment screening and the use of delayed test spots are fundamental safety measures.

• Deferral Gates: Elective laser treatment should be deferred in the presence of visible tanning, recent sunburn, active dermatitis, uncontrolled acne inflammation, or unresolved irritation^[30]. A 2025 FDA adverse event report described a tanned patient who developed burns after an operator switched from Nd:YAG to alexandrite, underscoring the risk of treating tanned skin^[30].
• Patient History Review: A thorough review of previous PIH, hypopigmentation, blistering, keloids, infection, and poor wound healing is essential^[31]. Medication and skin product history should also be reviewed to identify factors that might increase light sensitivity, irritation, bleeding, infection, or delayed healing risks^[31]. Patients should not be instructed to stop prescription drugs without the prescriber’s guidance^[31].
• Delayed Test Spots: A test spot should be performed in the actual treatment area, matching the planned wavelength, spot size, pulse width, fluence, cooling method, and pass count^[32]. The spot should be reviewed after enough time has passed for delayed pigment changes to appear^[32]. One manufacturer protocol cited in an FDA report suggested a 1 to 2 week wait for Fitzpatrick IV to VI or tanned skin, but timing must always adhere to specific device instructions^[32].
• Skin Priming: The evidence for skin priming is mixed. The 2025 global consensus supports using lightening agents for higher-risk procedures and avoiding irritants near treatment^[33]. However, the 2026 network analysis found no significant prevention benefit for whitening agents compared to sunscreen monotherapy^[33]. One trial in the review started topical care two weeks before laser, while 71.4% of interventions began after treatment^[33].

The Treatment-Day Process and Post-Treatment Care

Beyond initial screening and device selection, the execution of the treatment and subsequent aftercare play a pivotal role in preventing PIH.

Treatment-Day Protocol

• Formal Time-Out: Before beginning, a formal time-out is essential to confirm the patient, treatment area, diagnosis, device, wavelength, handpiece, spot size, pulse width, fluence, cooling setting, and test-spot result^[34]. The screen and handpiece should be checked before the first pulse and after any interruption or mode change^[34]. This process is a direct lesson from FDA reports detailing wrong wavelength selections^[34].
• Detailed Documentation: Every setting and clinical endpoint must be recorded in a laser log^[35]. This includes current skin color, tan status, skin preparation, cooling, number of passes, overlap pattern, pain response, and immediate tissue response^[35]. Comprehensive records allow future operators to reconstruct the session without relying on memory^[35].
• Individualized Fluence: Fluence numbers from papers or other devices should not be directly copied^[36]. Pulse shape, handpiece calibration, spot size, cooling, repetition rate, and beam profile can all affect the skin’s response^[36]. A 2025 FDA case highlighted the danger of assuming transferability, where a tanned patient suffered burns after a 755 nm alexandrite setting (15 J/cm², 20 ms, 18 mm handpiece) was used following Nd:YAG treatment, classified as a serious injury^[36].
• Heat Accumulation Control: Limiting heat accumulation is crucial^[37]. This involves using mapped passes, preventing unplanned overlap, and allowing adequate cooling between adjacent pulses as required by the device^[37]. This inference comes from fractional studies linking greater skin coverage to more PIH, and from reviews connecting PIH to thermal injury and inflammation^[37].
• Cooling Methods: Cooling evidence must be interpreted based on the specific method used^[38]. While the 2026 network analysis favored epidermal cooling over sunscreen alone, the 2025 skin-of-color review indicated that some cooling-air approaches worsened outcomes^[38]. Cooling should be applied precisely as validated for the device, ensuring the operator can still observe skin response^[38]. Cooling cannot compensate for an incorrect wavelength or excessive settings^[38].
• Immediate Stop Criteria: Treatment must be stopped if blistering, epidermal lifting, sharply patterned discoloration, or disproportionate pain occurs^[39]. Eye protection remains a mandatory safety control^[39]. A 2026 descriptive review reported ocular complications in about 2.1% of 70 periocular cases, highlighting the ongoing risk^[39].

Post-Treatment Care

• Inflammation Control: The primary goal after treatment is to reduce inflammation and protect the skin barrier^[40]. The wound-care method specified for the procedure should be followed, often involving a bland occlusive for ablative treatments^[40]. Patients should avoid rubbing, picking, heat, unapproved acids, retinoids, exfoliation, and fragranced products while the barrier is compromised^[40].
• Prescription Anti-inflammatories: As demonstrated in the 40-person Fitzpatrick IV trial, two days of clobetasol significantly reduced PIH rates from 75% to 40% after fractional CO2 laser^[40]. Given that clobetasol is a potent steroid and facial misuse can cause harm, this regimen should remain under the supervision of a qualified prescriber and not be disseminated as a general retail instruction^[40].
• Consistent Sunscreen Use: Sunscreen should be considered base care, despite some inconsistencies in prevention reviews^[41]. The 2026 network analysis found sunscreen monotherapy ineffective against placebo in its network, while the 2025 skin-of-color review identified it as the only measure with consistent prevention results^[41]. Controlled light-exposure studies consistently show that both ultraviolet and visible light can deepen pigment^[41].
• Tranexamic Acid as a Medical Option: Intradermal tranexamic acid, while promising with a relative risk of 0.02 against sunscreen in the 2026 analysis, should be presented as an emerging medical option, not a standard spa protocol^[42]. The trials included were small, and discomfort and bruising were reported from injections^[42]. Oral or injected use requires medical assessment and oversight^[42].
• Delayed Follow-up: Delayed follow-up is critical for detecting PIH early^[43]. A practical schedule includes a photo check at 48 to 72 hours, another at 7 to 14 days, and reassessment before any subsequent session^[43]. This timing is inferred from studies that monitored patients at various intervals, such as days 3, 5, 7, one month, and later^[43]. Laser treatment should not be repeated while inflammation or new pigment is still developing^[43].
• Management of PIH Onset: If PIH appears, further energy treatment must stop^[44]. The inflamed area or acne should be treated, photoprotection reinforced, and appropriate topical care initiated under local clinical rules^[44]. The global consensus prioritizes topical treatments first, reserving laser or peels for resistant cases^[44]. Immediate repeat laser treatment can worsen the injury that caused the pigment^[44].

The Role of Data and Safety Systems in Clinical Practice

To improve safety and outcomes, clinics need strong safety systems and transparent data collection.

• Specific Protocols: Clinics must maintain separate protocols for each device, wavelength, indication, body site, and skin-risk group^[45]. Each protocol should explicitly detail deferral rules, test-spot procedures, permitted starting ranges, cooling requirements, acceptable endpoints, stop criteria, follow-up timing, and escalation steps^[45]. There should not be a single, overarching Fitzpatrick IV to VI parameter chart^[45].
• Outcome Tracking: Tracking denominator-based outcomes is essential^[46]. Useful metrics include the percentage of eligible patients receiving test spots, the number of deferrals due to recent tans, PIH rates at 2 and 6 weeks, burns or blisters per 1,000 sessions, hypopigmentation, unplanned medical referrals, and adverse events categorized by operator, device, wavelength, treatment site, and measured skin color^[46]. The inconsistent reporting in current literature contributes to the wide variation in complication estimates^[46].
• Auditing Training and Errors: Auditing training events and mode-selection errors is crucial^[47]. FDA cases demonstrate that a device cleared for darker skin can still cause injury if the operator selects the wrong wavelength, treats tanned skin, skips a test spot, or fails to follow instructions^[47]. Device clearance signifies a condition of safe use, not a guarantee of safe operation^[47].
• Transparent Pricing and Consent: Careful pricing and clear consent are important^[48]. Conservative settings may necessitate more sessions; for instance, the 150-patient Nd:YAG cohort averaged 8.9 treatments for a 54.3% mean reduction^[48]. Clinics should avoid promising single-session results and instead explain the potential need for maintenance treatments, electrolysis, topical care, or specialist referral^[48].
• Closing the Fitzpatrick VI Evidence Gap: Internal reporting within clinics can help close the Fitzpatrick VI evidence gap^[49]. The 2025 prevention review included no Fitzpatrick VI patients, and only 6% of classified participants in the broader 2024 treatment review were Fitzpatrick VI^[49]. Clinics serving diverse populations may possess valuable safety data, but this data must be collected with patient consent, consistent definitions, and objective color measurements^[49].
• Example of Disclosure Gap: Bio2 Laser Studio, like many other providers, lists both laser and electrolysis services on its public site but does not report session counts, PIH rates, burn rates, outcomes by skin tone, or follow-up completion rates^[50]. This exemplifies a wider disclosure gap in the industry. Bio2 Laser Studio and its peers could enhance public trust by reporting clear, denominator-based safety measures without framing the data as promotional claims^[50].

Notable Clinical Examples and Their Lessons

Specific clinical studies and adverse event reports offer tangible lessons for improving laser safety:

• UCSF-led Skin Pigment Measurement Study: Michael S. Lipnick and colleagues published a comparative study in January 2026 involving 789 participants and 33,856 assessments across various body sites^[51]. They applied three subjective methods and two objective instruments to characterize skin pigment diversity^[51]. The measured result showed that, depending on the method, 7%, 14%, 16%, 23%, or 26% of the same cohort could be classified as “dark”^[51]. The key lesson is that clinics should combine Fitzpatrick type with untanned baseline color, objective measurement where available, and pigment history, rather than using race to set laser parameters^[51].
• Siriraj Hospital Post-CO2 Steroid Trial: In February 2015, Nutjira Cheyasak and colleagues at Siriraj Hospital, Mahidol University, published a study on 40 Fitzpatrick IV patients undergoing fractional CO2 laser for PIH^[52]. Both facial sides received laser treatment, but one side was treated with clobetasol 0.05% for two days followed by petrolatum, while the other received petrolatum alone for seven days^[52]. PIH occurred on 75% of petrolatum-only sides versus 40% of steroid-treated sides^[52]. The lesson is that early inflammation control can greatly reduce PIH after specific ablative procedures, but this regimen requires prescription control due to the strength of facial steroids^[52].
• Ramathibodi Laser Center Low-Density Fractional Protocol: Premjit Vaiyavatjamai and Penpun Wattanakrai reviewed 181 sessions in 119 Fitzpatrick III to V patients treated with a 1550 nm fractional laser, published in 2011^[53]. Operators used low maximum treatment density, cooling, and treatment intervals of at least four weeks^[53]. Total complications occurred after 3.3% of sessions, and PIH after 2.2%^[53]. This suggests that low tissue coverage and sufficient time for inflammation to resolve may be more important than simply using very low energy at high density, although its retrospective design means firm cause-and-effect conclusions cannot be made^[53].
• Jilin University and Yanbian University Split-Face CO2 Study: In a randomized 2014 trial, Xing-Hua Yuan and colleagues treated 20 Asian acne-scar patients with split-face fractional CO2 laser^[54]. They compared 10% versus 20% density at 20 mJ, and 10 mJ versus 20 mJ at 10% density^[54]. Scar improvement was not significantly different between settings, but adverse effects were more evident with higher density or higher fluence^[54]. The lesson is to use the lowest tissue burden that achieves the clinical goal, as more energy or coverage did not yield a clear efficacy gain in this small trial^[54].
• Mana Abdullah Alharbi’s 1927 nm PIH Pilot: In 2019, dermatologist Mana Abdullah Alharbi conducted a pilot study on nine patients with Fitzpatrick IV skin and PIH resistant to topical bleaching^[55]. Patients received one to four low-energy, low-density 1927 nm nonablative fractional laser sessions, combined with hydroquinone 4% post-treatment^[55]. Eight patients were assessed: 37.5% had an excellent response, 50% satisfactory, and 12.5% unsatisfactory^[55]. No paradoxical pigmentation was reported, with redness and swelling lasting five to seven days^[55]. This suggests carefully delivered fractional treatment may help resistant PIH, but the very small sample and combined hydroquinone use mean the result cannot be attributed to the device alone^[55].
• EL.EN and Cynosure Wrong-Wavelength FDA Case: A 2025 FDA adverse event report detailed a case where an operator began hair removal with a YAG source but then switched to a 755 nm alexandrite source on a tanned patient^[56]. The reported settings were 15 J/cm², 20 ms, an 18 mm handpiece, and one pass^[56]. The patient developed leg burns and blistering, particularly on the shin, classified as a serious injury^[56]. This case demonstrates that a dual-wavelength machine is not inherently safe for all skin states, emphasizing the necessity of tan screening, wavelength verification, a test spot, and a treatment-day time-out as core safety controls^[56].

Conclusion of Key Data and Clinical Evidence

The summarized data consistently highlights that laser treatment in Fitzpatrick IV-VI skin requires a cautious, individualized, and multi-faceted approach. Relying solely on Fitzpatrick skin type is inadequate; a comprehensive risk assessment, including patient history, objective measurements, and a thorough understanding of melanin absorption, is essential. While the evidence base for PIH prevention, especially in Fitzpatrick VI, is still developing, existing data points toward the effectiveness of conservative energy delivery, diligent epidermal cooling, targeted anti-inflammatory care, and consistent photoprotection. The industry, including providers like Bio2 Laser Studio, has an opportunity to enhance safety and trust through transparent outcome reporting and the implementation of strong, evidence-informed protocols. The subsequent section will elaborate on specific protocol steps derived from this body of evidence.

14. Case Studies in Laser Safety

Safe laser operation in individuals with Fitzpatrick skin types IV to VI requires a thorough understanding of potential risks and effective prevention strategies. This section examines notable case studies and research findings that highlight both best practices and adverse events in laser procedures. These examples illustrate the complex factors influencing post-inflammatory hyperpigmentation (PIH) and other complications. The information helps build a comprehensive clinical playbook for laser safety, moving beyond generalized recommendations to specific, evidence-based approaches. It is important to note that as of August 29, 2026, there is no single international standard termed the “Fitzpatrick IV to VI Laser Safety Protocol.” Instead, best practices come from consensus reports, controlled trials, device instructions, and adverse event data ^[1].

The core challenge in treating darker skin types is the presence of epidermal melanin, which absorbs part of the laser’s energy. This narrows the margin between a successful treatment and unintended outcomes such as excess heat, inflammation, burns, PIH, or loss of pigment ^[3]. Strategies like using longer wavelengths, conservative settings, controlled skin coverage, and epidermal cooling can help reduce these risks. However, no single measure makes laser treatment entirely risk-free ^[3].

Effective safety protocols begin with careful diagnosis and risk screening ^[4]. This includes confirming the treatment target, documenting prior PIH, scarring, current inflammation, recent tanning, previous procedures, medications, and the patient’s normal untanned skin color ^[4]. Stabilizing the skin by deferring elective laser treatment when there is a recent tan or active inflammatory disease is a critical step ^[5]. Device selection is also crucial; for hair reduction in Fitzpatrick V and VI, the long-pulsed 1064 nm Nd:YAG laser is generally preferred due to its lower epidermal melanin absorption compared to shorter wavelengths ^[6]. Diode systems may be used with caution, while Alexandrite 755 nm and broad-spectrum IPL require much greater care in darker or tanned skin ^[6].

A delayed test spot, using the exact device, wavelength, body site, cooling method, and planned settings, is a fundamental safety measure ^[7]. The spot should be reviewed after enough time for delayed pigment changes to appear. Some manufacturer protocols suggest a 1 to 2 week waiting period in Fitzpatrick IV to VI skin ^[7]. Conservative energy delivery is another important principle. Research indicates that treatment density, or the amount of skin covered, can be as important as the energy per microbeam ^[8]. One study showed PIH in 43% of lower-density areas compared to 71% in higher-density areas at the same energy setting ^[8].

Post-treatment care includes active inflammation control. A split-face trial involving 40 Fitzpatrick IV patients demonstrated that short-term, clinician-directed anti-inflammatory treatment with clobetasol significantly reduced PIH rates after fractional CO2 laser resurfacing ^[9]. Consistent daily broad-spectrum sunscreen use, with visible-light protection for pigment-prone patients, is also essential ^[10]. Despite these measures, prevention evidence remains limited, especially for Fitzpatrick VI skin ^[11]. Protocols for Fitzpatrick VI largely depend on physiological principles, small studies, expert opinion, and cautious clinical practice ^[11].

The Limits of Fitzpatrick Skin Type in Risk Assessment

The Fitzpatrick skin typing system, while widely used, has important limits when assessing laser treatment risk in individuals with darker skin tones. The system was originally developed to classify how skin reacts to sun exposure in terms of burning and tanning, not as a direct measure of epidermal melanin content or specific laser injury risk ^[16]. A 2025 Delphi study involving 22 skin-of-color experts found that 95% agreed on the clinical and research limits of the current Fitzpatrick system ^[16]. This consensus points to the need for a more comprehensive approach to risk assessment in 2026 and beyond ^[16].

One key issue is the significant variation within a single Fitzpatrick type. For example, a person classified as Fitzpatrick IV can have vastly different treatment risks depending on factors such as recent tanning, the specific body site being treated, any prior skin injuries, and the planned laser wavelength ^[17]. Therefore, relying solely on Fitzpatrick type can lead to an incomplete and potentially misleading risk assessment.

To overcome these limits, clinics should adopt a more detailed intake process. This should include recording the patient’s normal untanned skin color, their current skin color, recent sun exposure history, and any prior history of PIH, burns, or scarring ^[17]. Information about prior procedures, current medications, and the presence of any inflammation is also crucial ^[17]. For instance, treating existing PIH with laser should generally only occur after topical treatments have been applied, not as a primary treatment ^[4]. Similarly, elective laser treatments must be deferred if a patient has a recent tan or active inflammatory skin conditions in the treatment area ^[5].

Objective skin color measurements can provide valuable data that subjective assessments often miss. A 2026 study by Lipnick and colleagues, involving 789 adults and 33,856 assessments, showed large differences between subjective skin ratings and objective color measurements ^[17]. Depending on the method, anywhere from 7% to 26% of the same group could be classified as having dark skin ^[17]. This highlights how subjective scales can significantly alter who is considered to be in a high-risk group ^[17]. Clinics should use repeatable photographs with consistent room conditions, camera settings, distance, lighting, and patient positioning. When available, colorimetry or spectrophotometry can add more precise, objective data ^[17].

Beyond skin tone, the specific diagnosis is equally important. Different types of hyperpigmentation, such as brown epidermal PIH and blue-gray dermal PIH, respond differently to laser treatment ^[1]. Treating active inflammatory conditions before laser application is essential. The 2025 global consensus advises against using laser or intense pulsed light (IPL) during active inflammatory stages of acquired dermal pigment disorders because treatment may worsen pigmentation ^[1].

Table 14.1: Factors for Comprehensive Laser Risk Assessment

Factor	Relevance to Risk Assessment	Supporting Evidence
Fitzpatrick Skin Type	Initial classification, but limited for specific laser injury risk.	2025 Delphi study (95% expert agreement on limits) [16]
Normal Untanned Skin Color	Provides a baseline for pigment reactivity.	Step 1 of safety protocol [4]
Current Skin Color/Tan Status	Recent tanning increases epidermal melanin, raising risk.	FDA adverse event in tanned patient [19]
History of PIH/Scarring/Burns	Indicates individual skin reactivity and healing response.	Step 1 of safety protocol [4]
Current Inflammation/Active Disease	Increased risk of PIH or worsening existing conditions.	2025 global consensus [5]
Prior Procedures/Medications	Can affect skin sensitivity and healing.	General safety screening [20]
Treatment Site	Different body areas have varying skin thickness and pigment distribution.	Facial PIH is dominant in evidence [12]
Objective Color Measurements	Provides quantifiable, consistent data beyond subjective scales.	2026 Lipnick study (789 participants) [17]

For service providers, this means building a structured intake form that goes beyond a simple Fitzpatrick dropdown menu. Patients should understand that a safe consultation may result in deferral of treatment, a requirement for topical pre-treatment, a test spot, or the recommendation of a different device or procedure, such as electrolysis ^[16]. Device manufacturers and researchers should also aim to report objective pigment data alongside Fitzpatrick types to improve the quality and applicability of safety research ^[16].

Pre-Treatment Steps: Screening, Stabilization, and Test Spots

Before any laser treatment in Fitzpatrick IV to VI skin, a clear set of pre-treatment steps is essential to minimize the risk of adverse events, particularly PIH. These steps involve thorough screening, skin stabilization, and the use of delayed test spots.

Establishing Deferral Criteria

Clinics must have well-defined criteria for deferring elective laser treatment. This acts as a crucial safety gate. Visible tanning, recent sunburn, active dermatitis, uncontrolled acne inflammation, or unresolved irritation in the treatment area should all prompt a pause in treatment ^[5]. A documented adverse event in 2025 involved a tanned patient who developed burns after an operator switched from an Nd:YAG laser to an alexandrite laser ^[19]. This incident underscores the importance of strict adherence to deferral rules for tanned skin, regardless of the chosen laser type.

Reviewing a patient’s medical history for previous PIH, hypopigmentation, blistering, keloids, infections, or poor wound healing is also vital ^[20]. Additionally, a detailed review of all medications and topical skin products can help identify factors that might increase light sensitivity, irritation, bleeding, infection, or delay healing ^[20]. Providers should never instruct patients to stop prescription medications without consulting the prescribing medical professional ^[20].

The Critical Role of Test Spots

A delayed test spot is a non-negotiable safety measure, particularly for Fitzpatrick IV to VI skin types. This involves applying the laser to a small, inconspicuous area within the actual treatment site using the exact parameters planned for the full session: wavelength, spot size, pulse width, fluence, cooling method, and number of passes ^[7]. The area should then be observed for a period sufficient to detect delayed adverse reactions, especially pigment changes.

One manufacturer’s protocol, cited in an FDA report, specified a 1 to 2 week waiting period for reviewing test spots in Fitzpatrick IV to VI or tanned skin before proceeding with full treatment ^[7]. While this is a specific manufacturer’s example, it highlights the need for delayed observation, not immediate checks ^[7]. Clinicians must follow the specific instructions and recommendations provided by the device manufacturer for test spot timing.

Skin Priming and Photoprotection

The practice of skin priming before laser treatment, particularly with lightening agents, is an area with mixed evidence. The 2025 global consensus supports the use of lightening agents for higher-risk procedures and recommends avoiding irritants close to treatment ^[5]. However, a 2026 network analysis found no significant prevention benefit for whitening agents compared to sunscreen alone ^[12]. Some trials included in reviews initiated topical care two weeks before laser, while the majority of interventions began after treatment ^[12].

Photoprotection, primarily through sunscreen, should begin before the procedure, rather than waiting for pigment changes to appear. A 2026 trial involving 20 Fitzpatrick IV and V participants showed that a broad-spectrum sunscreen provided about 16 Individual Typology Angle (ITA) degrees of net protection after combined inflammation and light exposure ^[18]. Furthermore, iron-oxide formulas have shown better performance than non-tinted mineral SPF 50 products in preventing visible-light pigmentation in Fitzpatrick IV skin ^[21].

Table 14.2: Pre-Laser Checklist for Fitzpatrick IV to VI Skin

Action Item	Details	Rationale
Deferral Gate	Check for recent tan, sunburn, active dermatitis, uncontrolled acne, unresolved irritation.	Avoids increased risk of burns and PIH [19].
Medical History Review	Document prior PIH, hypopigmentation, blistering, keloids, infection, poor healing.	Identifies individual risk factors for complications [20].
Medication/Product Review	Assess current medications and topical products for photosensitivity or irritation.	Minimizes risk of adverse reactions [20].
Delayed Test Spot	Apply laser with planned settings, observe for 1-2 weeks in an inconspicuous area.	Allows detection of delayed pigment changes before full treatment [7].
Skin Priming (Consider)	Topical lightening agents may be used for high-risk procedures (evidence mixed).	May reduce PIH risk, but benefits debated [5].
Photoprotection Initiation	Start broad-spectrum sunscreen, especially with visible-light protection, before treatment.	Limits induced pigmentation before and after procedure [18].

From a stakeholder perspective, high-risk consultations and test spots should be structured as separate workflow stages. Clinics need to factor in the extra visit and waiting period into their pricing and scheduling models. Pressuring patients into same-day consultation and high-energy treatment can transform commercial urgency into clinical risk ^[19].

Device Selection and Wavelength Specificity

Matching the appropriate laser wavelength and understanding the tissue burden it imposes are fundamental to ensuring safety and efficacy in treating Fitzpatrick IV to VI skin. Incorrect device selection can lead to significant adverse events.

Hair Reduction in Darker Skin

For hair reduction in Fitzpatrick V and VI patients, the long-pulsed 1064 nm Nd:YAG laser is generally considered the safest primary option ^[6]. Its longer wavelength is absorbed less by epidermal melanin compared to shorter wavelengths like the 755 nm alexandrite laser ^[22]. This characteristic allows for more selective targeting of the hair follicle while minimizing epidermal heating and the risk of PIH. Diode systems operating near 800 to 810 nm can also be used, but require greater caution, especially in very dark or tanned skin, as they offer a smaller safety margin than the 1064 nm Nd:YAG ^[22].

While Nd:YAG is safer, it is not without limits. A retrospective study of 150 Fitzpatrick IV to VI patients treated with long-pulsed Nd:YAG lasers showed a mean hair reduction of 54.3% after an average of 8.9 sessions ^[13]. Eighty-six percent of patients experienced no complications, but temporary hyperpigmentation was the most frequent issue among those who did ^[13]. Another concern with laser hair removal is paradoxical hair growth, which occurred in 3% of laser and IPL patients in a meta-analysis, with a higher concentration on the face and neck ^[14]. This highlights that even with suitable devices, conservative settings and multiple sessions are often needed for effective and safe outcomes.

Pigment Procedures and Resurfacing

When treating pigmentary disorders in darker skin, shorter wavelengths like 532 nm interact strongly with epidermal pigment and demand extreme caution in Fitzpatrick V and VI individuals ^[23]. The European laser position statement recommends using the minimum effective fluence in darker skin to avoid complications ^[23]. Low-fluence 1064 nm Nd:YAG can be considered for selected resistant pigment disorders, but repeated “laser toning” can lead to mottled loss of pigment, an adverse outcome ^[23].

For skin resurfacing, reducing the total tissue injury is paramount. Fractional rather than full-field treatment is preferred when clinically appropriate. Lower treatment density, fewer passes, longer intervals between sessions, and careful avoidance of pulse overlap help to reduce accumulated inflammation ^[8]. Studies comparing fractional treatments have shown lower PIH rates with lower density settings, even when energy per treatment point is higher ^[11], ^[12]. For example, PIH rates were 7.1% versus 12.4% in one comparison and 43% versus 71% in another when lower-density and higher-density methods were used, respectively ^[12], ^[8].

Vascular Procedures and Other Considerations

Vascular procedures, such as those using pulsed dye lasers, have their own specific safety rules for darker skin. A 2023 review identified only nine studies involving 241 Fitzpatrick IV to VI patients treated with pulsed dye lasers ^[15]. While benefit was possible, concerns such as hyperpigmentation, hypopigmentation, and scarring remained ^[15]. It is crucial never to reuse a hair-removal protocol for vascular or pigment treatment, even if the device platform is the same ^[15].

When hair lacks sufficient pigment, such as blonde, red, gray, or white hair, refusing laser treatment is often the safer choice ^[24]. Such hair does not absorb enough laser energy to be effectively treated, leading to ineffective sessions and potential epidermal heating. Some practices, like Bio2 Laser Studio, offer both laser hair reduction and electrolysis ^[24]. This provides an alternative for patients whose hair pigment makes laser ineffective or unsafe, directing them toward electrolysis, which targets individual hair follicles directly. While electrolysis also causes local tissue injury and requires its own PIH controls, it removes the dependence on melanin absorption ^[24].

Treatment Day Protocol: Ensuring Safe Delivery

The actions taken on the day of treatment are as important as the chosen equipment. A structured, careful treatment-day protocol helps prevent adverse events and ensures patient safety, especially for Fitzpatrick IV to VI skin.

Formal Time-Out and Verification

Every laser session should begin with a formal time-out. This critical step involves confirming several details: the patient’s identity, the specific treatment area, the diagnosis, the exact device being used, the selected wavelength, the handpiece, spot size, pulse width, fluence, and cooling settings. Importantly, the result of the test spot must also be reviewed ^[25]. Before the first pulse is delivered, and after any interruption or change in mode, both the device screen and the handpiece should be checked to verify settings ^[25]. This verification process directly addresses lessons from FDA reports that document wrong wavelength selection errors, which can lead to severe burns ^[19].

Accurate Documentation

Detailed and accurate documentation in a laser log is essential. Every setting and clinical endpoint must be recorded. This includes the patient’s current skin color and tan status, details of skin preparation, the cooling method used, the number of passes, the pattern of overlap, the patient’s pain response, and the immediate tissue reaction ^[26]. The goal is to create a record so complete that any future operator could reconstruct the session without relying on memory ^[26]. This level of detail is vital for understanding outcomes and for continuous improvement of safety protocols.

Avoiding Copying Settings and Limiting Heat Accumulation

Clinicians must understand that a specific fluence number from a research paper or another device cannot be directly copied. Factors such as pulse shape, handpiece calibration, spot size, cooling method, repetition rate, and beam profile all influence the effect on the skin ^[19]. For example, in a 2025 FDA case, a tanned patient suffered severe burns and blisters after treatment started with an Nd:YAG laser but then switched to a 755 nm alexandrite source with settings of 15 J/cm², 20 ms, and an 18 mm handpiece ^[19]. This highlights the danger of assuming settings are transferable across devices or even within different modes of the same device without careful consideration.

Limiting heat accumulation is crucial for darker skin types. This involves using mapped passes, preventing unplanned overlap of laser pulses, and allowing sufficient cooling time between adjacent pulses when the device requires it ^[8]. This clinical inference is supported by fractional studies showing higher rates of PIH with greater skin coverage and reviews linking PIH to thermal injury and inflammation ^[8].

Cooling Methods and Eye Protection

The evidence regarding cooling methods must be interpreted carefully based on the specific technique used. A 2026 network analysis found epidermal cooling to be superior to sunscreen alone for preventing PIH ^[12]. However, a 2025 skin-of-color review noted that some cooling-air approaches actually worsened outcomes ^[12]. Therefore, cooling must be applied precisely as validated for the specific device and technique, while still allowing the operator to observe immediate skin responses ^[12]. Cooling is an adjunct safety measure and cannot correct fundamental errors like using the wrong wavelength or an excessive setting ^[12].

Eye protection is a mandatory safety control for both the patient and the operator. A 2026 review reported ocular complications in about 2.1% of periocular laser cases, emphasizing the serious risks associated with inadequate eye protection ^[27].

Stopping Criteria

Operators must be prepared to stop treatment immediately if blistering, epidermal lifting, sharply patterned discoloration, or pain disproportionate to the expected response occurs ^[27]. These are clear signs of excessive energy delivery or an adverse reaction that could lead to significant complications like PIH or scarring.

Post-Laser Care: Reducing Inflammation and Detecting PIH Early

Effective post-laser care is a critical component of preventing and managing PIH in patients with darker skin. This stage focuses on calming inflammation, protecting the skin barrier, and ensuring early detection of any emerging pigment changes.

Calming Inflammation and Barrier Protection

The immediate goal after a laser procedure is to reduce inflammation and protect the compromised skin barrier. This typically involves using the wound-care method specified for the procedure, which often includes a bland occlusive agent for ablative treatments ^[9]. Patients should be advised to avoid trauma to the treated area, including rubbing, picking, exposure to excessive heat, and the use of unapproved acids, retinoids, exfoliants, or fragranced products while the skin barrier is healing ^[9].

Prescription Anti-Inflammatory Treatment

For certain ablative procedures, short-term, prescription anti-inflammatory treatment can be beneficial. A 40-person Fitzpatrick IV trial demonstrated a significant reduction in observed PIH, from 75% to 40%, when two days of clobetasol were used after fractional CO2 laser, followed by petrolatum, compared to petrolatum alone ^[9]. However, clobetasol is a strong steroid, and its misuse on the face can cause harm. Therefore, such a regimen must remain under the direct supervision of a qualified prescriber and should not become a standard, self-administered instruction ^[9].

Consistent Photoprotection

Sunscreen should be considered base care for all patients after laser procedures, regardless of conflicting findings in prevention reviews ^[12]. While the 2026 network analysis found sunscreen monotherapy to be ineffective against placebo in its network, the 2025 skin-of-color review identified sunscreen as the most consistent preventive measure ^[12]. Controlled light-exposure studies further confirm that both ultraviolet and visible light can worsen pigmentary changes ^[18]. Therefore, continuous and appropriate photoprotection is non-negotiable.

Emerging Medical Options: Tranexamic Acid

Tranexamic acid represents an emerging medical option for PIH prevention and treatment, but it should not be adopted as a standard spa protocol. In the 2026 network analysis, intradermal tranexamic acid showed a relative risk of 0.02 against sunscreen, indicating promising results ^[28]. However, the included trials were small, and potential side effects like injection discomfort and bruising were reported ^[28]. Oral or injected forms of tranexamic acid require medical assessment and trained administration ^[28].

Delayed Follow-Up for Early Detection

Delayed follow-up appointments are crucial for detecting and addressing PIH or other complications early. A practical schedule includes a photo check at 48 to 72 hours, another at 7 to 14 days, and a reassessment before any subsequent treatment session ^[9]. This timing aligns with studies that observed patients at various intervals, allowing for the detection of delayed inflammatory and pigmentary responses ^[9]. It is imperative that further laser treatment is not initiated while inflammation or new pigmentation is still developing ^[9].

If PIH does appear, further energy-based treatments must be halted. The focus should shift to managing active inflammation or acne, strengthening photoprotection, and initiating appropriate topical care according to local clinical guidelines ^[1]. The global consensus places topical treatments as the first line of defense, reserving laser or chemical peels for resistant cases ^[1]. Repeating laser treatment too soon on newly formed PIH can deepen the injury and worsen the pigmentation ^[1].

Establishing a Measurable Safety System in Clinics

For laser clinics, particularly those serving diverse populations, a systematic and measurable approach to safety is paramount. This involves developing clear protocols, tracking outcomes, auditing processes, and ensuring transparent communication with patients.

custom Protocols and Documentation

Every clinic should maintain separate, specific protocols for each device, wavelength, treatment indication, body site, and skin-risk group. These protocols must clearly define deferral rules, test-spot requirements, permitted starting energy ranges, cooling requirements, acceptable clinical endpoints, stop criteria, follow-up timing, and escalation steps ^[26]. The notion of a single “Fitzpatrick IV to VI parameter chart” is insufficient and potentially unsafe ^[26].

Consistent and detailed documentation is key. Clinicians should track denominator-based outcomes to gain a clear picture of their safety performance. Useful metrics include:

• The percentage of eligible patients who receive test spots.
• The rate of deferrals due to recent tanning.
• PIH rates at 2 and 6 weeks post-treatment.
• Incidence of burns or blisters per 1,000 sessions.
• Occurrence of hypopigmentation.
• The number of unplanned medical referrals.
• Adverse events categorized by operator, device, wavelength, treatment site, and objective skin color measurements ^[26].

The current variability in complication estimates across the literature is largely due to inconsistent reporting, underscoring the need for standardized internal tracking ^[26].

Auditing and Training

Regular audits of training events and mode-selection errors are essential. FDA cases demonstrate that even devices cleared for darker skin types can cause injury if the operator selects the wrong wavelength, treats tanned skin, skips a test spot, or fails to follow instructions ^[19]. Device clearance signifies a condition of safe use, not an automatic guarantee of safe operation; human factors and adherence to protocols are critical ^[19].

Transparent Pricing and Consent

Clinics must implement careful pricing and consent practices. Conservative settings, often necessary for darker skin, may require more treatment sessions. For instance, a cohort of 150 Fitzpatrick IV to VI patients treated with Nd:YAG lasers for hair reduction averaged 8.9 sessions to achieve 54.3% mean hair reduction ^[13]. Clinics should avoid making promises of single-session results and should clearly explain the potential need for multiple sessions, maintenance treatments, adjunctive therapies like electrolysis, topical care, or specialist referrals ^[13].

Addressing the Fitzpatrick VI Evidence Gap

There is a significant gap in the literature regarding Fitzpatrick VI skin. The 2025 prevention review did not include any Fitzpatrick VI patients ^[11]. In a broader 2024 treatment review, only 6% of classified participants were Fitzpatrick VI ^[5]. Clinics that serve diverse populations, including those with Fitzpatrick VI skin, can contribute valuable safety data by implementing rigorous internal reporting. This data, if collected with patient consent, consistent definitions, and objective color measurements, can help bridge this evidence gap and improve overall safety guidelines ^[11].

For example, Bio2 Laser Studio, like many other service providers, offers both laser and electrolysis services ^[24]. While its public site outlines its services, it does not provide audited PIH rates, burn rates, outcomes by skin tone, or follow-up completion rates ^[24]. This reflects a wider industry gap in transparent safety reporting. Bio2 Laser Studio and similar peers could enhance public trust by reporting clear, denominator-based safety measures. Such reporting should focus on data integrity rather than promotional claims ^[24].

Notable Case Studies Illustrating Laser Safety Principles

The following case studies and research examples provide specific illustrations of the best practices and adverse events discussed, offering practical insights into laser safety protocols for Fitzpatrick IV to VI skin.

1. UCSF-led Skin Pigment Measurement Study

• Who: Michael S. Lipnick and colleagues from the University of California San Francisco, Harvard University, Makerere University, New York University, and Washington University ^[17].
• Background: Traditional laser risk assessment often over-relies on Fitzpatrick type or race as proxies for actual skin pigment ^[17].
• What happened and when: Published on January 6, 2026, this comparative study applied three subjective methods and two objective instruments at multiple body sites ^[17].
• Measured result: The study included 789 participants and 33,856 assessments. Depending on the method used, between 7%, 14%, 16%, 23%, or 26% of the same cohort could be classified as having dark skin ^[17].
• Lesson: Clinics should use Fitzpatrick type in conjunction with baseline untanned skin color, objective measurements where available, and a thorough pigment history. Race alone should not dictate laser parameters ^[17].

2. Siriraj Hospital Post-CO2 Steroid Trial

• Who: Nutjira Cheyasak, Woraphong Manuskiatti, Pitchaya Maneeprasopchoke, and Rungsima Wanitphakdeedecha at Siriraj Hospital, Mahidol University, Bangkok ^[9].
• Background: PIH is a common complication after ablative fractional CO2 resurfacing in Fitzpatrick IV skin ^[9].
• What happened and when: In a study published in February 2015, 40 participants received identical fractional CO2 laser treatment on both sides of their face. One side was treated with clobetasol 0.05% for two days, followed by petrolatum. The other side received petrolatum alone for seven days ^[9].
• Measured result: PIH occurred on 75% of the petrolatum-only treated sides, compared to 40% of the steroid-treated sides. The pigment was also less intense and covered a smaller area on the steroid-treated side ^[9].
• Lesson: Early control of inflammation can significantly reduce PIH after selected ablative procedures. However, this specific regimen involves a potent topical steroid and requires medical supervision, meaning it should not be universally applied to all laser procedures ^[9].

3. Ramathibodi Laser Center Low-Density Fractional Protocol

• Who: Premjit Vaiyavatjamai and Penpun Wattanakrai at Ramathibodi Hospital, Mahidol University, Bangkok ^[10].
• Background: Previous fractional laser reports indicated higher PIH rates with increasing skin type and treatment density ^[10].
• What happened and when: The team reviewed 181 sessions performed on 119 Thai patients with Fitzpatrick III to V skin, publishing their findings in 2011. Operators used a 1550 nm fractional laser with low maximum treatment density, active cooling, and treatment intervals of at least four weeks ^[10].
• Measured result: Total complications occurred after 3.3% of sessions. PIH occurred after 2.2% of sessions, while acne-like eruptions and skin peeling each occurred after 0.55% of sessions ^[10].
• Lesson: Low tissue coverage and sufficient time for inflammation to resolve may be more critical for safety than using very low energy at high density. The retrospective nature of this study means firm cause-and-effect conclusions cannot be drawn ^[10].

4. Jilin University and Yanbian University Split-Face CO2 Study

• Who: Xing-Hua Yuan, Shu-Xia Zhong, and Shan-Shan Li from the First Hospital of Jilin University and Yanbian University Hospital in China ^[11].
• Background: Higher CO2 laser energy and coverage are sometimes used to improve injury depth, but they also risk increasing inflammation and pigmentary changes ^[11].
• What happened and when: In a randomized 2014 trial, 20 Asian patients with acne scars received split-face treatment. Comparisons included 10% versus 20% density at 20 mJ, and 10 mJ versus 20 mJ at 10% density ^[11].
• Measured result: Scar improvement did not differ significantly between the compared settings. However, adverse effects were more evident with higher density or higher fluence settings ^[11].
• Lesson: Clinicians should use the lowest tissue burden that achieves the desired clinical goal. In this small trial, increased energy or coverage did not provide a clear advantage in efficacy but increased adverse events ^[11].

5. Mana Abdullah Alharbi’s 1927 nm PIH Pilot

• Who: Dermatologist and researcher Mana Abdullah Alharbi ^[30].
• Background: Participants had Fitzpatrick IV skin and PIH that had not responded well to at least three months of topical bleaching treatment ^[30].
• What happened and when: During 2019, nine patients received one to four low-energy, low-density 1927 nm nonablative fractional laser sessions, spaced six weeks apart. Hydroquinone 4% was applied twice daily for six weeks after treatment ^[30].
• Measured result: Eight patients were assessed. Three (37.5%) had an excellent response, four (50%) had a satisfactory response, and one (12.5%) had an unsatisfactory response. No paradoxical pigmentation was reported. Redness and swelling lasted five to seven days ^[30].
• Lesson: Carefully delivered fractional treatment may help resistant PIH, but this was a very small sample study. The laser treatment was combined with hydroquinone, meaning the positive outcomes cannot be attributed solely to the device ^[30].

6. EL.EN and Cynosure Wrong-Wavelength FDA Case

• Who: EL.EN. Electronic Engineering, U.S. importer Cynosure, an unnamed clinic operator, and a patient whose identifying information was removed from the FDA report ^[19].
• Background: The patient had recently returned from vacation, and the treatment area remained tanned ^[19].
• What happened and when: In a 2025 event, the operator began hair removal with a YAG laser source and then switched to a 755 nm alexandrite source. Reported settings were 15 J/cm², 20 ms, an 18 mm handpiece, and one pass ^[19].
• Measured result: The patient developed leg burns and blistering, with the worst injury on the shin. The manufacturer classified this event as a serious injury, as medical care might be needed to prevent lasting impairment ^[19].
• Lesson: A dual-wavelength machine is not inherently safe for all skin conditions. Thorough tan screening, wavelength verification, mandatory test spots, and a treatment-day time-out are fundamental safety controls to prevent such serious adverse events ^[19].

These case studies underscore the critical need for a structured, evidence-based approach to laser safety in Fitzpatrick IV to VI skin. The variability in skin response, the limitations of current classification systems, and the impact of operator decisions highlight that continuous vigilance and education are essential for preventing adverse outcomes. The next section will build upon these findings by exploring specific treatment protocols in greater detail.

Sources for Section 14

¹ Global consensus on the management of melanin hyperpigmentation disorders – Journal of the European Academy of Dermatology and Venereology – December 2025 ^[1]

² Beyond Fitzpatrick skin types: A Delphi consensus on key considerations for a universal skin typing classification – Journal of the American Academy of Dermatology and Skin of Color Society – 2025 ^[2]

³ Special considerations for darker-skinned patients. – PubMed – 2011 ^[3]

⁴ Global consensus on the management of melanin hyperpigmentation disorders – Journal of the European Academy of Dermatology and Venereology – December 2025 ^[4]

⁵ Global consensus on the management of melanin hyperpigmentation disorders – Journal of the European Academy of Dermatology and Venereology – December 2025 ^[5]

⁶ Laser and Light Treatments for Hair Reduction in Fitzpatrick Skin Types IV-VI: A Comprehensive Review of the Literature – PubMed – 2017 ^[6]

⁷ MAUDE Adverse Event Report: CANDELA GENTLEMAX PRO; GMAX PRO – U.S. Food and Drug Administration – Report concerning an unspecified event ^[7]

⁸ Nonablative Fractional Laser Resurfacing in Skin of Color: Evidence-based Review – PubMed Central – 2017 ^[8]

⁹ Topical corticosteroids minimise the risk of postinflammatory hyper-pigmentation after ablative fractional CO2 laser resurfacing in Asians – PubMed – February 2015 ^[9]

¹⁰ An Investigator-Blinded, Randomized Trial of a Broad-Spectrum Sunscreen Containing Sclareolide and Niacinamide for the Prevention of Post-inflammatory Hyperpigmentation in Skin of Color – PubMed – January 2026 ^[10]

¹¹ Prevention of Post-Inflammatory Hyperpigmentation in Skin of Colour: A Systematic Review – PubMed Central – May 2025 ^[11]

¹² Interventions to Prevent Postinflammatory Hyperpigmentation After Laser and Energy-Based Device Treatments: A Systematic Review and Network Meta-Analysis – PubMed Central – 2026 ^[12]

¹³ Long-Pulsed Nd:YAG Laser-Assisted Hair Removal in Fitzpatrick Skin Types IV to VI – PubMed – 2011 ^[13]

¹⁴ Paradoxical Hypertrichosis Associated With Laser and Light Therapy for Hair Removal: A Systematic Review and Meta-Analysis – PubMed – 2021 ^[14]

¹⁵ A Review of Treatment of Port-Wine Stains With Pulsed Dye Laser in Fitzpatrick Skin Type IV to VI – PubMed – 2023 ^[15]

¹⁶ Beyond Fitzpatrick skin types: A Delphi consensus on key considerations for a universal skin typing classification – Journal of the American Academy of Dermatology and Skin of Color Society – 2025 ^[16]

¹⁷ Comparison of Methods for Characterizing Skin Pigment Diversity in Research Cohorts – PubMed – January 6, 2026 ^[17]

¹⁸ An Investigator-Blinded, Randomized Trial of a Broad-Spectrum Sunscreen Containing Sclareolide and Niacinamide for the Prevention of Post-inflammatory Hyperpigmentation in Skin of Color – PubMed – January 2026 ^[18]

¹⁹ MAUDE Adverse Event Report: EL.EN. ELECTRONIC ENGINEERING S.P.A. ELITE IQ – U.S. Food and Drug Administration – Report concerning a 2025 event ^[19]

²⁰ Complications of dermatologic lasers in high Fitzpatrick phototypes and management: an updated narrative review – PubMed – 2024 ^[20]

²¹ Impact of Iron-Oxide Containing Formulations Against Visible Light-Induced Skin Pigmentation in Skin of Color Individuals – PubMed – July 1, 2020 ^[21]

²² Lasers and light-based therapies in ethnic skin: treatment options and recommendations for Fitzpatrick skin types V and VI. – PubMed – 2013 ^[22]

²³ Laser treatment of hyperpigmented lesions: position statement of the European Society of Laser in Dermatology – Journal of the European Academy of Dermatology and Venereology – 2019 ^[23]

²⁴ Laser Hair Removal, Electrolysis and RF Body Contouring – Bio2 Laser Studio – Accessed August 2026 ^[24]

²⁵ Facial laser complications (A Five Year Review) – Lasers in Medical Science – 2026 ^[25]

²⁶ Facial laser complications (A Five Year Review) – Lasers in Medical Science – 2026 ^[26]

²⁷ Facial laser complications (A Five Year Review) – Lasers in Medical Science – 2026 ^[27]

²⁸ Interventions to Prevent Postinflammatory Hyperpigmentation After Laser and Energy-Based Device Treatments: A Systematic Review and Network Meta-Analysis – PubMed Central – 2026 ^[28]

²⁹ Side effects and complications of fractional 1550 nm erbium fiber laser treatment among Asians – ResearchGate – 2011 ^[29]

³⁰ 1927 nm Thulium Laser Successfully Treats PostInflammatory Hyperpigmentation in Skin of Color – PubMed – 2021 ^[30]

15. Frequently Asked Questions

Laser and energy-based procedures offer effective solutions for a range of skin concerns. However, for individuals with Fitzpatrick skin types IV-VI, these treatments carry a higher risk of complications, particularly post-inflammatory hyperpigmentation (PIH). This section addresses common questions about laser safety protocols for darker skin tones, methods for preventing PIH, and clinical best practices. It combines findings from consensus reports, controlled trials, device instructions, and adverse event data to provide practical guidance for 2026. This information is designed for clinical use, not for making product claims.

What is Post-Inflammatory Hyperpigmentation (PIH) and why is it a concern for Fitzpatrick IV-VI skin?

Post-inflammatory hyperpigmentation (PIH) is a common skin condition where inflammation or injury leaves behind darkened patches of skin. This discoloration happens because the skin overproduces melanin in response to the injury. For individuals with Fitzpatrick skin types IV-VI, which have higher baseline melanin content, the risk of developing PIH after laser or energy-based treatments is greater ^[1]. The central safety problem is that epidermal melanin absorbs part of the laser’s energy. This absorption reduces the margin between an effective treatment and too much heat, which can cause inflammation, burns, PIH, or pigment loss ^[2]. When PIH occurs, it can be stubborn and may take months or even years to resolve, often requiring additional treatment ^[3]. Laser treatment of existing PIH should usually follow topical treatment rather than serve as the first treatment ^[4].

The severity of PIH can vary. In a 2015 study of 40 Fitzpatrick IV patients undergoing fractional CO2 laser treatment, PIH occurred on 75% of facial sides treated with petrolatum alone ^[5]. This highlights the high incidence of PIH in this patient group without specific preventative measures. Furthermore, studies show that laser procedures cause a significant portion of PIH risk. A 2025 skin-of-color review found that laser procedures caused 95.4% of the studied PIH risk, with the face accounting for 85.3% of reported sites ^[6]. This makes laser-related facial PIH the dominant setting in published prevention evidence ^[7].

The consequences of PIH extend beyond cosmetic appearance. It can cause distress and dissatisfaction for patients. Preventing PIH is therefore a main goal of laser safety protocols for Fitzpatrick IV-VI skin. This involves careful patient selection, device choice, treatment settings, and aftercare ^[8].

Is there a single “Fitzpatrick IV to VI Laser Safety Protocol”?

No, as of August 29, 2026, there is no single international standard called the “Fitzpatrick IV to VI Laser Safety Protocol” ^[9]. The idea of a fixed protocol suggests a level of standardization that does not exist across the many devices, treatment indications, body sites, and individual patient differences ^[9]. Instead, the safest approach is to use a clinical playbook built from consensus reports, controlled trials, device instructions, and adverse event data ^[9]. Fixed settings cannot be applied across devices, indications, body sites, or patients ^[9].

The Fitzpatrick system, while widely used, has important limits. A 2025 Delphi study, which gathered opinions from 22 skin-of-color experts, found that 95% of them agreed that the current Fitzpatrick system has clinical and research limits ^[10]. A 2026 study of 789 adults also found large differences between subjective skin ratings and objective color measurements ^[11]. This means Fitzpatrick type should be only one input in a complete risk assessment, not the only factor ^[12].

A comprehensive safety approach requires a personalized assessment for each patient. This includes evaluating the patient’s normal untanned skin color, current color, recent sun exposure, history of PIH, prior burns, scar history, treatment site, target depth, and current inflammation ^[13]. For example, a person classified as Fitzpatrick IV can have very different treatment risks depending on tanning, body site, prior injury, and the planned wavelength ^[13]. Clinics need a structured intake form that goes beyond a single Fitzpatrick dropdown menu ^[14]. Patients should understand that a safe consultation may result in deferring treatment, using topical treatments, performing a test spot, or using a different device ^[14].

The evidence base for PIH prevention, especially for Fitzpatrick VI skin, is still small. A 2025 systematic review of 369 cases reported ethnicity as 100% Asian, with only 4.1% of classified participants being Fitzpatrick V, and none being Fitzpatrick VI ^[15]. Therefore, protocols for Fitzpatrick VI skin rely heavily on understanding skin physiology, small studies, expert opinion, and careful clinical practice ^[15]. Claims of proven Fitzpatrick VI safety should be viewed with caution ^[16].

What steps should be taken before laser treatment to prevent PIH in darker skin?

Preventing PIH in Fitzpatrick IV-VI skin starts with a series of careful steps before treatment ^[17]. These steps aim to identify risks, stabilize the skin, and choose the most appropriate treatment parameters.

The first step is a thorough diagnosis and risk screening ^[18]. This involves confirming the treatment target and gathering a detailed patient history. Important information includes any prior PIH, scarring, current inflammation, recent tanning, previous procedures, medications, and the patient’s normal untanned skin color ^[18]. The diagnosis matters as much as skin tone. Brown epidermal PIH and blue-gray dermal PIH do not respond in the same way ^[19]. Active inflammatory conditions should be controlled first. The 2025 global consensus advises avoiding laser or IPL during active inflammatory stages of acquired dermal pigment disorders because treatment may worsen pigmentation ^[19].

This screening also involves a deferral gate. Laser treatment should be postponed if there is visible tanning, recent sunburn, active dermatitis, uncontrolled acne inflammation, or unresolved irritation in the treatment area ^[20]. An FDA adverse event report from 2025 described a tanned patient who developed burns after an operator switched from an Nd:YAG laser to an alexandrite laser ^[20]. This highlights the danger of treating tanned skin. Reviewing previous PIH, hypopigmentation, blistering, keloids, infection, and poor wound healing is also crucial ^[21]. Information on medications and skin products should also be reviewed to identify factors that might increase light sensitivity, irritation, bleeding, infection, or delayed healing risks ^[21].

The second step is skin stabilization ^[22]. This means deferring elective laser treatment when there is a recent tan or active inflammatory disease in the area ^[22]. The 2025 global consensus also recommends avoiding irritants close to procedures and preparing high-risk skin before treatment, although evidence for routine hydroquinone or other lightening agents remains mixed ^[22]. Pre-treatment photoprotection is also important. A 2026 trial in 20 Fitzpatrick IV and V participants found about 16 Individual Typology Angle degrees of net protection from a tested broad-spectrum sunscreen after combined inflammation and light exposure ^[23]. Iron-oxide formulas have also performed better than non-tinted mineral SPF 50 products against visible-light pigmentation in Fitzpatrick IV skin ^[24].

The third step is a delayed test spot ^[25]. This involves treating a small area with the exact device, wavelength, body site, cooling method, and planned settings. The test spot should be reviewed after enough time has passed for any delayed pigment change to appear ^[25]. One manufacturer protocol cited in an FDA report suggested a 1 to 2 week wait in Fitzpatrick IV to VI skin ^[25]. However, the exact timing must follow the specific device instructions ^[25]. High-risk consultations and test spots should be separate workflow stages, and clinics should factor the extra visit and waiting period into price quotes and scheduling ^[26]. Same-day consultation and high-energy treatment can increase clinical risk ^[26].

How is the correct laser device and settings chosen for Fitzpatrick IV-VI skin?

Selecting the right laser device and settings for Fitzpatrick IV-VI skin is critical for safety and effectiveness. This choice relies on minimizing epidermal melanin absorption while still targeting the intended chromophore.

For hair reduction, the long-pulsed 1064 nm Nd:YAG laser is generally considered the safest starting point for Fitzpatrick V and VI skin ^[27]. This is because its longer wavelength is absorbed less by epidermal melanin compared to shorter wavelengths like the 755 nm alexandrite laser ^[27]. Diode systems (near 800-810 nm) may be used with caution in selected patients if they have suitable pulse control and cooling, but they offer less safety margin than 1064 nm in very dark or tanned skin ^[28]. Alexandrite 755 nm and broad-spectrum IPL require much greater caution in dark or tanned skin ^[29]. It is important to remember that “safer” does not mean risk-free. In a retrospective study of 150 Fitzpatrick IV to VI patients, long-pulsed Nd:YAG produced a 54.3% mean hair reduction after an average of 8.9 sessions ^[30]. While 86% had no complications, temporary hyperpigmentation was the most frequent complication among those who did ^[30]. A separate meta-analysis found paradoxical hair growth in 3% of laser and IPL hair-removal patients, mainly on the face and neck ^[31]. Specific consent regarding increased hair growth is needed for women receiving face or neck treatment ^[31].

For pigment procedures, shorter wavelengths such as 532 nm interact strongly with epidermal pigment and require added caution in Fitzpatrick V and VI skin ^[32]. The European laser position statement recommends using the minimum effective fluence in darker skin ^[32]. Low-fluence 1064 nm Nd:YAG may be considered for selected resistant pigment disorders, but repeated “laser toning” can cause mottled pigment loss ^[32].

For resurfacing procedures, the goal is to reduce total tissue injury ^[33]. Fractional rather than full-field treatment should be used where clinically suitable ^[33]. Lower density, fewer passes, longer intervals, and avoiding pulse overlap help to reduce accumulated inflammation ^[33]. Published fractional studies have reported PIH rates of 7.1% versus 12.4% and 43% versus 71% when comparing lower-density and higher-density methods, respectively ^[34]. This highlights that treatment density matters as much as or more than the energy per microbeam ^[35]. A small 2016 split-face study, summarized in a 2017 review, observed PIH in 43% of lower-density areas and 71% of higher-density areas at the same 40 mJ setting, indicating that treatment density is a major safety control ^[36].

Vascular procedures have their own specific rules ^[37]. A review found only nine pulsed dye laser studies involving 241 Fitzpatrick IV to VI patients ^[37]. While benefits were possible, hyperpigmentation, hypopigmentation, and scarring remained concerns ^[37]. A hair removal protocol should never be reused for vascular or pigment treatment, even if the device platform is the same ^[37]. Vascular-laser protocols need conservative fluence and careful endpoint monitoring ^[38].

When hair lacks enough pigment for laser treatment, refusing the laser can be the safer choice ^[39]. Clinics like Bio2 Laser Studio offer both laser hair reduction and electrolysis ^[40]. This operating model provides an option for patients with blonde, red, gray, white, or very fine hair, which do not respond well to laser treatment due to insufficient pigment ^[39]. Electrolysis still causes local tissue injury and requires its own PIH controls ^[40].

What are the critical steps during the laser treatment session?

The treatment-day process is as important as device selection for ensuring safety and preventing PIH in Fitzpatrick IV-VI skin. Strict adherence to protocols and careful monitoring are essential.

Every session should begin with a formal time-out ^[41]. This involves confirming the patient, treatment area, diagnosis, specific device, wavelength, handpiece, spot size, pulse width, fluence, cooling setting, and the result of the test spot ^[41]. The screen and handpiece should be checked before the first pulse and after any interruption or mode change. This practice directly addresses lessons learned from FDA reports involving wrong wavelength selection ^[41]. For example, a 2025 FDA case reported severe burns and blisters after an operator switched from an Nd:YAG to an alexandrite source on a tanned patient without proper verification ^[42].

Detailed and accurate documentation is also critical. Every setting and clinical endpoint must be recorded in a laser log ^[43]. This includes current skin color, tan status, skin preparation, cooling method, number of passes, overlap pattern, patient pain response, and immediate tissue response ^[43]. This level of detail ensures that a future operator can reconstruct the session without relying on memory ^[43].

Operators must understand that fluence numbers are not universal ^[44]. A fluence number from one paper or another device cannot be simply copied ^[44]. Pulse shape, handpiece calibration, spot size, cooling, repetition rate, and beam profile all affect the skin’s response ^[44]. The 2025 FDA case mentioned earlier illustrates this danger: a tanned patient developed burns and blisters when treated with a 755 nm alexandrite setting of 15 J/cm², 20 ms, and an 18 mm handpiece after treatment began with Nd:YAG ^[45].

Limiting heat accumulation is another key principle ^[46]. This involves using mapped passes, preventing unplanned overlap, and allowing enough cooling time between adjacent pulses as required by the device ^[46]. This practice is inferred from fractional studies showing higher PIH rates with greater skin coverage and reviews linking PIH to thermal injury and inflammation ^[47].

Cooling methods must be applied precisely according to device validation ^[48]. While a 2026 network analysis favored epidermal cooling over sunscreen alone, a 2025 skin-of-color review found that some cooling-air approaches worsened outcomes ^[48]. Cooling should be used exactly as validated for the specific device, and the operator must still be able to observe the skin’s response ^[48]. Cooling cannot fix an incorrect wavelength or an excessive setting ^[48].

Finally, there are clear stop criteria. Treatment must be immediately stopped if blistering, epidermal lifting, sharply patterned discoloration, or pain that is out of proportion to the expected response occurs ^[49]. Eye protection is a mandatory safety control for both patient and operator. A 2026 descriptive review reported ocular complications in about 2.1% of a 70-case periocular subset, underscoring the importance of eye safety ^[49].

What post-laser care is essential to reduce PIH risk?

After laser treatment, careful aftercare is crucial to reduce inflammation and detect any delayed pigment changes early. This helps prevent or minimize the impact of PIH, especially in Fitzpatrick IV-VI skin.

The first goal is to calm inflammation and protect the skin barrier ^[50]. The wound-care method specified for the procedure should be followed, often involving a bland occlusive for ablative treatments ^[50]. Patients should be advised to avoid rubbing, picking, excessive heat, unapproved acids, retinoids, exfoliation, and fragranced products while the skin barrier is impaired ^[50].

Prescription anti-inflammatory treatment can be helpful after specific ablative procedures. In a 40-person Fitzpatrick IV trial, two days of clobetasol reduced observed PIH from 75% to 40% ^[51]. Clobetasol is a strong steroid, and its facial misuse can cause harm. Therefore, this regimen should remain under the control of a qualified prescriber and not be given as a standard retail instruction ^[51].

Sunscreen should always be considered base care, despite some disagreements in prevention reviews ^[52]. A 2026 network analysis found sunscreen monotherapy ineffective against placebo in its network, while a 2025 skin-of-color review stated that sunscreen was the only measure with consistent prevention results ^[52]. Controlled light-exposure studies also confirm that ultraviolet and visible light can deepen pigment ^[52]. A 2026 trial in Fitzpatrick IV and V participants showed about 16 Individual Typology Angle degrees of net protection from a tested broad-spectrum formula ^[53].

Tranexamic acid is an emerging medical option, not a standard spa protocol ^[54]. Intradermal treatment produced a relative risk of 0.02 against sunscreen in the 2026 analysis, though the included trials were small ^[54]. Injection discomfort and bruising were reported side effects ^[54]. Oral or injected use of tranexamic acid requires medical assessment and trained administration ^[54]. This is not suitable for routine salon use ^[55].

Delayed follow-up is essential ^[56]. A practical schedule could include a photo check at 48 to 72 hours, another at 7 to 14 days, and a reassessment before the next session ^[56]. This timing is based on studies that followed patients at various intervals like day 3, 5, 7, and one month ^[57]. Treatment should not be repeated while inflammation or new pigment is still developing ^[56].

If PIH appears, further energy treatment must stop ^[58]. The clinician should treat any active inflammation or acne, strengthen photoprotection measures, and begin appropriate topical care according to local clinical rules ^[58]. The global consensus places topical treatments first, reserving laser or peels for resistant cases ^[58]. Immediate repeat laser treatment can worsen the injury that caused the pigment ^[58].

What role do clinics play in tracking and reducing PIH rates?

Clinics have a major role in tracking and reducing PIH rates by establishing strong safety systems. This involves standardized protocols, outcome tracking, training, and transparent communication.

First, clinics need to maintain separate and detailed protocols ^[59]. There should be distinct protocols for each device, wavelength, indication, body site, and skin-risk group ^[59]. Each protocol must clearly state deferral rules, test-spot rules, permitted starting ranges, cooling requirements, acceptable clinical endpoints, stop criteria, follow-up timing, and escalation steps ^[59]. The idea of a single “Fitzpatrick IV to VI parameter chart” is outdated and unsafe ^[59].

Second, clinics should track denominator-based outcomes ^[60]. This means recording outcomes relative to the total number of patients or sessions. Useful measures include the percentage of eligible patients who received test spots, the number of recent-tan deferrals, PIH rates at 2 and 6 weeks, burns or blisters per 1,000 sessions, hypopigmentation occurrences, unplanned medical referrals, and adverse events broken down by operator, device, wavelength, site, and measured skin color ^[60]. The inconsistent reporting in current literature contributes to the wide variation in complication estimates ^[60].

Third, auditing training events and mode-selection errors is essential ^[61]. FDA cases clearly show that even machines cleared for darker skin can cause injury if an operator selects the wrong wavelength, treats tanned skin, skips a test spot, or fails to follow instructions ^[61]. Device clearance means safe use under specific conditions, not a guarantee of safe operation regardless of technique ^[61].

Fourth, careful pricing and consent procedures are important ^[62]. Using conservative settings, which are safer for darker skin, may mean that more sessions are needed to achieve the desired results ^[62]. For example, a 150-patient Nd:YAG cohort averaged 8.9 treatments for a 54.3% mean hair reduction ^[63]. Clinics should avoid making promises of one-session results and should clearly explain the possible need for multiple treatments, ongoing maintenance, alternative treatments like electrolysis, topical care, or specialist referrals ^[62].

Fifth, clinics can help to close the Fitzpatrick VI evidence gap through internal reporting ^[64]. The 2025 prevention review included no Fitzpatrick VI patients, and only 6% of classified participants in the broader 2024 treatment review were Fitzpatrick VI ^[64]. Clinics that serve diverse populations hold valuable safety data that, if collected with consent, consistent definitions, and objective color measures, could significantly contribute to the overall knowledge base ^[64].

For example, Bio2 Laser Studio lists both laser hair reduction and electrolysis services on its public site ^[65]. However, like many other clinics, it does not report session counts, PIH rates, burn rates, outcomes by skin tone, or follow-up completion ^[66]. This illustrates a wider disclosure gap in the industry. Bio2 Laser Studio and its peers could build public trust by reporting clear, denominator-based safety measures without turning this data into promotional claims ^[66].

What are some examples of clinical studies that have influenced current safety protocols?

Several studies and real-world incidents have significantly shaped our understanding of laser safety for darker skin and PIH prevention. These examples highlight specific findings and lessons learned:

• UCSF-led skin pigment measurement study (2026): Michael S. Lipnick and his team published a study on January 6, 2026 ^[67]. They compared three subjective methods and two objective instruments across different body sites in 789 participants, conducting 33,856 assessments ^[67]. The results showed that depending on the method, 7%, 14%, 16%, 23%, or 26% of the same group could be classified as having dark skin ^[67]. This study taught clinics to use Fitzpatrick type alongside untanned baseline color, objective measurements (where available), and a patient’s pigment history. It also reinforced that race alone should not determine laser parameters ^[67].
• Siriraj Hospital post-CO2 steroid trial (2015): Researchers led by Nutjira Cheyasak at Siriraj Hospital in Bangkok studied 40 Fitzpatrick IV patients undergoing fractional CO2 laser resurfacing ^[68]. They treated both sides of the patients’ faces, giving one side clobetasol 0.05% for two days followed by petrolatum, and the other side petrolatum alone for seven days ^[68]. PIH occurred on 75% of the petrolatum-only sides but only on 40% of the steroid-treated sides ^[68]. This showed that early inflammation control can greatly reduce PIH after certain ablative procedures. However, this regimen requires medical supervision due to the strength of the steroid ^[68].
• Ramathibodi Laser Center low-density fractional protocol (2011): Premjit Vaiyavatjamai and Penpun Wattanakrai reviewed 181 sessions on 119 Fitzpatrick III to V patients using a 1550 nm fractional laser ^[69]. They used low maximum treatment density, cooling, and treatment intervals of at least four weeks ^[69]. Total complications occurred after 3.3% of sessions, with PIH occurring after 2.2% ^[69]. This suggests that low tissue coverage and sufficient time for inflammation to settle might be more important for reducing risk than simply using very low energy at high density ^[69].
• Jilin University and Yanbian University split-face CO2 study (2014): This randomized trial involved 20 Asian acne-scar patients who received split-face CO2 laser treatment ^[70]. The study compared different densities (10% vs. 20% at 20 mJ) and fluences (10 mJ vs. 20 mJ at 10% density) ^[70]. Scar improvement did not differ much between the settings, but adverse effects were more common with higher density or higher fluence ^[70]. The lesson here is to use the lowest tissue burden that achieves the clinical goal, as more energy or coverage did not show a clear benefit in this small trial ^[70].
• Mana Abdullah Alharbi’s 1927 nm PIH pilot (2019): Dermatologist Mana Abdullah Alharbi conducted a pilot study on nine Fitzpatrick IV patients with PIH resistant to topical treatments ^[71]. Patients received one to four low-energy, low-density 1927 nm nonablative fractional laser sessions, spaced six weeks apart, combined with 4% hydroquinone post-treatment ^[71]. Eight patients were assessed, with 37.5% showing an excellent response and 50% a satisfactory response ^[71]. No paradoxical pigmentation was reported ^[71]. This showed that carefully delivered fractional treatment, combined with topical agents, might help resistant PIH, although the sample size was very small ^[71].
• EL.EN and Cynosure wrong-wavelength FDA case (2025): An FDA report described an adverse event where a patient, who had recently returned from vacation and was tanned, received hair removal ^[72]. The operator began with a YAG source but then switched to a 755 nm alexandrite source. The patient developed severe burns and blistering on the legs ^[72]. This incident highlights that a dual-wavelength machine is not automatically safe for all skin states. Tan screening, wavelength verification, a test spot, and a treatment-day time-out are essential safety controls ^[72].

What are the current limitations in the evidence for PIH prevention in Fitzpatrick IV-VI skin?

Despite increased attention to skin of color, there are still notable limitations in the evidence base for preventing PIH in Fitzpatrick IV-VI skin. These limits affect how confidently protocols can be applied across all individuals with darker skin tones.

One primary limitation is the small number of randomized controlled trials (RCTs) focused on prevention. A 2026 network meta-analysis, which searched evidence up to February 2025, included only 14 trials, with 11 suitable for network comparison ^[73]. While this represents a move from narrative advice to comparative evidence, the trial base remains small given the vast number of devices, settings, indications, and skin tones in use ^[73]. This means no single preventive regimen can be declared a universal standard ^[73].

There is a significant lack of representation for the darkest skin types. The 2025 skin-of-color prevention review included 369 cases, but 100% of the reported ethnicity was Asian ^[74]. Among classified participants, only 4.1% were Fitzpatrick V, and none were Fitzpatrick VI ^[74]. This means that as skin pigmentation increases, the evidence becomes thinner ^[75]. Claims of proven Fitzpatrick VI safety should therefore be viewed with caution ^[75]. While a 2024 systematic review of PIH treatment included a more diverse group (40% Fitzpatrick IV, 34% V, and 6% VI), treatment results cannot be automatically assumed to answer prevention questions ^[76].

The efficacy of common interventions is debated, or the evidence is limited. For example, data on sunscreen and cooling appears to conflict ^[77]. A 2025 skin-of-color review found sunscreen to be the most consistent preventive measure, but reported worse outcomes with some cooling-air protocols ^[77]. In contrast, a 2026 network analysis found epidermal cooling and several medical interventions superior to sunscreen alone ^[77]. These discrepancies likely arise from different populations, cooling methods, comparators, and study endpoints ^[77]. This emphasizes that cooling should follow device instructions rather than a blanket rule ^[77].

Emerging medical options like intradermal tranexamic acid show promise, with a relative risk of 0.02 against sunscreen monotherapy in the 2026 analysis ^[78]. However, this result comes from limited data with a wide confidence interval, meaning it is promising but not yet a basis for routine salon use and requires medical assessment ^[78].

Finally, the reliance on the Fitzpatrick scale as a sole risk assessment tool is problematic. A 2025 Delphi study reported that 95% of skin-of-color experts agreed that the Fitzpatrick system has limits for clinical and research purposes ^[79]. A 2026 study showed that subjective skin ratings and objective color measurements can differ greatly, affecting who is placed in a high-risk group ^[80]. This calls for more objective and comprehensive methods for assessing skin pigment and risk ^[81].

***

This comprehensive overview of frequently asked questions aims to clarify key considerations for laser safety and PIH prevention in Fitzpatrick IV-VI skin. The following section will discuss specific clinical considerations for managing complications.

References

1. Global consensus on the management of melanin hyperpigmentation disorders
2. Beyond Fitzpatrick skin types: A Delphi consensus on key considerations for a universal skin typing classification
3. Special considerations for darker-skinned patients.
4. Global consensus on the management of melanin hyperpigmentation disorders
5. Global consensus on the management of melanin hyperpigmentation disorders
6. Laser and Light Treatments for Hair Reduction in Fitzpatrick Skin Types IV-VI: A Comprehensive Review of the Literature – PubMed
7. MAUDE Adverse Event Report: CANDELA GENTLEMAX PRO; GMAX PRO
8. Nonablative Fractional Laser Resurfacing in Skin of Color: Evidence-based Review – PMC
9. Topical corticosteroids minimise the risk of postinflammatory hyper-pigmentation after ablative fractional CO2 laser resurfacing in Asians – PubMed
10. An Investigator-Blinded, Randomized Trial of a Broad-Spectrum Sunscreen Containing Sclareolide and Niacinamide for the Prevention of Post-inflammatory Hyperpigmentation in Skin of Color – PubMed
11. Prevention of Post‐Inflammatory Hyperpigmentation in Skin of Colour: A Systematic Review – PMC
12. Prevention of Post-Inflammatory Hyperpigmentation in Skin of Colour: A Systematic Review – PubMed
13. Long-pulsed Nd:YAG laser-assisted hair removal in Fitzpatrick skin types IV-VI – PubMed
14. Interventions to Prevent Postinflammatory Hyperpigmentation After Laser and Energy‐Based Device Treatments: A Systematic Review and Network Meta‐Analysis – PMC
15. Interventions to Prevent Postinflammatory Hyperpigmentation After Laser and Energy‐Based Device Treatments: A Systematic Review and Network Meta‐Analysis – PMC
16. Prevention of Post‐Inflammatory Hyperpigmentation in Skin of Colour: A Systematic Review – PMC
17. Prevention of Post‐Inflammatory Hyperpigmentation in Skin of Colour: A Systematic Review – PMC
18. Treatment of Post-Inflammatory Hyperpigmentation in Skin of Colour: A Systematic Review – PMC
19. Treatment of Post-Inflammatory Hyperpigmentation in Skin of Colour: A Systematic Review – PubMed
20. Post-inflammatory hyperpigmentation: A systematic review of treatment outcomes – PubMed
21. Topical corticosteroids minimise the risk of postinflammatory hyper-pigmentation after ablative fractional CO2 laser resurfacing in Asians – PubMed
22. Side effects and complications of fractional 1550nm erbium fiber laser treatment among Asians
23. A retrospective chart review to assess the safety of nonablative fractional laser resurfacing in Fitzpatrick skin types IV to VI – PubMed
24. Nonablative Fractional Laser Resurfacing in Skin of Color: Evidence-based Review – PMC
25. Side effects and complications of fractional 1550nm erbium fiber laser treatment among Asians
26. Long-pulsed Nd:YAG laser-assisted hair removal in Fitzpatrick skin types IV-VI – PubMed
27. Paradoxical Hypertrichosis Associated with Laser and Light Therapy for Hair Removal: A Systematic Review and Meta-analysis.
28. A review of treatment of port-wine stains with pulsed dye laser in fitzpatrick skin type IV-VI.
29. Beyond Fitzpatrick skin types: A Delphi consensus on key considerations for a universal skin typing classification
30. Comparison of methods for characterizing skin pigment diversity in research cohorts – PubMed
31. An Investigator-Blinded, Randomized Trial of a Broad-Spectrum Sunscreen Containing Sclareolide and Niacinamide for the Prevention of Post-inflammatory Hyperpigmentation in Skin of Color – PubMed
32. Beyond Fitzpatrick skin types: A Delphi consensus on key considerations for a universal skin typing classification
33. Special considerations for darker-skinned patients.
34. Comparison of methods for characterizing skin pigment diversity in research cohorts – PubMed
35. Global consensus on the management of melanin hyperpigmentation disorders
36. Beyond Fitzpatrick skin types: A Delphi consensus on key considerations for a universal skin typing classification
37. MAUDE Adverse Event Report: EL.EN. ELECTRONIC ENGINEERING S.P.A. ELITE IQ
38. Complications of dermatologic lasers in high Fitzpatrick phototypes and management: an updated narrative review – PubMed
39. MAUDE Adverse Event Report: CANDELA GENTLEMAX PRO; GMAX PRO
40. Global consensus on the management of melanin hyperpigmentation disorders
41. An Investigator-Blinded, Randomized Trial of a Broad-Spectrum Sunscreen Containing Sclareolide and Niacinamide for the Prevention of Post-inflammatory Hyperpigmentation in Skin of Color – PubMed
42. MAUDE Adverse Event Report: EL.EN. ELECTRONIC ENGINEERING S.P.A. ELITE IQ
43. Lasers and light-based therapies in ethnic skin: treatment options and recommendations for Fitzpatrick skin types V and VI.
44. Long-pulsed Nd:YAG laser-assisted hair removal in Fitzpatrick skin types IV-VI – PubMed
45. Laser treatment of hyperpigmented lesions: position statement of the European Society of Laser in Dermatology – Passeron – 2019 – Journal of the European Academy of Dermatology and Venereology – Wiley Online Library
46. Side effects and complications of fractional 1550nm erbium fiber laser treatment among Asians
47. A review of treatment of port-wine stains with pulsed dye laser in fitzpatrick skin type IV-VI.
48. Laser Hair Removal | Electrolysis | RF Body Contouring
49. MAUDE Adverse Event Report: EL.EN. ELECTRONIC ENGINEERING S.P.A. ELITE IQ
50. Facial laser complications (A Five Year Review) | Lasers in Medical Science | Springer Nature Link
51. MAUDE Adverse Event Report: EL.EN. ELECTRONIC ENGINEERING S.P.A. ELITE IQ
52. Nonablative Fractional Laser Resurfacing in Skin of Color: Evidence-based Review – PMC
53. Interventions to Prevent Postinflammatory Hyperpigmentation After Laser and Energy‐Based Device Treatments: A Systematic Review and Network Meta‐Analysis – PMC
54. Facial laser complications (A Five Year Review) | Lasers in Medical Science | Springer Nature Link
55. Topical corticosteroids minimise the risk of postinflammatory hyper-pigmentation after ablative fractional CO2 laser resurfacing in Asians – PubMed
56. Topical corticosteroids minimise the risk of postinflammatory hyper-pigmentation after ablative fractional CO2 laser resurfacing in Asians – PubMed
57. Interventions to Prevent Postinflammatory Hyperpigmentation After Laser and Energy‐Based Device Treatments: A Systematic Review and Network Meta‐Analysis – PMC
58. Interventions to Prevent Postinflammatory Hyperpigmentation After Laser and Energy‐Based Device Treatments: A Systematic Review and Network Meta‐Analysis – PMC
59. Topical corticosteroids minimise the risk of postinflammatory hyper-pigmentation after ablative fractional CO2 laser resurfacing in Asians – PubMed
60. Global consensus on the management of melanin hyperpigmentation disorders
61. Facial laser complications (A Five Year Review) | Lasers in Medical Science | Springer Nature Link
62. Facial laser complications (A Five Year Review) | Lasers in Medical Science | Springer Nature Link
63. MAUDE Adverse Event Report: EL.EN. ELECTRONIC ENGINEERING S.P.A. ELITE IQ
64. Long-pulsed Nd:YAG laser-assisted hair removal in Fitzpatrick skin types IV-VI – PubMed
65. Prevention of Post‐Inflammatory Hyperpigmentation in Skin of Colour: A Systematic Review – PMC
66. Laser Hair Removal | Electrolysis | RF Body Contouring
67. Comparison of methods for characterizing skin pigment diversity in research cohorts – PubMed
68. Topical corticosteroids minimise the risk of postinflammatory hyper-pigmentation after ablative fractional CO2 laser resurfacing in Asians – PubMed
69. Side effects and complications of fractional 1550nm erbium fiber laser treatment among Asians
70. Comparison study of fractional carbon dioxide laser resurfacing using different fluences and densities for acne scars in Asians: a randomized split-face trial – PubMed
71. 1927 nm Thulium Laser Successfully Treats PostInflammatory Hyperpigmentation in Skin of Color – PubMed
72. MAUDE Adverse Event Report: EL.EN. ELECTRONIC ENGINEERING S.P.A. ELITE IQ
73. Interventions to Prevent Postinflammatory Hyperpigmentation After Laser and Energy‐Based Device Treatments: A Systematic Review and Network Meta‐Analysis – PMC
74. Prevention of Post‐Inflammatory Hyperpigmentation in Skin of Colour: A Systematic Review – PMC
75. Global consensus on the management of melanin hyperpigmentation disorders – PMC
76. Treatment of Post-Inflammatory Hyperpigmentation in Skin of Colour: A Systematic Review – PMC
77. Post-inflammatory hyperpigmentation: A systematic review of treatment outcomes – PubMed
78. Beyond Fitzpatrick skin types: A Delphi consensus on key considerations for a universal skin typing classification
79. Comparison of methods for characterizing skin pigment diversity in research cohorts – PubMed
80. Nonablative Fractional Laser Resurfacing in Skin of Color: Evidence-based Review – PMC
81. Topical corticosteroids minimise the risk of postinflammatory hyper-pigmentation after ablative fractional CO2 laser resurfacing in Asians – PubMed
82. Side effects and complications of fractional 1550nm erbium fiber laser treatment among Asians
83. Comparison study of fractional carbon dioxide laser resurfacing using different fluences and densities for acne scars in Asians: a randomized split-face trial – PubMed
84. Long-pulsed Nd:YAG laser-assisted hair removal in Fitzpatrick skin types IV-VI – PubMed
85. Paradoxical Hypertrichosis Associated with Laser and Light Therapy for Hair Removal: A Systematic Review and Meta-analysis.
86. A review of treatment of port-wine stains with pulsed dye laser in fitzpatrick skin type IV-VI.
87. An Investigator-Blinded, Randomized Trial of a Broad-Spectrum Sunscreen Containing Sclareolide and Niacinamide for the Prevention of Post-inflammatory Hyperpigmentation in Skin of Color – PubMed
88. Impact of Iron-Oxide Containing Formulations Against Visible Light-Induced Skin Pigmentation in Skin of Color Individuals – PubMed
89. MAUDE Adverse Event Report: EL.EN. ELECTRONIC ENGINEERING S.P.A. ELITE IQ
90. Laser Hair Removal | Electrolysis | RF Body Contouring